Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Publications indexed to the term Transplantation, Homologous

FacultyTitle
7Graft Cryopreservation Does Not Impact Overall Survival after Allogeneic Hematopoietic Cell Transplantation Using Post-Transplantation Cyclophosphamide for Graft-versus-Host Disease Prophylaxis. (Hamadani M, Zhang MJ, Tang XY, Fei M, Brunstein C, Chhabra S, D'Souza A, Milano F, Phelan R, Saber W, Shaw BE, Weisdorf D, Devine SM, Horowitz MM) Biol Blood Marrow Transplant 2020 07;26(7):1312-1317       4 Citations
3Allogeneic transplantation in elderly patients ≥65 years with non-Hodgkin lymphoma: a time-trend analysis. (Shah NN, Ahn KW, Litovich C, Sureda A, Kharfan-Dabaja MA, Awan FT, Ganguly S, Gergis U, Inwards D, Karmali R, Lazaryan A, Lekakis L, Munshi P, Nathan S, Saad AA, Solh M, Steinberg A, Vij R, Wood WA, Fenske TS, Smith S, Hamadani M) Blood Cancer J 2019 12 03;9(12):97       1 Citation
1Choice of conditioning regimens for bone marrow transplantation in severe aplastic anemia. (Bejanyan N, Kim S, Hebert KM, Kekre N, Abdel-Azim H, Ahmed I, Aljurf M, Badawy SM, Beitinjaneh A, Boelens JJ, Diaz MA, Dvorak CC, Gadalla S, Gajewski J, Gale RP, Ganguly S, Gennery AR, George B, Gergis U, Gómez-Almaguer D, Vicent MG, Hashem H, Kamble RT, Kasow KA, Lazarus HM, Mathews V, Orchard PJ, Pulsipher M, Ringden O, Schultz K, Teira P, Woolfrey AE, Saldaña BD, Savani B, Winiarski J, Yared J, Weisdorf DJ, Antin JH, Eapen M) Blood Adv 2019 10 22;3(20):3123-3131       4 Citations
3Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study. (Eapen M, Brazauskas R, Walters MC, Bernaudin F, Bo-Subait K, Fitzhugh CD, Hankins JS, Kanter J, Meerpohl JJ, Bolaños-Meade J, Panepinto JA, Rondelli D, Shenoy S, Williamson J, Woolford TL, Gluckman E, Wagner JE, Tisdale JF) Lancet Haematol 2019 Nov;6(11):e585-e596       13 Citations
1Increased overall and bacterial infections following myeloablative allogeneic HCT for patients with AML in CR1. (Ustun C, Kim S, Chen M, Beitinjaneh AM, Brown VI, Dahi PB, Daly A, Diaz MA, Freytes CO, Ganguly S, Hashmi S, Hildebrandt GC, Lazarus HM, Nishihori T, Olsson RF, Page KM, Papanicolaou G, Saad A, Seo S, William BM, Wingard JR, Wirk B, Yared JA, Perales MA, Auletta JJ, Komanduri KV, Lindemans CA, Riches ML) Blood Adv 2019 09 10;3(17):2525-2536    
2Related and unrelated donor transplantation for β-thalassemia major: results of an international survey. (Li C, Mathews V, Kim S, George B, Hebert K, Jiang H, Li C, Zhu Y, Keesler DA, Boelens JJ, Dvorak CC, Agarwal R, Auletta JJ, Goyal RK, Hanna R, Kasow K, Shenoy S, Smith AR, Walters MC, Eapen M) Blood Adv 2019 09 10;3(17):2562-2570       3 Citations
1Multiple functional variants in the IL1RL1 region are pretransplant markers for risk of GVHD and infection deaths. (Karaesmen E, Hahn T, Dile AJ, Rizvi AA, Wang J, Wang T, Haagenson MD, Preus L, Zhu Q, Liu Q, Yan L, Liu S, Haiman CA, Stram D, Pooler L, Sheng X, Van Den Berg D, Brock G, Webb A, McCarthy PL, Pasquini MC, Spellman SR, Lee SJ, Paczesny S, Sucheston-Campbell LE) Blood Adv 2019 08 27;3(16):2512-2524       2 Citations
1Case report series of a novel application of neostigmine to successfully relieve refractory ileus status post-pediatric orthotopic liver transplantation. (Petersen PC, Balakrishnan B, Vitola B, Hong JC) Pediatr Transplant 2019 11;23(7):e13564    
3Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. (Marsh RA, Leiding JW, Logan BR, Griffith LM, Arnold DE, Haddad E, Falcone EL, Yin Z, Patel K, Arbuckle E, Bleesing JJ, Sullivan KE, Heimall J, Burroughs LM, Skoda-Smith S, Chandrakasan S, Yu LC, Oshrine BR, Cuvelier GDE, Thakar MS, Chen K, Teira P, Shenoy S, Phelan R, Forbes LR, Chellapandian D, Dávila Saldaña BJ, Shah AJ, Weinacht KG, Joshi A, Boulad F, Quigg TC, Dvorak CC, Grossman D, Torgerson T, Graham P, Prasad V, Knutsen A, Chong H, Miller H, de la Morena MT, DeSantes K, Cowan MJ, Notarangelo LD, Kohn DB, Stenger E, Pai SY, Routes JM, Puck JM, Kapoor N, Pulsipher MA, Malech HL, Parikh S, Kang EM, submitted on behalf of the Primary Immune Deficiency Treatment Consortium) J Clin Immunol 2019 10;39(7):653-667       2 Citations
4Survival outcomes of allogeneic hematopoietic cell transplants with EBV-positive or EBV-negative post-transplant lymphoproliferative disorder, A CIBMTR study. (Naik S, Riches M, Hari P, Kim S, Chen M, Bachier C, Shaughnessy P, Hill J, Ljungman P, Battiwalla M, Chhabra S, Daly A, Storek J, Ustun C, Diaz MA, Cerny J, Beitinjaneh A, Yared J, Brown V, Page K, Dahi PB, Ganguly S, Seo S, Chao N, Freytes CO, Saad A, Savani BN, Woo Ahn K, Boeckh M, Heslop HE, Lazarus HM, Auletta JJ, Kamble RT) Transpl Infect Dis 2019 Oct;21(5):e13145       4 Citations
4Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report. (Kim HT, Ahn KW, Hu ZH, Davids MS, Volpe VO, Antin JH, Sorror ML, Shadman M, Press O, Pidala J, Hogan W, Negrin R, Devine S, Uberti J, Agura E, Nash R, Mehta J, McGuirk J, Forman S, Langston A, Giralt SA, Perales MA, Battiwalla M, Hale GA, Gale RP, Marks DI, Hamadani M, Ganguly S, Bacher U, Lazarus H, Reshef R, Hildebrandt GC, Inamoto Y, Cahn JY, Solh M, Kharfan-Dabaja MA, Ghosh N, Saad A, Aljurf M, Schouten HC, Hill BT, Pawarode A, Kindwall-Keller T, Saba N, Copelan EA, Nathan S, Beitinjaneh A, Savani BN, Cerny J, Grunwald MR, Yared J, Wirk BM, Nishihori T, Chhabra S, Olsson RF, Bashey A, Gergis U, Popat U, Sobecks R, Alyea E, Saber W, Brown JR) Clin Cancer Res 2019 08 15;25(16):5143-5155       1 Citation
2Inferior Access to Allogeneic Transplant in Disadvantaged Populations: A Center for International Blood and Marrow Transplant Research Analysis. (Paulson K, Brazauskas R, Khera N, He N, Majhail N, Akpek G, Aljurf M, Buchbinder D, Burns L, Beattie S, Freytes C, Garcia A, Gajewski J, Hahn T, Knight J, LeMaistre C, Lazarus H, Szwajcer D, Seftel M, Wirk B, Wood W, Saber W) Biol Blood Marrow Transplant 2019 10;25(10):2086-2090       3 Citations
2Pulmonary Complications in Pediatric and Adolescent Patients Following Allogeneic Hematopoietic Cell Transplantation. (Broglie L, Fretham C, Al-Seraihy A, George B, Kurtzberg J, Loren A, MacMillan M, Martinez C, Davies SM, Pasquini MC) Biol Blood Marrow Transplant 2019 10;25(10):2024-2030       2 Citations
1Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study. (Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS) Leukemia 2019 11;33(11):2599-2609       10 Citations
2Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Cell Transplantation Program, Part I: Minimum Requirements and Beyond. (Pasquini MC, Srivastava A, Ahmed SO, Aljurf M, Atsuta Y, Doleysh C, Galeano S, Gluckman E, Greinix H, Hale GA, Hari P, Hashmi SK, Kamani N, Laughlin MJ, Niederwieser D, Seber A, Szer J, Snowden JA, Van Biesen K, Watry P, Weisdorf DJ, Apperley J) Biol Blood Marrow Transplant 2019 12;25(12):2322-2329       2 Citations
2FLT3 Inhibitor Maintenance After Allogeneic Transplantation: Is a Placebo-Controlled, Randomized Trial Ethical? (Levis MJ, Chen YB, Hamadani M, Horowitz MM, Jones RJ, Blood and Marrow Transplant Clinical Trials Network) J Clin Oncol 2019 07 01;37(19):1604-1607       8 Citations
5Worldwide Network for Blood and Marrow Transplantation Recommendations for Establishing a Hematopoietic Stem Cell Transplantation Program in Countries with Limited Resources, Part II: Clinical, Technical, and Socioeconomic Considerations. (Aljurf M, Weisdorf D, Hashmi S, Nassar A, Gluckman E, Mohty M, Rizzo D, Pasquini M, Hamadani M, Saber W, Hari P, Kharfan-Dabaja M, Majhail N, Gerges U, Hamidieh AA, Hussain F, Elhaddad A, Mahmoud HK, Tbakhi A, Othman TB, Hamladji RM, Bekadja MA, Ahmed P, Bazarbachi A, Adil S, Alkindi S, Ladeb S, Dennison D, Patel M, Lu P, Quessar AE, Okamoto S, Atsuta Y, Alhejazi A, Ayas MF, Ahmed SO, Novitzky N, Srivastava A, Seber A, Solh HE, Ghavamzadeh A, Confer D, Kodera Y, Hildegard G, Szer J, Horowitz MM, Niederwieser D) Biol Blood Marrow Transplant 2019 12;25(12):2330-2337       4 Citations
4Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells. (Chen YB, Le-Rademacher J, Brazauskas R, Kiefer DM, Hamadani M, DiPersio JF, Litzow MR, Craig M, Horwitz ME, Artz AS, McClune BL, Fernandez HF, Duong HK, Kobusingye H, Proue M, Drexler RJ, Horowitz MM, Shaw BE, Miller JP, Hosoba S, Waller EK, Devine SM) Blood Adv 2019 03 26;3(6):875-883       2 Citations
1Mixed vs full donor engraftment early after hematopoietic cell transplant: Impact on incidence and control of cytomegalovirus infection. (Green JS, Shanley RM, Brunstein CG, Young JH, Verneris MR) Transpl Infect Dis 2019 Jun;21(3):e13070       1 Citation
1Inflammatory Cytokine Networks in Gastrointestinal Tract Graft vs. Host Disease. (Piper C, Drobyski WR) Front Immunol 2019;10:163       9 Citations
1Development of Secondary Osteosarcoma After TBI and Allogeneic Bone Marrow Transplant: A Case Series of 3 Patients. (Scheuermann A, Phelan R, Browning M) J Pediatr Hematol Oncol 2020 03;42(2):e100-e103    
1Novel Health Information Technology Tool Use by Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplantation: Longitudinal Quantitative and Qualitative Patient-Reported Outcomes. (Runaas L, Hoodin F, Munaco A, Fauer A, Sankaran R, Churay T, Mohammed S, Seyedsalehi S, Chappell G, Carlozzi N, Fetters MD, Kentor R, McDiarmid L, Brookshire K, Warfield C, Byrd M, Kaziunas S, Maher M, Magenau J, An L, Cohn A, Hanauer DA, Choi SW) JCO Clin Cancer Inform 2018 12;2:1-12       2 Citations
1Functional and Radiologic Assessment of the Brain after Reduced-Intensity Unrelated Donor Transplantation for Severe Sickle Cell Disease: Blood and Marrow Transplant Clinical Trials Network Study 0601. (King AA, McKinstry RC, Wu J, Eapen M, Abel R, Varughese T, Kamani N, Shenoy S) Biol Blood Marrow Transplant 2019 05;25(5):e174-e178       4 Citations
4Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. (Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M) J Hematol Oncol 2019 01 10;12(1):6       9 Citations
1Clinical Outcomes and Healthcare Resource Utilization for Gastrointestinal Acute Graft-versus-Host Disease after Allogeneic Transplantation for Hematologic Malignancy: A Retrospective US Administrative Claims Database Analysis. (Johnson BH, Taylor A, Kim G, Drahos J, Yang J, Akbari M, Shah NN) Biol Blood Marrow Transplant 2019 04;25(4):834-841       2 Citations
4Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results. (Pulsipher MA, Logan BR, Kiefer DM, Chitphakdithai P, Riches ML, Rizzo JD, Anderlini P, Leitman SF, Varni JW, Kobusingye H, Besser RM, Miller JP, Drexler RJ, Abdel-Mageed A, Ahmed IA, Ball ED, Bolwell BJ, Bunin NJ, Cheerva A, Delgado DC, Dvorak CC, Gillio AP, Hahn TE, Hale GA, Haight AE, Hayes-Lattin BM, Kasow KA, Linenberger M, Magalhaes-Silverman M, Mori S, Prasad VK, Quigg TC, Sahdev I, Schriber JR, Shenoy S, Tse WT, Yanik GA, Navarro WH, Horowitz MM, Confer DL, Shaw BE, Switzer GE) Biol Blood Marrow Transplant 2019 05;25(5):955-964       2 Citations
1The Role of Micronutrients in Graft-VS.-Host Disease: Immunomodulatory Effects of Vitamins A and D. (Chen X, Mayne CG) Front Immunol 2018;9:2853       2 Citations
15Outcomes of Reduced-Intensity Conditioning Allogeneic Hematopoietic Cell Transplantation Performed in the Inpatient versus Outpatient Setting. (Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runaas L, Shah NN, Shaw B, Saber W, Fenske T, Hamadani M) Biol Blood Marrow Transplant 2019 04;25(4):827-833       7 Citations
2The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. (Thakar MS, Broglie L, Logan B, Artz A, Bunin N, Burroughs LM, Fretham C, Jacobsohn DA, Loren AW, Kurtzberg J, Martinez CA, Mineishi S, Nelson AS, Woolfrey A, Pasquini MC, Sorror ML) Blood 2019 02 14;133(7):754-762       11 Citations
3Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation. (Ustun C, Young JH, Papanicolaou GA, Kim S, Ahn KW, Chen M, Abdel-Azim H, Aljurf M, Beitinjaneh A, Brown V, Cerny J, Chhabra S, Kharfan-Dabaja MA, Dahi PB, Daly A, Dandoy CE, Dvorak CC, Freytes CO, Hashmi S, Lazarus H, Ljungman P, Nishihori T, Page K, Pingali SRK, Saad A, Savani BN, Weisdorf D, Williams K, Wirk B, Auletta JJ, Lindemans CA, Komanduri K, Riches M) Bone Marrow Transplant 2019 08;54(8):1254-1265       8 Citations
3Non-GVHD ocular complications after hematopoietic cell transplantation: expert review from the Late Effects and Quality of Life Working Committee of the CIBMTR and Transplant Complications Working Party of the EBMT. (Inamoto Y, Petriček I, Burns L, Chhabra S, DeFilipp Z, Hematti P, Rovó A, Schears R, Shah A, Agrawal V, Al-Khinji A, Ahmed I, Ali A, Aljurf M, Alkhateeb H, Beitinjaneh A, Bhatt N, Buchbinder D, Byrne M, Callander N, Fahnehjelm K, Farhadfar N, Gale RP, Ganguly S, Hildebrandt GC, Horn E, Jakubowski A, Kamble RT, Law J, Lee C, Nathan S, Penack O, Pingali R, Prasad P, Pulanic D, Rotz S, Shreenivas A, Steinberg A, Tabbara K, Tichelli A, Wirk B, Yared J, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Valdés-Sanz N) Bone Marrow Transplant 2019 05;54(5):648-661       3 Citations
2Ocular Graft-versus-Host Disease after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and Transplant Complications Working Party of the European Society of Blood and Marrow Transplantation. (Inamoto Y, Valdés-Sanz N, Ogawa Y, Alves M, Berchicci L, Galvin J, Greinix H, Hale GA, Horn B, Kelly D, Liu H, Rowley S, Schoemans H, Shah A, Lupo Stanghellini MT, Agrawal V, Ahmed I, Ali A, Bhatt N, Byrne M, Chhabra S, DeFilipp Z, Fahnehjelm K, Farhadfar N, Horn E, Lee C, Nathan S, Penack O, Prasad P, Rotz S, Rovó A, Yared J, Pavletic S, Basak GW, Battiwalla M, Duarte R, Savani BN, Flowers MED, Shaw BE, Petriček I) Biol Blood Marrow Transplant 2019 02;25(2):e46-e54       4 Citations
1Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review. (Fløisand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zachée P, Taylor A, Akbari M, Quadri S, Parfionovas A, Chen YB) Biol Blood Marrow Transplant 2019 04;25(4):720-727       10 Citations
4Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. (Chhabra S, Ahn KW, Hu ZH, Jain S, Assal A, Cerny J, Copelan EA, Daly A, DeFilipp Z, Gadalla SM, Gale RP, Ganguly S, Hamilton BK, Hildebrandt GC, Hsu JW, Inamoto Y, Kanate AS, Khoury HJ, Lazarus HM, Litzow MR, Nathan S, Olsson RF, Pawarode A, Ringden O, Rowe JM, Saad A, Savani BN, Schouten HC, Seo S, Shah NN, Solh M, Stuart RK, Ustun C, Woolfrey AE, Yared JA, Alyea EP, Kalaycio ME, Popat U, Sobecks RM, Saber W) Blood Adv 2018 11 13;2(21):2922-2936       9 Citations
4Post-transplantation employment status of adult survivors of childhood allogeneic hematopoietic cell transplant: A report from the Center for International Blood and Marrow Transplant Research (CIBMTR). (Bhatt NS, Brazauskas R, Tecca HR, Carreras J, Burns LJ, Phelan R, Salit RB, Syrjala KL, Talano JM, Shaw BE) Cancer 2019 01 01;125(1):144-152       1 Citation
1Practice Patterns of Physician Treatment for Pediatric Chronic Myelogenous Leukemia. (Andolina JR, Burke MJ, Hijiya N, Chaudhury S, Schultz KR, Roth ME) Biol Blood Marrow Transplant 2019 02;25(2):321-327       1 Citation
1Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma. (Maffini E, Storer BE, Sandmaier BM, Bruno B, Sahebi F, Shizuru JA, Chauncey TR, Hari P, Lange T, Pulsipher MA, McSweeney PA, Holmberg L, Becker PS, Green DJ, Mielcarek M, Maloney DG, Storb R) Haematologica 2019 02;104(2):380-391       10 Citations
1Allogeneic Hematopoietic Cell Transplantation in Patients Aged 50Years or Older with Severe Aplastic Anemia. (Rice C, Eikema DJ, Marsh JCW, Knol C, Hebert K, Putter H, Peterson E, Deeg HJ, Halkes S, Pidala J, Anderlini P, Tischer J, Kroger N, McDonald A, Antin JH, Schaap NP, Hallek M, Einsele H, Mathews V, Kapoor N, Boelens JJ, Mufti GJ, Potter V, Pefault de la Tour R, Eapen M, Dufour C) Biol Blood Marrow Transplant 2019 03;25(3):488-495       7 Citations
4Outcomes of Measurable Residual Disease in Pediatric Acute Myeloid Leukemia before and after Hematopoietic Stem Cell Transplant: Validation of Difference from Normal Flow Cytometry with Chimerism Studies and Wilms Tumor 1 Gene Expression. (Jacobsohn DA, Loken MR, Fei M, Adams A, Brodersen LE, Logan BR, Ahn KW, Shaw BE, Kletzel M, Olszewski M, Khan S, Meshinchi S, Keating A, Harris A, Teira P, Duerst RE, Margossian SP, Martin PL, Petrovic A, Dvorak CC, Nemecek ER, Boyer MW, Chen AR, Davis JH, Shenoy S, Savasan S, Hudspeth MP, Adams RH, Lewis VA, Kheradpour A, Kasow KA, Gillio AP, Haight AE, Bhatia M, Bambach BJ, Haines HL, Quigg TC, Greiner RJ, Talano JM, Delgado DC, Cheerva A, Gowda M, Ahuja S, Ozkaynak M, Mitchell D, Schultz KR, Fry TJ, Loeb DM, Pulsipher MA) Biol Blood Marrow Transplant 2018 10;24(10):2040-2046       10 Citations
4Female Sex is Associated With Poor Health-related Quality of Life in Children at 12 Months Post-Hematopoietic Cell Transplantation. (Bhatt NS, Brazauskas R, Tecca HR, Vogel J, Mattila D, Lee SJ, Horowitz MM, Rizzo JD, Shaw BE) J Pediatr Hematol Oncol 2019 04;41(3):233-237       1 Citation
1The safety and efficacy of clofarabine in combination with high-dose cytarabine and total body irradiation myeloablative conditioning and allogeneic stem cell transplantation in children, adolescents, and young adults (CAYA) with poor-risk acute leukemia. (Hochberg J, Zahler S, Geyer MB, Chen N, Krajewski J, Harrison L, Militano O, Ozkaynak MF, Cheerva AC, Talano J, Moore TB, Gillio AP, Walters MC, Baxter-Lowe LA, Hamby C, Cairo MS) Bone Marrow Transplant 2019 02;54(2):226-235       3 Citations
1Patient-reported outcomes and health status associated with chronic graft-versus-host disease. (Lee SJ, Onstad L, Chow EJ, Shaw BE, Jim HSL, Syrjala KL, Baker KS, Buckley S, Flowers ME) Haematologica 2018 09;103(9):1535-1541       13 Citations
1Prevention of relapse after allogeneic hematopoietic cell transplantation by donor and cell source selection. (Fleischhauer K, Hsu KC, Shaw BE) Bone Marrow Transplant 2018 12;53(12):1498-1507       3 Citations
2Treosulfan, Fludarabine, and Low-Dose Total Body Irradiation for Children and Young Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Cell Transplantation: Prospective Phase II Trial of the Pediatric Blood and Marrow Transplant Consortium. (Nemecek ER, Hilger RA, Adams A, Shaw BE, Kiefer D, Le-Rademacher J, Levine JE, Yanik G, Leung W, Talano JA, Haut P, Delgado D, Kapoor N, Petrovic A, Adams R, Hanna R, Rangarajan H, Dalal J, Chewning J, Verneris MR, Epstein S, Burroughs L, Perez-Albuerne ED, Pulsipher MA, Delaney C) Biol Blood Marrow Transplant 2018 08;24(8):1651-1656       6 Citations
1Allogeneic Hematopoietic Cell Transplantation for Chronic Granulomatous Disease: Controversies and State of the Art. (Connelly JA, Marsh R, Parikh S, Talano JA) J Pediatric Infect Dis Soc 2018 May 09;7(suppl_1):S31-S39       11 Citations
1B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. (Miggelbrink AM, Logan BR, Buckley RH, Parrott RE, Dvorak CC, Kapoor N, Abdel-Azim H, Prockop SE, Shyr D, Decaluwe H, Hanson IC, Gillio A, Dávila Saldaña BJ, Eibel H, Hopkins G, Walter JE, Whangbo JS, Kohn DB, Puck JM, Cowan MJ, Griffith LM, Haddad E, O'Reilly RJ, Notarangelo LD, Pai SY) Blood 2018 06 28;131(26):2967-2977       11 Citations
5Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. (Shah NN, Ahn KW, Litovich C, Fenske TS, Ahmed S, Battiwalla M, Bejanyan N, Dahi PB, Bolaños-Meade J, Chen AI, Ciurea SO, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera AF, Haverkos BM, Holmberg L, Hossain NM, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D'Souza A, Savani BN, Ulrickson ML, Waller EK, Sureda A, Smith SM, Hamadani M) Blood Adv 2018 04 24;2(8):933-940       15 Citations
3Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. (Smith SM, Godfrey J, Ahn KW, DiGilio A, Ahmed S, Agrawal V, Bachanova V, Bacher U, Bashey A, Bolaños-Meade J, Cairo M, Chen A, Chhabra S, Copelan E, Dahi PB, Aljurf M, Farooq U, Ganguly S, Hertzberg M, Holmberg L, Inwards D, Kanate AS, Karmali R, Kenkre VP, Kharfan-Dabaja MA, Klein A, Lazarus HM, Mei M, Mussetti A, Nishihori T, Ramakrishnan Geethakumari P, Saad A, Savani BN, Schouten HC, Shah N, Urbano-Ispizua A, Vij R, Vose J, Sureda A, Hamadani M) Cancer 2018 06 15;124(12):2541-2551       16 Citations
1Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation. (Zhu Q, Yan L, Liu Q, Zhang C, Wei L, Hu Q, Preus L, Clay-Gilmour AI, Onel K, Stram DO, Pooler L, Sheng X, Haiman CA, Zhu X, Spellman SR, Pasquini M, McCarthy PL, Liu S, Hahn T, Sucheston-Campbell LE) Blood 2018 05 31;131(22):2490-2499       5 Citations
5Prevalence of self-reported sleep dysfunction before allogeneic hematopoietic cell transplantation. (D'Souza A, Millard H, Knight J, Brazauskas R, Lee SJ, Flynn KE, Rizzo JD, Shaw BE) Bone Marrow Transplant 2018 08;53(8):1079-1082       1 Citation
4Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. (Sureda A, Zhang MJ, Dreger P, Carreras J, Fenske T, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumedil A, Hamadani M, Pasquini MC) Cancer 2018 04 15;124(8):1733-1742       20 Citations
5Survival of Lymphoma Patients Experiencing Relapse or Progression after an Allogeneic Hematopoietic Cell Transplantation. (Epperla N, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, Fenske TS, Craig MD, Kanate AS, Bachanova V) Biol Blood Marrow Transplant 2018 05;24(5):983-988       4 Citations
2Pretransplant Consolidation Is Not Beneficial for Adults with ALL Undergoing Myeloablative Allogeneic Transplantation. (Bejanyan N, Zhang MJ, Wang HL, Lazaryan A, de Lima M, Marks DI, Sandmaier BM, Bachanova V, Rowe J, Tallman M, Kebriaei P, Kharfan-Dabaja M, Peter Gale R, Lazarus HM, Ustun C, Copelan E, Ky Hamilton B, Schiller G, Hogan W, Hashmi S, Seftel M, Kanakry CG, Olsson RF, Martino R, Saber W, Khoury HJ, Weisdorf DJ) Biol Blood Marrow Transplant 2018 05;24(5):945-955       2 Citations
1No association between donor telomere length and outcomes after allogeneic unrelated hematopoietic cell transplant in patients with acute leukemia. (Gadalla SM, Wang T, Loftus D, Friedman L, Dagnall C, Haagenson M, Spellman SR, Buturovic L, Blauwkamp M, Shelton J, Fleischhauer K, Hsu KC, Verneris MR, Krstajic D, Hicks B, Jones K, Lee SJ, Savage SA) Bone Marrow Transplant 2018 04;53(4):383-391       5 Citations
2Allogeneic Transplantation for Follicular Lymphoma: Does One Size Fit All? (Hamadani M, Horowitz MM) J Oncol Pract 2017 12;13(12):798-806       4 Citations
4Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. (Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske TS, Sureda A, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2018 01;24(1):78-85       2 Citations
2Haematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a North American multicentre collaborative study. (Kharfan-Dabaja MA, Al Malki MM, Deotare U, Raj RV, El-Jurdi N, Majhail N, Cherry MA, Bashir Q, Darrah J, Nishihori T, Sibai H, Hamadani M, de Lima M, Gerds AT, Selby G, Qazilbash MH, Forman SJ, Ayala E, Lipton JH, Hari PN, Muzzafar T, Zhang L, Olteanu H, Perkins J, Sokol L, Kumar A, Ahmed S) Br J Haematol 2017 12;179(5):781-789       27 Citations
2Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. (Stroncek DF, Shaw BE, Logan BR, Kiefer DM, Savani BN, Anderlini P, Bredeson CN, Hematti P, Ganguly S, Diaz MA, Abdel-Azim H, Ahmed I, Maharaj D, Seftel M, Beitinjaneh A, Seo S, Yared JA, Halter J, O'Donnell PV, Hale GA, DeFilipp Z, Lazarus H, Liesveld JL, Zhou Z, Munshi P, Olsson RF, Kasow KA, Szer J, Switzer GE, Chitphakdithai P, Shah N, Confer DL, Pulsipher MA) Biol Blood Marrow Transplant 2018 01;24(1):175-184       1 Citation
2Clinical risks and healthcare utilization of hematopoietic cell transplantation for sickle cell disease in the USA using merged databases. (Arnold SD, Brazauskas R, He N, Li Y, Aplenc R, Jin Z, Hall M, Atsuta Y, Dalal J, Hahn T, Khera N, Bonfim C, Majhail NS, Diaz MA, Freytes CO, Wood WA, Savani BN, Kamble RT, Parsons S, Ahmed I, Sullivan K, Beattie S, Dandoy C, Munker R, Marino S, Bitan M, Abdel-Azim H, Aljurf M, Olsson RF, Joshi S, Buchbinder D, Eckrich MJ, Hashmi S, Lazarus H, Marks DI, Steinberg A, Saad A, Gergis U, Krishnamurti L, Abraham A, Rangarajan HG, Walters M, Lipscomb J, Saber W, Satwani P) Haematologica 2017 11;102(11):1823-1832       19 Citations
5Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful. (Shaw BE, Brazauskas R, Millard HR, Fonstad R, Flynn KE, Abernethy A, Vogel J, Petroske C, Mattila D, Drexler R, Lee SJ, Horowitz MM, Rizzo JD) Cancer 2017 Dec 01;123(23):4687-4700       15 Citations
1The immune reconstitution of the skin following sex-mismatched allogeneic haematopoietic stem cell transplant: a prospective case series utilizing fluorescence in situ hybridization and immunohistochemistry. (Stewart CL, Cornejo CM, Wanat KA, Sander I, Samimi S, Prouty S, Seykora J, Zhang P, Rosenbach M, Kim EJ, Micheletti RG) Br J Dermatol 2018 01;178(1):e55-e56    
3Allogeneic haematopoietic cell transplantation for extranodal natural killer/T-cell lymphoma, nasal type: a CIBMTR analysis. (Kanate AS, DiGilio A, Ahn KW, Al Malki M, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, Fenske TS, Smith SM, Sureda A, Olteanu H, Hamadani M) Br J Haematol 2018 09;182(6):916-920       21 Citations
4Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. (Muffly L, Pasquini MC, Martens M, Brazauskas R, Zhu X, Adekola K, Aljurf M, Ballen KK, Bajel A, Baron F, Battiwalla M, Beitinjaneh A, Cahn JY, Carabasi M, Chen YB, Chhabra S, Ciurea S, Copelan E, D'Souza A, Edwards J, Foran J, Freytes CO, Fung HC, Gale RP, Giralt S, Hashmi SK, Hildebrandt GC, Ho V, Jakubowski A, Lazarus H, Luskin MR, Martino R, Maziarz R, McCarthy P, Nishihori T, Olin R, Olsson RF, Pawarode A, Peres E, Rezvani AR, Rizzieri D, Savani BN, Schouten HC, Sabloff M, Seftel M, Seo S, Sorror ML, Szer J, Wirk BM, Wood WA, Artz A) Blood 2017 08 31;130(9):1156-1164       83 Citations
3Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. (Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M) J Hematol Oncol 2017 06 12;10(1):117       11 Citations
2Current Use and Trends in Hematopoietic Cell Transplantation in the United States. (D'Souza A, Lee S, Zhu X, Pasquini M) Biol Blood Marrow Transplant 2017 Sep;23(9):1417-1421       90 Citations
2Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. (Burroughs LM, Shimamura A, Talano JA, Domm JA, Baker KK, Delaney C, Frangoul H, Margolis DA, Baker KS, Nemecek ER, Geddis AE, Sandmaier BM, Deeg HJ, Storb R, Woolfrey AE) Biol Blood Marrow Transplant 2017 Oct;23(10):1669-1677       23 Citations
3Personalized Prognostic Risk Score for Long-Term Survival for Children with Acute Leukemia after Allogeneic Transplantation. (Bitan M, Ahn KW, Millard HR, Pulsipher MA, Abdel-Azim H, Auletta JJ, Brown V, Chan KW, Diaz MA, Dietz A, Vincent MG, Guilcher G, Hale GA, Hayashi RJ, Keating A, Mehta P, Myers K, Page K, Prestidge T, Shah NN, Smith AR, Woolfrey A, Thiel E, Davies SM, Eapen M) Biol Blood Marrow Transplant 2017 Sep;23(9):1523-1530       7 Citations
1Tools for the Precision Medicine Era: How to Develop Highly Personalized Treatment Recommendations From Cohort and Registry Data Using Q-Learning. (Krakow EF, Hemmer M, Wang T, Logan B, Arora M, Spellman S, Couriel D, Alousi A, Pidala J, Last M, Lachance S, Moodie EEM) Am J Epidemiol 2017 07 15;186(2):160-172       7 Citations
3PD-1 blockade for relapsed lymphoma post-allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. (Haverkos BM, Abbott D, Hamadani M, Armand P, Flowers ME, Merryman R, Kamdar M, Kanate AS, Saad A, Mehta A, Ganguly S, Fenske TS, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM) Blood 2017 07 13;130(2):221-228       119 Citations
2Comparing outcomes of matched related donor and matched unrelated donor hematopoietic cell transplants in adults with B-Cell acute lymphoblastic leukemia. (Segal E, Martens M, Wang HL, Brazauskas R, Weisdorf D, Sandmaier BM, Khoury HJ, de Lima M, Saber W) Cancer 2017 Sep 01;123(17):3346-3355       8 Citations
4Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. (Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME) J Clin Oncol 2017 Apr 10;35(11):1154-1161       216 Citations
1Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas? (Kharfan-Dabaja MA, El-Jurdi N, Ayala E, Kanate AS, Savani BN, Hamadani M) Bone Marrow Transplant 2017 Nov;52(11):1487-1494       7 Citations
1Improved survival after acute graft-versus-host disease diagnosis in the modern era. (Khoury HJ, Wang T, Hemmer MT, Couriel D, Alousi A, Cutler C, Aljurf M, Antin JH, Ayas M, Battiwalla M, Cahn JY, Cairo M, Chen YB, Gale RP, Hashmi S, Hayashi RJ, Jagasia M, Juckett M, Kamble RT, Kharfan-Dabaja M, Litzow M, Majhail N, Miller A, Nishihori T, Qayed M, Schoemans H, Schouten HC, Socie G, Storek J, Verdonck L, Vij R, Wood WA, Yu L, Martino R, Carabasi M, Dandoy C, Gergis U, Hematti P, Solh M, Jamani K, Lehmann L, Savani B, Schultz KR, Wirk BM, Spellman S, Arora M, Pidala J) Haematologica 2017 05;102(5):958-966       26 Citations
1Investigating the Association of Genetic Admixture and Donor/Recipient Genetic Disparity with Transplant Outcomes. (Madbouly A, Wang T, Haagenson M, Paunic V, Vierra-Green C, Fleischhauer K, Hsu KC, Verneris MR, Majhail NS, Lee SJ, Spellman SR, Maiers M) Biol Blood Marrow Transplant 2017 Jun;23(6):1029-1037       3 Citations
1Healthcare Costs and Utilization for Patients Age 50 to 64 Years with Acute Myeloid Leukemia Treated with Chemotherapy or with Chemotherapy and Allogeneic Hematopoietic Cell Transplantation. (Preussler JM, Meyer CL, Mau LW, Majhail NS, Denzen EM, Edsall KC, Farnia SH, Saber W, Burns LJ, Vanness DJ) Biol Blood Marrow Transplant 2017 Jun;23(6):1021-1028       12 Citations
2Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. (Lindsley RC, Saber W, Mar BG, Redd R, Wang T, Haagenson MD, Grauman PV, Hu ZH, Spellman SR, Lee SJ, Verneris MR, Hsu K, Fleischhauer K, Cutler C, Antin JH, Neuberg D, Ebert BL) N Engl J Med 2017 02 09;376(6):536-547       232 Citations
4Allogeneic Hematopoietic Cell Transplantation for Aggressive NK Cell Leukemia. A Center for International Blood and Marrow Transplant Research Analysis. (Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee JW, Ayala E, Chao N, Hari P, Bolaños-Meade J, Gress R, Smedegaard Anderson N, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, Fenske TS, Olteanu H) Biol Blood Marrow Transplant 2017 May;23(5):853-856       13 Citations
2Cytogenetic risk determines outcomes after allogeneic transplantation in older patients with acute myeloid leukemia in their second complete remission: A Center for International Blood and Marrow Transplant Research cohort analysis. (Michelis FV, Gupta V, Zhang MJ, Wang HL, Aljurf M, Bacher U, Beitinjaneh A, Chen YB, DeFilipp Z, Gale RP, Kebriaei P, Kharfan-Dabaja M, Lazarus HM, Nishihori T, Olsson RF, Oran B, Rashidi A, Rizzieri DA, Tallman MS, de Lima M, Khoury HJ, Sandmaier BM, Weisdorf D, Saber W, Acute Leukemia Working Committee of the Center for International Blood and Marrow Transplant Research, aresearch collaboration between the National Marrow Donor Program/Be the Match Registry and theMedicalCollegeofWisconsin) Cancer 2017 06 01;123(11):2035-2042       7 Citations
3Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. (Liu HD, Ahn KW, Hu ZH, Hamadani M, Nishihori T, Wirk B, Beitinjaneh A, Rizzieri D, Grunwald MR, Sabloff M, Olsson RF, Bajel A, Bredeson C, Daly A, Inamoto Y, Majhail N, Saad A, Gupta V, Gerds A, Malone A, Tallman M, Reshef R, Marks DI, Copelan E, Gergis U, Savoie ML, Ustun C, Litzow MR, Cahn JY, Kindwall-Keller T, Akpek G, Savani BN, Aljurf M, Rowe JM, Wiernik PH, Hsu JW, Cortes J, Kalaycio M, Maziarz R, Sobecks R, Popat U, Alyea E, Saber W) Biol Blood Marrow Transplant 2017 May;23(5):767-775       21 Citations
4Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission. (Weisdorf DJ, Millard HR, Horowitz MM, Hyare PS, Champlin R, Ho V, Mielcarek M, Rezvani A, Stockerl-Goldstein K, Khoury HJ, De Lima M, Saber W, Sandmaier B, Zhang MJ, Eapen M) Cancer 2017 06 01;123(11):2025-2034       21 Citations
4Impact of pre-transplant depression on outcomes of allogeneic and autologous hematopoietic stem cell transplantation. (El-Jawahri A, Chen YB, Brazauskas R, He N, Lee SJ, Knight JM, Majhail N, Buchbinder D, Schears RM, Wirk BM, Wood WA, Ahmed I, Aljurf M, Szer J, Beattie SM, Battiwalla M, Dandoy C, Diaz MA, D'Souza A, Freytes CO, Gajewski J, Gergis U, Hashmi SK, Jakubowski A, Kamble RT, Kindwall-Keller T, Lazarus HM, Malone AK, Marks DI, Meehan K, Savani BN, Olsson RF, Rizzieri D, Steinberg A, Speckhart D, Szwajcer D, Schoemans H, Seo S, Ustun C, Atsuta Y, Dalal J, Sales-Bonfim C, Khera N, Hahn T, Saber W) Cancer 2017 05 15;123(10):1828-1838       27 Citations
1Allogeneic hematopoietic stem cell transplantation for MDS and CMML: recommendations from an international expert panel. (de Witte T, Bowen D, Robin M, Malcovati L, Niederwieser D, Yakoub-Agha I, Mufti GJ, Fenaux P, Sanz G, Martino R, Alessandrino EP, Onida F, Symeonidis A, Passweg J, Kobbe G, Ganser A, Platzbecker U, Finke J, van Gelder M, van de Loosdrecht AA, Ljungman P, Stauder R, Volin L, Deeg HJ, Cutler C, Saber W, Champlin R, Giralt S, Anasetti C, Kröger N) Blood 2017 03 30;129(13):1753-1762       95 Citations
1CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation. (Locke FL, Pidala J, Storer B, Martin PJ, Pulsipher MA, Chauncey TR, Jacobsen N, Kröger N, Walker I, Light S, Shaw BE, Beato F, Laport GG, Nademanee A, Keating A, Socie G, Anasetti C) Biol Blood Marrow Transplant 2017 Mar;23(3):405-411       3 Citations
1Effect of Pretransplant Continuous-Flow Left Ventricular Assist Devices on Cellular and Antibody-Mediated Rejection and Subsequent Allograft Outcomes. (Nestorovic EM, Grupper A, Joyce LD, Milic NM, Stulak JM, Edwards BS, Pereira NL, Daly RC, Kushwaha SS) Am J Cardiol 2017 Feb 01;119(3):452-456       3 Citations
1Risk factors and epidemiology of Clostridium difficile infection in hematopoietic stem cell transplant recipients during the peritransplant period. (Aldrete SD, Kraft CS, Magee MJ, Chan A, Hutcherson D, Langston AA, Greenwell BI, Burd EM, Friedman-Moraco R) Transpl Infect Dis 2017 Feb;19(1)       5 Citations
1Cancer and treatment distress psychometric evaluation over time: A BMT CTN 0902 secondary analysis. (Syrjala KL, Sutton SK, Jim HS, Knight JM, Wood WA, Lee SJ, Jacobsen PB, Abidi MH, Yi JC) Cancer 2017 Apr 15;123(8):1416-1423       11 Citations
1Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post-allogeneic HCT. (Abu Zaid M, Wu J, Wu C, Logan BR, Yu J, Cutler C, Antin JH, Paczesny S, Choi SW) Blood 2017 01 12;129(2):162-170       35 Citations
3The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes. (Artz AS, Logan B, Zhu X, Akpek G, Bufarull RM, Gupta V, Lazarus HM, Litzow M, Loren A, Majhail NS, Maziarz RT, McCarthy P, Popat U, Saber W, Spellman S, Ringden O, Wickrema A, Pasquini MC, Cooke KR, from the Center for International Blood and Marrow Transplantation Research) Haematologica 2016 11;101(11):1426-1433       31 Citations
4Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. (Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P) Biol Blood Marrow Transplant 2017 01;23(1):60-66       11 Citations
1Replication of associations between genetic polymorphisms and chronic graft-versus-host disease. (Martin PJ, Fan W, Storer BE, Levine DM, Zhao LP, Warren EH, Flowers ME, Lee SJ, Carpenter PA, Boeckh M, Hingorani S, Yan L, Hu Q, Preus L, Liu S, Spellman S, Zhu X, Pasquini M, McCarthy P, Stram D, Sheng X, Pooler L, Haiman CA, Sucheston-Campbell L, Hahn T, Hansen JA) Blood 2016 11 17;128(20):2450-2456       15 Citations
1Recipient HLA-C Haplotypes and microRNA 148a/b Binding Sites Have No Impact on Allogeneic Hematopoietic Cell Transplantation Outcomes. (Hoff GA, Fischer JC, Hsu K, Cooley S, Miller JS, Wang T, Haagenson M, Spellman S, Lee SJ, Uhrberg M, Venstrom JM, Verneris MR) Biol Blood Marrow Transplant 2017 01;23(1):153-160       8 Citations
1Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. (Kharfan-Dabaja MA, Kumar A, Hamadani M, Stilgenbauer S, Ghia P, Anasetti C, Dreger P, Montserrat E, Perales MA, Alyea EP, Awan FT, Ayala E, Barrientos JC, Brown JR, Castro JE, Furman RR, Gribben J, Hill BT, Mohty M, Moreno C, O'Brien S, Pavletic SZ, Pinilla-Ibarz J, Reddy NM, Sorror M, Bredeson C, Carpenter P, Savani BN) Biol Blood Marrow Transplant 2016 12;22(12):2117-2125       42 Citations
3Comparable outcomes with marrow or peripheral blood as stem cell sources for hematopoietic cell transplantation from haploidentical donors after non-ablative conditioning: a matched-pair analysis. (O'Donnell PV, Eapen M, Horowitz MM, Logan BR, DiGilio A, Brunstein C, Fuchs EJ, Flowers ME, Salit R, Raj K, Pagliuca A, Bradstock K, Granata A, Castagna L, Furst S, Blaise D) Bone Marrow Transplant 2016 12;51(12):1599-1601       27 Citations
1Reduced-intensity or myeloablative allogeneic hematopoietic cell transplantation for mantle cell lymphoma: a systematic review. (Kharfan-Dabaja MA, Reljic T, El-Asmar J, Nishihori T, Ayala E, Hamadani M, Kumar A) Future Oncol 2016 Nov;12(22):2631-2642       7 Citations
3Donor and recipient sex in allogeneic stem cell transplantation: what really matters. (Kim HT, Zhang MJ, Woolfrey AE, St Martin A, Chen J, Saber W, Perales MA, Armand P, Eapen M) Haematologica 2016 10;101(10):1260-1266       19 Citations
3Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study. (D'Souza A, Pasquini M, Logan B, Giralt S, Krishnan A, Antin J, Howard A, Goodman S, Qazilbash M, Knust K, Sahebi F, Weisdorf D, Vesole D, Stadtmauer E, Maloney D, Hari P) Br J Haematol 2017 09;178(5):816-819       2 Citations
1Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. (Qin YZ, Wang Y, Zhu HH, Gale RP, Zhang MJ, Jiang Q, Jiang H, Xu LP, Chen H, Zhang XH, Liu YR, Lai YY, Jiang B, Liu KY, Huang XJ) Chin J Cancer 2016 May 19;35:46       10 Citations
2Metabolic Syndrome and Cardiovascular Disease after Hematopoietic Cell Transplantation: Screening and Preventive Practice Recommendations from the CIBMTR and EBMT. (DeFilipp Z, Duarte RF, Snowden JA, Majhail NS, Greenfield DM, Miranda JL, Arat M, Baker KS, Burns LJ, Duncan CN, Gilleece M, Hale GA, Hamadani M, Hamilton BK, Hogan WJ, Hsu JW, Inamoto Y, Kamble RT, Lupo-Stanghellini MT, Malone AK, McCarthy P, Mohty M, Norkin M, Paplham P, Ramanathan M, Richart JM, Salooja N, Schouten HC, Schoemans H, Seber A, Steinberg A, Wirk BM, Wood WA, Battiwalla M, Flowers MED, Savani BN, Shaw BE, CIBMTR Late Effects and Quality of Life Working Committee, EBMT Complications and Quality of Life Working Party) Biol Blood Marrow Transplant 2016 08;22(8):1493-1503       31 Citations
9Allogeneic Hematopoietic Cell Transplantation in Multiple Myeloma: Impact of Disease Risk and Post Allograft Minimal Residual Disease on Survival. (Dhakal B, D'Souza A, Martens M, Kapke J, Harrington AM, Pasquini M, Saber W, Drobyski WR, Zhang MJ, Hamadani M, Hari PN) Clin Lymphoma Myeloma Leuk 2016 07;16(7):379-86       8 Citations
1Intravenous Busulfan-Based Myeloablative Conditioning Regimens Prior to Hematopoietic Cell Transplantation for Hematologic Malignancies. (Pasquini MC, Le-Rademacher J, Zhu X, Artz A, DiPersio J, Fernandez HF, Mineishi S, Kamishohara M, Mehta J, Nakamura Y, Ratanatharathorn V, Sobecks R, Burkart J, Bredeson C) Biol Blood Marrow Transplant 2016 08;22(8):1424-1430       11 Citations
1Vascularization is delayed in long nerve constructs compared with nerve grafts. (Farber SJ, Hoben GM, Hunter DA, Yan Y, Johnson PJ, Mackinnon SE, Wood MD) Muscle Nerve 2016 08;54(2):319-21       9 Citations
1Impact of intravenous magnesium infusion rate during ambulatory replacements on serum magnesium concentrations after allogeneic stem cell transplant. (Snyder M, Shillingburg A, Newton M, Hamadani M, Kanate AS, Craig M, Cumpston A) Support Care Cancer 2016 10;24(10):4237-40       3 Citations
1Safety of Living Donation of Hematopoietic Stem Cells. (Szer J, Elmoazzen H, Fechter M, Hwang W, Korhonen M, Miller J, Mengling T, Shaw B, Stein J) Transplantation 2016 06;100(6):1329-31       4 Citations
1Consensus Opinion on Allogeneic Hematopoietic Cell Transplantation in Advanced Systemic Mastocytosis. (Ustun C, Gotlib J, Popat U, Artz A, Litzow M, Reiter A, Nakamura R, Kluin-Nelemans HC, Verstovsek S, Gajewski J, Perales MA, George T, Shore T, Sperr W, Saber W, Kota V, Yavuz AS, Pullarkat V, Rogosheske J, Hogan W, Van Besien K, Hagglund H, Damaj G, Arock M, Horny HP, Metcalfe DD, Deeg HJ, Devine S, Weisdorf D, Akin C, Valent P) Biol Blood Marrow Transplant 2016 08;22(8):1348-1356       36 Citations
2Allogeneic Hematopoietic Cell Transplantation as Curative Therapy for Patients with Non-Hodgkin Lymphoma: Increasingly Successful Application to Older Patients. (Fenske TS, Hamadani M, Cohen JB, Costa LJ, Kahl BS, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E, Bredeson C) Biol Blood Marrow Transplant 2016 09;22(9):1543-1551       22 Citations
3Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network. (Laport GG, Wu J, Logan B, Bachanova V, Hosing C, Fenske T, Longo W, Devine SM, Nademanee A, Gersten I, Horowitz M, Lazarus HM, Riches ML, Blood and Marrow Transplant Clinical Trials Network) Biol Blood Marrow Transplant 2016 08;22(8):1440-1448       24 Citations
1Financial impact of allogeneic hematopoietic cell transplantation on patients and families over 2 years: results from a multicenter pilot study. (Denzen EM, Thao V, Hahn T, Lee SJ, McCarthy PL, Rizzo JD, Ammi M, Drexler R, Flesch S, James H, Omondi N, Murphy E, Pederson K, Majhail NS) Bone Marrow Transplant 2016 Sep;51(9):1233-40       11 Citations
1Prognostic impact of IKZF1 deletion in adults with common B-cell acute lymphoblastic leukemia. (Yao QM, Liu KY, Gale RP, Jiang B, Liu YR, Jiang Q, Jiang H, Zhang XH, Zhang MJ, Chen SS, Huang XJ, Xu LP, Ruan GR) BMC Cancer 2016 Apr 11;16:269       19 Citations
2Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. (Shaffer BC, Ahn KW, Hu ZH, Nishihori T, Malone AK, Valcárcel D, Grunwald MR, Bacher U, Hamilton B, Kharfan-Dabaja MA, Saad A, Cutler C, Warlick E, Reshef R, Wirk BM, Sabloff M, Fasan O, Gerds A, Marks D, Olsson R, Wood WA, Costa LJ, Miller AM, Cortes J, Daly A, Kindwall-Keller TL, Kamble R, Rizzieri DA, Cahn JY, Gale RP, William B, Litzow M, Wiernik PH, Liesveld J, Savani BN, Vij R, Ustun C, Copelan E, Popat U, Kalaycio M, Maziarz R, Alyea E, Sobecks R, Pavletic S, Tallman M, Saber W) J Clin Oncol 2016 06 01;34(16):1864-71       37 Citations
1Advances in understanding the pathogenesis of graft-versus-host disease. (Magenau J, Runaas L, Reddy P) Br J Haematol 2016 Apr;173(2):190-205       36 Citations
5Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. (Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M) Br J Haematol 2016 07;174(2):235-48       58 Citations
1Inadvertent completely HLA-mismatched allogeneic unrelated bone marrow transplant: lessons learned. (Sorensen BS, Szer J, Shaw B, Korhonen M, Mengling T, Fechter M, Elmoazzen H, Lindberg B, Chapman J, Nørgaard JM, Foeken L, Hwang WY, Nielsen B) Bone Marrow Transplant 2016 07;51(7):1016-8       7 Citations
1Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. (Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA) Immunotherapy 2016;8(4):435-47       7 Citations
3Outcomes of Allogeneic Hematopoietic Cell Transplantation in Children and Young Adults with Chronic Myeloid Leukemia: A CIBMTR Cohort Analysis. (Chaudhury S, Sparapani R, Hu ZH, Nishihori T, Abdel-Azim H, Malone A, Olsson R, Hamadani M, Daly A, Bacher U, Wirk BM, Kamble RT, Gale RP, Wood WA, Hale G, Wiernik PH, Hashmi SK, Marks D, Ustun C, Munker R, Savani BN, Alyea E, Popat U, Sobecks R, Kalaycio M, Maziarz R, Hijiya N, Saber W) Biol Blood Marrow Transplant 2016 06;22(6):1056-1064       11 Citations
2Allogeneic Hematopoietic Cell Transplantation for Patients with Mixed Phenotype Acute Leukemia. (Munker R, Brazauskas R, Wang HL, de Lima M, Khoury HJ, Gale RP, Maziarz RT, Sandmaier BM, Weisdorf D, Saber W, Center for International Blood and Marrow Transplant Research) Biol Blood Marrow Transplant 2016 06;22(6):1024-1029       24 Citations
2Hematopoietic stem cell transplantation activity worldwide in 2012 and a SWOT analysis of the Worldwide Network for Blood and Marrow Transplantation Group including the global survey. (Niederwieser D, Baldomero H, Szer J, Gratwohl M, Aljurf M, Atsuta Y, Bouzas LF, Confer D, Greinix H, Horowitz M, Iida M, Lipton J, Mohty M, Novitzky N, Nunez J, Passweg J, Pasquini MC, Kodera Y, Apperley J, Seber A, Gratwohl A) Bone Marrow Transplant 2016 Jun;51(6):778-85       146 Citations
2Reduced intensity haplo plus single cord transplant compared to double cord transplant: improved engraftment and graft-versus-host disease-free, relapse-free survival. (van Besien K, Hari P, Zhang MJ, Liu HT, Stock W, Godley L, Odenike O, Larson R, Bishop M, Wickrema A, Gergis U, Mayer S, Shore T, Tsai S, Rhodes J, Cushing MM, Korman S, Artz A) Haematologica 2016 05;101(5):634-43       25 Citations
3Graft-versus-Host Disease after HLA-Matched Sibling Bone Marrow or Peripheral Blood Stem Cell Transplantation: Comparison of North American Caucasian and Japanese Populations. (Kanda J, Brazauskas R, Hu ZH, Kuwatsuka Y, Nagafuji K, Kanamori H, Kanda Y, Miyamura K, Murata M, Fukuda T, Sakamaki H, Kimura F, Seo S, Aljurf M, Yoshimi A, Milone G, Wood WA, Ustun C, Hashimi S, Pasquini M, Bonfim C, Dalal J, Hahn T, Atsuta Y, Saber W) Biol Blood Marrow Transplant 2016 Apr;22(4):744-751       24 Citations
2Global Use of Peripheral Blood vs Bone Marrow as Source of Stem Cells for Allogeneic Transplantation in Patients With Bone Marrow Failure. (Yoshimi A, Baldomero H, Horowitz M, Szer J, Niederwieser D, Gratwohl A, Kodera Y, Worldwide Network of Blood and Marrow Transplantation (WBMT)) JAMA 2016 Jan 12;315(2):198-200       12 Citations
3Pediatric-inspired therapy compared to allografting for Philadelphia chromosome-negative adult ALL in first complete remission. (Seftel MD, Neuberg D, Zhang MJ, Wang HL, Ballen KK, Bergeron J, Couban S, Freytes CO, Hamadani M, Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Paulson K, Saber W, Sallan SE, Soiffer R, Tallman MS, Woolfrey AE, DeAngelo DJ, Weisdorf DJ, Acute Leukemia Committee of the CIBMTR and the Dana Farber ALL Consortium) Am J Hematol 2016 Mar;91(3):322-9       36 Citations
1Polymorphism in TGFB1 is associated with worse non-relapse mortality and overall survival after stem cell transplantation with unrelated donors. (Arrieta-Bolaños E, Mayor NP, Marsh SG, Madrigal JA, Apperley JF, Kirkland K, Mackinnon S, Marks DI, McQuaker G, Perry J, Potter MN, Russell NH, Thomson K, Shaw BE) Haematologica 2016 Mar;101(3):382-90       3 Citations
1Phase II Study of Allogeneic Transplantation for Older Patients With Acute Myeloid Leukemia in First Complete Remission Using a Reduced-Intensity Conditioning Regimen: Results From Cancer and Leukemia Group B 100103 (Alliance for Clinical Trials in Oncology)/Blood and Marrow Transplant Clinical Trial Network 0502. (Devine SM, Owzar K, Blum W, Mulkey F, Stone RM, Hsu JW, Champlin RE, Chen YB, Vij R, Slack J, Soiffer RJ, Larson RA, Shea TC, Hars V, Sibley AB, Giralt S, Carter S, Horowitz MM, Linker C, Alyea EP) J Clin Oncol 2015 Dec 10;33(35):4167-75       79 Citations
3Patient-reported physical functioning predicts the success of hematopoietic cell transplantation (BMT CTN 0902). (Wood WA, Le-Rademacher J, Syrjala KL, Jim H, Jacobsen PB, Knight JM, Abidi MH, Wingard JR, Majhail NS, Geller NL, Rizzo JD, Fei M, Wu J, Horowitz MM, Lee SJ) Cancer 2016 Jan 01;122(1):91-8       27 Citations
2American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. (Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E) Biol Blood Marrow Transplant 2015 Dec;21(12):2039-2051       95 Citations
1Inhibitory effects of merocyanine 540-mediated photodynamic therapy on cellular immune functions: A role in the prophylaxis of graft-versus-host disease? (Traul DL, Sieber F) J Photochem Photobiol B 2015 Dec;153:153-63       7 Citations
2Hematopoietic Cell Transplantation as Curative Therapy for Patients with Myelofibrosis: Long-Term Success in all Age Groups. (Deeg HJ, Bredeson C, Farnia S, Ballen K, Gupta V, Mesa RA, Popat U, Hari P, Saber W, Seftel M, Tamari R, Petersdorf EW) Biol Blood Marrow Transplant 2015 Nov;21(11):1883-7       20 Citations
1Curative treatment for severe sickle cell disease: allogeneic transplantation. (Oshrine B, Talano JA) Clin Adv Hematol Oncol 2015 Apr;13(4):249-56       2 Citations
3Transplant Outcomes for Children with T Cell Acute Lymphoblastic Leukemia in Second Remission: A Report from the Center for International Blood and Marrow Transplant Research. (Burke MJ, Verneris MR, Le Rademacher J, He W, Abdel-Azim H, Abraham AA, Auletta JJ, Ayas M, Brown VI, Cairo MS, Chan KW, Diaz Perez MA, Dvorak CC, Egeler RM, Eldjerou L, Frangoul H, Guilcher GMT, Hayashi RJ, Ibrahim A, Kasow KA, Leung WH, Olsson RF, Pulsipher MA, Shah N, Shah NN, Thiel E, Talano JA, Kitko CL) Biol Blood Marrow Transplant 2015 Dec;21(12):2154-2159       13 Citations
2In Vivo T Cell Depletion with Myeloablative Regimens on Outcomes after Cord Blood Transplantation for Acute Lymphoblastic Leukemia in Children. (Ponce DM, Eapen M, Sparapani R, O'Brien TA, Chan KW, Chen J, Craddock J, Schultz KR, Wagner JE, Perales MA, Barker JN) Biol Blood Marrow Transplant 2015 Dec;21(12):2173-2179       17 Citations
1Indications for Autologous and Allogeneic Hematopoietic Cell Transplantation: Guidelines from the American Society for Blood and Marrow Transplantation. (Majhail NS, Farnia SH, Carpenter PA, Champlin RE, Crawford S, Marks DI, Omel JL, Orchard PJ, Palmer J, Saber W, Savani BN, Veys PA, Bredeson CN, Giralt SA, LeMaistre CF) Biol Blood Marrow Transplant 2015 Nov;21(11):1863-1869       173 Citations
4Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. (Klyuchnikov E, Bacher U, Kröger NM, Hari PN, Ahn KW, Carreras J, Bachanova V, Bashey A, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Hertzberg MS, Holmberg LA, Kharfan-Dabaja MA, Klein A, Ku GH, Laport GG, Lazarus HM, Miller AM, Mussetti A, Olsson RF, Slavin S, Usmani SZ, Vij R, Wood WA, Maloney DG, Sureda AM, Smith SM, Hamadani M) Biol Blood Marrow Transplant 2015 Dec;21(12):2091-2099       36 Citations
1Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. (Vaughn JE, Sorror ML, Storer BE, Chauncey TR, Pulsipher MA, Maziarz RT, Maris MB, Hari P, Laport GG, Franke GN, Agura ED, Langston AA, Rezvani AR, Storb R, Sandmaier BM, Maloney DG) Cancer 2015 Oct 15;121(20):3709-16       22 Citations
1Allogeneic hematopoietic cell transplantation after failed autologous transplant for lymphoma using TLI and anti-thymocyte globulin conditioning. (Rezvani AR, Kanate AS, Efron B, Chhabra S, Kohrt HE, Shizuru JA, Laport GG, Miklos DB, Benjamin JE, Johnston LJ, Arai S, Weng WK, Negrin RS, Strober S, Lowsky R) Bone Marrow Transplant 2015 Oct;50(10):1286-92       4 Citations
2CYP2C19*17 genetic polymorphism--an uncommon cause of voriconazole treatment failure. (Abidi MZ, D'Souza A, Kuppalli K, Ledeboer N, Hari P) Diagn Microbiol Infect Dis 2015 Sep;83(1):46-8       7 Citations
3Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia. (Mehta PA, Zhang MJ, Eapen M, He W, Seber A, Gibson B, Camitta BM, Kitko CL, Dvorak CC, Nemecek ER, Frangoul HA, Abdel-Azim H, Kasow KA, Lehmann L, Gonzalez Vicent M, Diaz Pérez MA, Ayas M, Qayed M, Carpenter PA, Jodele S, Lund TC, Leung WH, Davies SM) Biol Blood Marrow Transplant 2015 Jul;21(7):1273-7       13 Citations
4Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. (Sorror ML, Logan BR, Zhu X, Rizzo JD, Cooke KR, McCarthy PL, Ho VT, Horowitz MM, Pasquini MC) Biol Blood Marrow Transplant 2015 Aug;21(8):1479-87       80 Citations
2The Sequence of Cyclophosphamide and Myeloablative Total Body Irradiation in Hematopoietic Cell Transplantation for Patients with Acute Leukemia. (Holter-Chakrabarty JL, Pierson N, Zhang MJ, Zhu X, Akpek G, Aljurf MD, Artz AS, Baron F, Bredeson CN, Dvorak CC, Epstein RB, Lazarus HM, Olsson RF, Selby GB, Williams KM, Cooke KR, Pasquini MC, McCarthy PL) Biol Blood Marrow Transplant 2015 Jul;21(7):1251-7       6 Citations
1Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. (Veys PA, Nanduri V, Baker KS, He W, Bandini G, Biondi A, Dalissier A, Davis JH, Eames GM, Egeler RM, Filipovich AH, Fischer A, Jürgens H, Krance R, Lanino E, Leung WH, Matthes S, Michel G, Orchard PJ, Pieczonka A, Ringdén O, Schlegel PG, Sirvent A, Vettenranta K, Eapen M) Br J Haematol 2015 Jun;169(5):711-8       26 Citations
2Primary graft failure after myeloablative allogeneic hematopoietic cell transplantation for hematologic malignancies. (Olsson RF, Logan BR, Chaudhury S, Zhu X, Akpek G, Bolwell BJ, Bredeson CN, Dvorak CC, Gupta V, Ho VT, Lazarus HM, Marks DI, Ringdén OT, Pasquini MC, Schriber JR, Cooke KR) Leukemia 2015 Aug;29(8):1754-62       48 Citations
2Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. (Shah N, Callander N, Ganguly S, Gul Z, Hamadani M, Costa L, Sengsayadeth S, Abidi M, Hari P, Mohty M, Chen YB, Koreth J, Landau H, Lazarus H, Leather H, Majhail N, Nath R, Osman K, Perales MA, Schriber J, Shaughnessy P, Vesole D, Vij R, Wingard J, Giralt S, Savani BN, American Society for Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2015 Jul;21(7):1155-66       67 Citations
1Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime? (Sucheston-Campbell LE, Clay A, McCarthy PL, Zhu Q, Preus L, Pasquini M, Onel K, Hahn T) Curr Hematol Malig Rep 2015 Mar;10(1):45-58       10 Citations
1Smoothing the crescent curve: sickle cell disease. (Talano JA, Cairo MS) Hematology Am Soc Hematol Educ Program 2014 Dec 05;2014(1):468-74       2 Citations
1Predictive value of bronchiolitis obliterans syndrome stage 0p in chronic graft-versus-host disease of the lung. (Abedin S, Yanik GA, Braun T, Pawarode A, Magenau J, Goldstein SC, Levine JE, Kitko CL, Couriel DR) Biol Blood Marrow Transplant 2015 Jun;21(6):1127-31       22 Citations
1Association between donor leukocyte telomere length and survival after unrelated allogeneic hematopoietic cell transplantation for severe aplastic anemia. (Gadalla SM, Wang T, Haagenson M, Spellman SR, Lee SJ, Williams KM, Wong JY, De Vivo I, Savage SA) JAMA 2015 Feb 10;313(6):594-602       43 Citations
1Use of allogeneic stem cell transplantation for moderate-severe Glanzmann thrombasthenia. (Walz A, Lenzen A, Curtis B, Canner J, Schneiderman J) Platelets 2015;26(7):702-4       1 Citation
1Toll-like receptor polymorphisms in allogeneic hematopoietic cell transplantation. (Kornblit B, Enevold C, Wang T, Spellman S, Haagenson M, Lee SJ, Müller K) Biol Blood Marrow Transplant 2015 Feb;21(2):259-65       2 Citations
4Increasing incidence of chronic graft-versus-host disease in allogeneic transplantation: a report from the Center for International Blood and Marrow Transplant Research. (Arai S, Arora M, Wang T, Spellman SR, He W, Couriel DR, Urbano-Ispizua A, Cutler CS, Bacigalupo AA, Battiwalla M, Flowers ME, Juckett MB, Lee SJ, Loren AW, Klumpp TR, Prockup SE, Ringdén OT, Savani BN, Socié G, Schultz KR, Spitzer T, Teshima T, Bredeson CN, Jacobsohn DA, Hayashi RJ, Drobyski WR, Frangoul HA, Akpek G, Ho VT, Lewis VA, Gale RP, Koreth J, Chao NJ, Aljurf MD, Cooper BW, Laughlin MJ, Hsu JW, Hematti P, Verdonck LF, Solh MM, Norkin M, Reddy V, Martino R, Gadalla S, Goldberg JD, McCarthy PL, Pérez-Simón JA, Khera N, Lewis ID, Atsuta Y, Olsson RF, Saber W, Waller EK, Blaise D, Pidala JA, Martin PJ, Satwani P, Bornhäuser M, Inamoto Y, Weisdorf DJ, Horowitz MM, Pavletic SZ, Graft-vs-Host Disease Working Committee of the CIBMTR) Biol Blood Marrow Transplant 2015 Feb;21(2):266-74       157 Citations
5Chronic GVHD and concurrent new-onset nephrotic syndrome in allogeneic transplant recipients. Incidence, pattern and therapeutic outcomes. (Dhakal B, Singavi A, Cohen EP, Dangal M, Palmer J, Dall A, D'Souza A, Hamadani M, Hari PN) Bone Marrow Transplant 2015 Mar;50(3):449-51       3 Citations
2Long-term survival and late effects among one-year survivors of second allogeneic hematopoietic cell transplantation for relapsed acute leukemia and myelodysplastic syndromes. (Duncan CN, Majhail NS, Brazauskas R, Wang Z, Cahn JY, Frangoul HA, Hayashi RJ, Hsu JW, Kamble RT, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Maziarz RT, Mehta P, Myers KC, Norkin M, Pidala JA, Porter DL, Reddy V, Saber W, Savani BN, Schouten HC, Steinberg A, Wall DA, Warwick AB, Wood WA, Yu LC, Jacobsohn DA, Sorror ML) Biol Blood Marrow Transplant 2015 Jan;21(1):151-8       31 Citations
2Recommendations for donor human leukocyte antigen assessment and matching for allogeneic stem cell transplantation: consensus opinion of the Blood and Marrow Transplant Clinical Trials Network (BMT CTN). (Howard CA, Fernandez-Vina MA, Appelbaum FR, Confer DL, Devine SM, Horowitz MM, Mendizabal A, Laport GG, Pasquini MC, Spellman SR) Biol Blood Marrow Transplant 2015 Jan;21(1):4-7       39 Citations
2Long-term survival after transplantation of unrelated donor peripheral blood or bone marrow hematopoietic cells for hematologic malignancy. (Eapen M, Logan BR, Appelbaum FR, Antin JH, Anasetti C, Couriel DR, Chen J, Maziarz RT, McCarthy PL, Nakamura R, Ratanatharathorn V, Vij R, Champlin RE) Biol Blood Marrow Transplant 2015 Jan;21(1):55-9       19 Citations
1Clopidogrel use as a risk factor for poor outcomes after kidney transplantation. (Williams JM, Tuttle-Newhall JE, Schnitzler M, Dzebisashvili N, Xiao H, Axelrod D, Mogal H, Lentine KL) Am J Surg 2014 Oct;208(4):556-62       5 Citations
1Hematopoietic stem cell transplantation for sickle cell disease: state of the science. (Talano JA, Cairo MS) Eur J Haematol 2015 May;94(5):391-9       18 Citations
4Nonpermissive HLA-DPB1 mismatch increases mortality after myeloablative unrelated allogeneic hematopoietic cell transplantation. (Pidala J, Lee SJ, Ahn KW, Spellman S, Wang HL, Aljurf M, Askar M, Dehn J, Fernandez Viña M, Gratwohl A, Gupta V, Hanna R, Horowitz MM, Hurley CK, Inamoto Y, Kassim AA, Nishihori T, Mueller C, Oudshoorn M, Petersdorf EW, Prasad V, Robinson J, Saber W, Schultz KR, Shaw B, Storek J, Wood WA, Woolfrey AE, Anasetti C) Blood 2014 Oct 16;124(16):2596-606       135 Citations
1Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. (Ustun C, Reiter A, Scott BL, Nakamura R, Damaj G, Kreil S, Shanley R, Hogan WJ, Perales MA, Shore T, Baurmann H, Stuart R, Gruhn B, Doubek M, Hsu JW, Tholouli E, Gromke T, Godley LA, Pagano L, Gilman A, Wagner EM, Shwayder T, Bornhäuser M, Papadopoulos EB, Böhm A, Vercellotti G, Van Lint MT, Schmid C, Rabitsch W, Pullarkat V, Legrand F, Yakoub-Agha I, Saber W, Barrett J, Hermine O, Hagglund H, Sperr WR, Popat U, Alyea EP, Devine S, Deeg HJ, Weisdorf D, Akin C, Valent P) J Clin Oncol 2014 Oct 10;32(29):3264-74       80 Citations
1Myelodysplastic syndrome evolving from aplastic anemia treated with immunosuppressive therapy: efficacy of hematopoietic stem cell transplantation. (Kim SY, Le Rademacher J, Antin JH, Anderlini P, Ayas M, Battiwalla M, Carreras J, Kurtzberg J, Nakamura R, Eapen M, Deeg HJ) Haematologica 2014 Dec;99(12):1868-75       16 Citations
1A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation. (Kornblit B, Maloney DG, Storer BE, Maris MB, Vindeløv L, Hari P, Langston AA, Pulsipher MA, Bethge WA, Chauncey TR, Lange T, Petersen FB, Hübel K, Woolfrey AE, Flowers ME, Storb R, Sandmaier BM) Haematologica 2014 Oct;99(10):1624-31       25 Citations
2Second solid cancers after allogeneic hematopoietic cell transplantation using reduced-intensity conditioning. (Ringdén O, Brazauskas R, Wang Z, Ahmed I, Atsuta Y, Buchbinder D, Burns LJ, Cahn JY, Duncan C, Hale GA, Halter J, Hayashi RJ, Hsu JW, Jacobsohn DA, Kamble RT, Kamani NR, Kasow KA, Khera N, Lazarus HM, Loren AW, Marks DI, Myers KC, Ramanathan M, Saber W, Savani BN, Schouten HC, Socie G, Sorror ML, Steinberg A, Popat U, Wingard JR, Mattsson J, Majhail NS) Biol Blood Marrow Transplant 2014 Nov;20(11):1777-84       34 Citations
1Engraftment kinetics and graft failure after single umbilical cord blood transplantation using a myeloablative conditioning regimen. (Ruggeri A, Labopin M, Sormani MP, Sanz G, Sanz J, Volt F, Michel G, Locatelli F, Diaz De Heredia C, O'Brien T, Arcese W, Iori AP, Querol S, Kogler G, Lecchi L, Pouthier F, Garnier F, Navarrete C, Baudoux E, Fernandes J, Kenzey C, Eapen M, Gluckman E, Rocha V, Saccardi R, Eurocord, Cord Blood Committee EBMT, Netcord) Haematologica 2014 Sep;99(9):1509-15       26 Citations
3Multicenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: Blood and Marrow Transplant Clinical Trials Network #1102 study rationale, design, and methods. (Saber W, Le Rademacher J, Sekeres M, Logan B, Lewis M, Mendizabal A, Leifer E, Appelbaum FR, Horowitz MM, Nakamura R, Cutler CS) Biol Blood Marrow Transplant 2014 Oct;20(10):1566-72       11 Citations
1Sequential myeloablative autologous stem cell transplantation and reduced intensity allogeneic hematopoietic cell transplantation is safe and feasible in children, adolescents and young adults with poor-risk refractory or recurrent Hodgkin and non-Hodgkin lymphoma. (Satwani P, Jin Z, Martin PL, Bhatia M, Garvin JH, George D, Chaudhury S, Talano J, Morris E, Harrison L, Sosna J, Peterson M, Militano O, Foley S, Kurtzberg J, Cairo MS) Leukemia 2015 Feb;29(2):448-55       27 Citations
2Exercise and stress management training prior to hematopoietic cell transplantation: Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 0902. (Jacobsen PB, Le-Rademacher J, Jim H, Syrjala K, Wingard JR, Logan B, Wu J, Majhail NS, Wood W, Rizzo JD, Geller NL, Kitko C, Faber E, Abidi MH, Slater S, Horowitz MM, Lee SJ) Biol Blood Marrow Transplant 2014 Oct;20(10):1530-6       36 Citations
1Low CD34 dose is associated with poor survival after reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndrome. (Törlén J, Ringdén O, Le Rademacher J, Batiwalla M, Chen J, Erkers T, Ho V, Kebriaei P, Keever-Taylor C, Kindwall-Keller T, Lazarus HM, Laughlin MJ, Lill M, O'Brien T, Perales MA, Rocha V, Savani BN, Szwajcer D, Valcarcel D, Eapen M) Biol Blood Marrow Transplant 2014 Sep;20(9):1418-25       26 Citations
1Mismatched related and unrelated donors for allogeneic hematopoietic cell transplantation for adults with hematologic malignancies. (Eapen M, O'Donnell P, Brunstein CG, Wu J, Barowski K, Mendizabal A, Fuchs EJ) Biol Blood Marrow Transplant 2014 Oct;20(10):1485-92       36 Citations
1New frontiers in pediatric Allo-SCT. (Talano JM, Pulsipher MA, Symons HJ, Militano O, Shereck EB, Giller RH, Hancock L, Morris E, Cairo MS) Bone Marrow Transplant 2014 Sep;49(9):1139-45       4 Citations
1Rapid tolerance induction by hematopoietic progenitor cells in the absence of donor-matched lymphoid cells. (Domen J, Li Y, Sun L, Simpson P, Gandy K) Transpl Immunol 2014 Aug;31(2):112-8    
2Lenalidomide maintenance for high-risk multiple myeloma after allogeneic hematopoietic cell transplantation. (Alsina M, Becker PS, Zhong X, Adams A, Hari P, Rowley S, Stadtmauer EA, Vesole DH, Logan B, Weisdorf D, Qazilbash M, Popplewell LL, McClune B, Bensinger W, Riches M, Giralt SA, Pasquini MC, Resource for Clinical Investigation in Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2014 Aug;20(8):1183-9       55 Citations
4Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. (Armand P, Kim HT, Logan BR, Wang Z, Alyea EP, Kalaycio ME, Maziarz RT, Antin JH, Soiffer RJ, Weisdorf DJ, Rizzo JD, Horowitz MM, Saber W) Blood 2014 Jun 05;123(23):3664-71       336 Citations
2Effect of body mass in children with hematologic malignancies undergoing allogeneic bone marrow transplantation. (Aplenc R, Zhang MJ, Sung L, Zhu X, Ho VT, Cooke K, Dvorak C, Hale G, Isola LM, Lazarus HM, McCarthy PL, Olsson R, Pulsipher M, Pasquini MC, Bunin N, Regimen-Related Toxicity Working Committee, Center for International Blood and Marrow Transplant Research) Blood 2014 May 29;123(22):3504-11       17 Citations
1Unrelated adult stem cell donor medical suitability: recommendations from the World Marrow Donor Association Clinical Working Group Committee. (Lown RN, Philippe J, Navarro W, van Walraven SM, Philips-Johnson L, Fechter M, Pawson R, Bengtsson M, Beksac M, Field S, Yang H, Shaw BE, World Marrow Donor Association Clinical Working Group Committee) Bone Marrow Transplant 2014 Jul;49(7):880-6       28 Citations
4Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. (Wirk B, Fenske TS, Hamadani M, Zhang MJ, Hu ZH, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell B, Cairo MS, Cashen A, Chen YB, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller EK, Wiernik PH, Gale RP, Burns LJ, Saber W) Biol Blood Marrow Transplant 2014 Jul;20(7):951-9       23 Citations
3Allotransplantation for patients age ≥40 years with non-Hodgkin lymphoma: encouraging progression-free survival. (McClune BL, Ahn KW, Wang HL, Antin JH, Artz AS, Cahn JY, Deol A, Freytes CO, Hamadani M, Holmberg LA, Jagasia MH, Jakubowski AA, Kharfan-Dabaja MA, Lazarus HM, Miller AM, Olsson R, Pedersen TL, Pidala J, Pulsipher MA, Rowe JM, Saber W, van Besien KW, Waller EK, Aljurf MD, Akpek G, Bacher U, Chao NJ, Chen YB, Cooper BW, Dehn J, de Lima MJ, Hsu JW, Lewis ID, Marks DI, McGuirk J, Cairo MS, Schouten HC, Szer J, Ramanathan M, Savani BN, Seftel M, Socie G, Vij R, Warlick ED, Weisdorf DJ) Biol Blood Marrow Transplant 2014 Jul;20(7):960-8       27 Citations
1Total lymphoid irradiation-antithymocyte globulin conditioning and allogeneic transplantation for patients with myelodysplastic syndromes and myeloproliferative neoplasms. (Benjamin J, Chhabra S, Kohrt HE, Lavori P, Laport GG, Arai S, Johnston L, Miklos DB, Shizuru JA, Weng WK, Negrin RS, Lowsky R) Biol Blood Marrow Transplant 2014 Jun;20(6):837-43       13 Citations
1Survival improvements in adolescents and young adults after myeloablative allogeneic transplantation for acute lymphoblastic leukemia. (Wood WA, Lee SJ, Brazauskas R, Wang Z, Aljurf MD, Ballen KK, Buchbinder DK, Dehn J, Freytes CO, Lazarus HM, Lemaistre CF, Mehta P, Szwajcer D, Joffe S, Majhail NS) Biol Blood Marrow Transplant 2014 Jun;20(6):829-36       23 Citations
2Randomized, double-blind, placebo-controlled trial of soluble tumor necrosis factor receptor: enbrel (etanercept) for the treatment of idiopathic pneumonia syndrome after allogeneic stem cell transplantation: blood and marrow transplant clinical trials network protocol. (Yanik GA, Horowitz MM, Weisdorf DJ, Logan BR, Ho VT, Soiffer RJ, Carter SL, Wu J, Wingard JR, Difronzo NL, Ferrara JL, Giralt S, Madtes DK, Drexler R, White ES, Cooke KR) Biol Blood Marrow Transplant 2014 Jun;20(6):858-64       35 Citations
3Graft-versus-host disease and survival after cord blood transplantation for acute leukemia: a comparison of Japanese versus White populations. (Kuwatsuka Y, Atsuta Y, Horowitz MM, Inagaki J, Kanda J, Kato K, Koh K, Zhang MJ, Eapen M, Center for International Blood and Marrow Transplant Research (CIBMTR), and Donor/Source and GVHD Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT)) Biol Blood Marrow Transplant 2014 May;20(5):662-7       18 Citations
1Pre-transplant MRD predicts outcome following reduced-intensity and myeloablative allogeneic hemopoietic SCT in AML. (Anthias C, Dignan FL, Morilla R, Morilla A, Ethell ME, Potter MN, Shaw BE) Bone Marrow Transplant 2014 May;49(5):679-83       40 Citations
1Antithymocyte globulin before allogeneic stem cell transplantation for progressive myelodysplastic syndrome: a study from the French Society of Bone Marrow Transplantation and Cellular Therapy. (Duléry R, Mohty M, Duhamel A, Robin M, Beguin Y, Michallet M, Vigouroux S, Lioure B, Garnier A, El Cheikh J, Bulabois CE, Huynh A, Bay JO, Daguindau E, Ceballos P, Clément L, Dauriac C, Maillard N, Legrand F, Cornillon J, Guillerm G, François S, Lapusan S, Chevallier P, Damaj G, Yakoub-Agha I) Biol Blood Marrow Transplant 2014 May;20(5):646-54       21 Citations
1Transplantation for children with acute myeloid leukemia: a comparison of outcomes with reduced intensity and myeloablative regimens. (Bitan M, He W, Zhang MJ, Abdel-Azim H, Ayas MF, Bielorai B, Carpenter PA, Cairo MS, Diaz MA, Horan JT, Jodele S, Kitko CL, Schultz KR, Kletzel M, Kasow KA, Lehmann LE, Mehta PA, Shah N, Pulsipher MA, Prestidge T, Seber A, Shenoy S, Woolfrey AE, Yu LC, Davies SM) Blood 2014 Mar 06;123(10):1615-20       40 Citations
1Ethnicity, length of time on the register and sex predict donor availability at the confirmatory typing stage. (Lown RN, Marsh SG, Switzer GE, Latham KA, Madrigal JA, Shaw BE) Bone Marrow Transplant 2014 Apr;49(4):525-31       11 Citations
1Clinical guide to fertility preservation in hematopoietic cell transplant recipients. (Joshi S, Savani BN, Chow EJ, Gilleece MH, Halter J, Jacobsohn DA, Pidala J, Quinn GP, Cahn JY, Jakubowski AA, Kamani NR, Lazarus HM, Rizzo JD, Schouten HC, Socie G, Stratton P, Sorror ML, Warwick AB, Wingard JR, Loren AW, Majhail NS) Bone Marrow Transplant 2014 Apr;49(4):477-84       54 Citations
1Antithymocyte globulin in reduced-intensity conditioning allografting: is the benefit simply in the eyes of the transplanter? (Hamadani M) Biol Blood Marrow Transplant 2014 Mar;20(3):292-4       2 Citations
1Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. (Li X, Brazauskas R, Wang Z, Al-Seraihy A, Baker KS, Cahn JY, Frangoul HA, Gajewski JL, Hale GA, Hsu JW, Kamble RT, Lazarus HM, Marks DI, Maziarz RT, Savani BN, Shah AJ, Shah N, Sorror ML, Wood WA, Majhail NS) Biol Blood Marrow Transplant 2014 Apr;20(4):587-92       15 Citations
1Predictors and impact of thirty-day readmission on patient outcomes and health care costs after reduced-toxicity conditioning allogeneic hematopoietic cell transplantation. (Rauenzahn S, Truong Q, Cumpston A, Goff L, Leadmon S, Evans K, Zhang J, Wen S, Craig M, Hamadani M, Kanate AS) Biol Blood Marrow Transplant 2014 Mar;20(3):415-20       12 Citations
4Autologous or reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle-cell lymphoma: analysis of transplantation timing and modality. (Fenske TS, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen A, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg LA, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales MA, Rizzieri DA, Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Maloney DG, Montoto S, Hari PN) J Clin Oncol 2014 Feb 01;32(4):273-81       81 Citations
1Pulmonary symptoms measured by the national institutes of health lung score predict overall survival, nonrelapse mortality, and patient-reported outcomes in chronic graft-versus-host disease. (Palmer J, Williams K, Inamoto Y, Chai X, Martin PJ, Tomas LS, Cutler C, Weisdorf D, Kurland BF, Carpenter PA, Pidala J, Pavletic SZ, Wood W, Jacobsohn D, Arai S, Arora M, Jagasia M, Vogelsang GB, Lee SJ) Biol Blood Marrow Transplant 2014 Mar;20(3):337-44       47 Citations
1Second transplants for multiple myeloma relapsing after a previous autotransplant-reduced-intensity allogeneic vs autologous transplantation. (Freytes CO, Vesole DH, LeRademacher J, Zhong X, Gale RP, Kyle RA, Reece DE, Gibson J, Schouten HC, McCarthy PL, Lonial S, Krishnan AY, Dispenzieri A, Hari PN) Bone Marrow Transplant 2014 Mar;49(3):416-21       38 Citations
1Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients. (Kurtzberg J, Prockop S, Teira P, Bittencourt H, Lewis V, Chan KW, Horn B, Yu L, Talano JA, Nemecek E, Mills CR, Chaudhury S) Biol Blood Marrow Transplant 2014 Feb;20(2):229-35       110 Citations
4Effect of postremission therapy before reduced-intensity conditioning allogeneic transplantation for acute myeloid leukemia in first complete remission. (Warlick ED, Paulson K, Brazauskas R, Zhong X, Miller AM, Camitta BM, George B, Savani BN, Ustun C, Marks DI, Waller EK, Baron F, Freytes CO, Socie G, Akpek G, Schouten HC, Lazarus HM, Horwitz EM, Koreth J, Cahn JY, Bornhauser M, Seftel M, Cairo MS, Laughlin MJ, Sabloff M, Ringdén O, Gale RP, Kamble RT, Vij R, Gergis U, Mathews V, Saber W, Chen YB, Liesveld JL, Cutler CS, Ghobadi A, Uy GL, Eapen M, Weisdorf DJ, Litzow MR) Biol Blood Marrow Transplant 2014 Feb;20(2):202-8       24 Citations
1Sibling donor and recipient immune modulation with atorvastatin for the prophylaxis of acute graft-versus-host disease. (Hamadani M, Gibson LF, Remick SC, Wen S, Petros W, Tse W, Brundage KM, Vos JA, Cumpston A, Bunner P, Craig MD) J Clin Oncol 2013 Dec 10;31(35):4416-23       19 Citations
4Reduced-intensity hematopoietic cell transplantation for patients with primary myelofibrosis: a cohort analysis from the center for international blood and marrow transplant research. (Gupta V, Malone AK, Hari PN, Ahn KW, Hu ZH, Gale RP, Ballen KK, Hamadani M, Olavarria E, Gerds AT, Waller EK, Costa LJ, Antin JH, Kamble RT, van Besien KM, Savani BN, Schouten HC, Szer J, Cahn JY, de Lima MJ, Wirk B, Aljurf MD, Popat U, Bejanyan N, Litzow MR, Norkin M, Lewis ID, Hale GA, Woolfrey AE, Miller AM, Ustun C, Jagasia MH, Lill M, Maziarz RT, Cortes J, Kalaycio ME, Saber W) Biol Blood Marrow Transplant 2014 Jan;20(1):89-97       67 Citations
2Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia. (Eckrich MJ, Ahn KW, Champlin RE, Coccia P, Godder K, Horan J, Margolis D, Deeg HJ, Eapen M) Am J Hematol 2014 Feb;89(2):125-9       16 Citations
1Impact of the duration of antiviral prophylaxis on rates of varicella-zoster virus reactivation disease in autologous hematopoietic cell transplantation recipients. (Truong Q, Veltri L, Kanate AS, Hu Y, Craig M, Hamadani M, Cumpston A) Ann Hematol 2014 Apr;93(4):677-82       12 Citations
4Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. (Copelan EA, Hamilton BK, Avalos B, Ahn KW, Bolwell BJ, Zhu X, Aljurf M, van Besien K, Bredeson C, Cahn JY, Costa LJ, de Lima M, Gale RP, Hale GA, Halter J, Hamadani M, Inamoto Y, Kamble RT, Litzow MR, Loren AW, Marks DI, Olavarria E, Roy V, Sabloff M, Savani BN, Seftel M, Schouten HC, Ustun C, Waller EK, Weisdorf DJ, Wirk B, Horowitz MM, Arora M, Szer J, Cortes J, Kalaycio ME, Maziarz RT, Saber W) Blood 2013 Dec 05;122(24):3863-70       96 Citations
3Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. (Bachanova V, Marks DI, Zhang MJ, Wang H, de Lima M, Aljurf MD, Arellano M, Artz AS, Bacher U, Cahn JY, Chen YB, Copelan EA, Drobyski WR, Gale RP, Greer JP, Gupta V, Hale GA, Kebriaei P, Lazarus HM, Lewis ID, Lewis VA, Liesveld JL, Litzow MR, Loren AW, Miller AM, Norkin M, Oran B, Pidala J, Rowe JM, Savani BN, Saber W, Vij R, Waller EK, Wiernik PH, Weisdorf DJ) Leukemia 2014 Mar;28(3):658-65       65 Citations
1Comparative cost-effectiveness analysis of voriconazole and fluconazole for prevention of invasive fungal infection in patients receiving allogeneic hematopoietic cell transplants. (Mauskopf J, Chirila C, Graham J, Gersten ID, Leather H, Maziarz RT, Baden LR, Bolaños-Meade J, Brown JM, Walsh TJ, Horowitz MH, Kurtzberg J, Marr KA, Wingard JR) Am J Health Syst Pharm 2013 Sep 01;70(17):1518-27       8 Citations
2Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. (Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN) J Clin Oncol 2013 Sep 01;31(25):3100-9       113 Citations
1Attenuation of cardiac allograft vasculopathy by sirolimus: Relationship to time interval after heart transplantation. (Matsuo Y, Cassar A, Yoshino S, Flammer AJ, Li J, Gulati R, Topilsky Y, Raichlin E, Lennon RJ, Lerman LO, Rihal CS, Kushwaha SS, Lerman A) J Heart Lung Transplant 2013 Aug;32(8):784-91       31 Citations
5Impact of donor source on hematopoietic cell transplantation outcomes for patients with myelodysplastic syndromes (MDS). (Saber W, Cutler CS, Nakamura R, Zhang MJ, Atallah E, Rizzo JD, Maziarz RT, Cortes J, Kalaycio ME, Horowitz MM) Blood 2013 Sep 12;122(11):1974-82       57 Citations
1Murine NK-cell licensing is reflective of donor MHC-I following allogeneic hematopoietic stem cell transplantation in murine cytomegalovirus responses. (Sungur CM, Tang-Feldman YJ, Zamora AE, Alvarez M, Pomeroy C, Murphy WJ) Blood 2013 Aug 22;122(8):1518-21       15 Citations
1Intermittent zoledronic Acid prevents bone loss in adults after allogeneic hematopoietic cell transplantation. (Hari P, DeFor TE, Vesole DH, Bredeson CN, Burns LJ) Biol Blood Marrow Transplant 2013 Sep;19(9):1361-7       16 Citations
1Outcomes of allogeneic hematopoietic cell transplantation in patients with dyskeratosis congenita. (Gadalla SM, Sales-Bonfim C, Carreras J, Alter BP, Antin JH, Ayas M, Bodhi P, Davis J, Davies SM, Deconinck E, Deeg HJ, Duerst RE, Fasth A, Ghavamzadeh A, Giri N, Goldman FD, Kolb EA, Krance R, Kurtzberg J, Leung WH, Srivastava A, Or R, Richman CM, Rosenberg PS, Toledo Codina JS, Shenoy S, Socié G, Tolar J, Williams KM, Eapen M, Savage SA) Biol Blood Marrow Transplant 2013 Aug;19(8):1238-43       63 Citations
1Significant improvement in survival after allogeneic hematopoietic cell transplantation during a period of significantly increased use, older recipient age, and use of unrelated donors. (Hahn T, McCarthy PL Jr, Hassebroek A, Bredeson C, Gajewski JL, Hale GA, Isola LM, Lazarus HM, Lee SJ, Lemaistre CF, Loberiza F, Maziarz RT, Rizzo JD, Joffe S, Parsons S, Majhail NS) J Clin Oncol 2013 Jul 01;31(19):2437-49       155 Citations
1Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how? (Klyuchnikov E, Bacher U, Kroll T, Shea TC, Lazarus HM, Bredeson C, Fenske TS) Bone Marrow Transplant 2014 Jan;49(1):1-7       20 Citations
1Polymorphism in the interleukin-7 receptor-alpha and outcome after allogeneic hematopoietic cell transplantation with matched unrelated donor. (Shamim Z, Spellman S, Haagenson M, Wang T, Lee SJ, Ryder LP, Müller K) Scand J Immunol 2013 Aug;78(2):214-20       18 Citations
2Unrelated donor allogeneic transplantation after failure of autologous transplantation for acute myelogenous leukemia: a study from the center for international blood and marrow transplantation research. (Foran JM, Pavletic SZ, Logan BR, Agovi-Johnson MA, Pérez WS, Bolwell BJ, Bornhäuser M, Bredeson CN, Cairo MS, Camitta BM, Copelan EA, Dehn J, Gale RP, George B, Gupta V, Hale GA, Lazarus HM, Litzow MR, Maharaj D, Marks DI, Martino R, Maziarz RT, Rowe JM, Rowlings PA, Savani BN, Savoie ML, Szer J, Waller EK, Wiernik PH, Weisdorf DJ) Biol Blood Marrow Transplant 2013 Jul;19(7):1102-8       15 Citations
1Monoclonal antibodies in conditioning regimens for hematopoietic cell transplantation. (Kharfan-Dabaja MA, Nishihori T, Otrock ZK, Haidar N, Mohty M, Hamadani M) Biol Blood Marrow Transplant 2013 Sep;19(9):1288-300       7 Citations
1Lentivirus IL-10 gene therapy down-regulates IL-17 and attenuates mouse orthotopic lung allograft rejection. (Hirayama S, Sato M, Loisel-Meyer S, Matsuda Y, Oishi H, Guan Z, Saito T, Yeung J, Cypel M, Hwang DM, Medin JA, Liu M, Keshavjee S) Am J Transplant 2013 Jun;13(6):1586-93       30 Citations
1Allogeneic hematopoietic cell transplantation in first remission abrogates poor outcomes associated with high-risk pediatric acute myeloid leukemia. (Burke MJ, Wagner JE, Cao Q, Ustun C, Verneris MR) Biol Blood Marrow Transplant 2013 Jul;19(7):1021-5       18 Citations
2Allogeneic hematopoietic cell transplantation for fanconi anemia in patients with pretransplantation cytogenetic abnormalities, myelodysplastic syndrome, or acute leukemia. (Ayas M, Saber W, Davies SM, Harris RE, Hale GA, Socie G, LeRademacher J, Thakar M, Deeg HJ, Al-Seraihy A, Battiwalla M, Camitta BM, Olsson R, Bajwa RS, Bonfim CM, Pasquini R, Macmillan ML, George B, Copelan EA, Wirk B, Al Jefri A, Fasth AL, Guinan EC, Horn BN, Lewis VA, Slavin S, Stepensky P, Bierings M, Gale RP) J Clin Oncol 2013 May 01;31(13):1669-76       43 Citations
1Donor lymphocyte infusion for relapsed hematological malignancies after allogeneic hematopoietic cell transplantation: prognostic relevance of the initial CD3+ T cell dose. (Bar M, Sandmaier BM, Inamoto Y, Bruno B, Hari P, Chauncey T, Martin PJ, Storb R, Maloney DG, Storer B, Flowers ME) Biol Blood Marrow Transplant 2013 Jun;19(6):949-57       57 Citations
1Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. (Storb R, Gyurkocza B, Storer BE, Sorror ML, Blume K, Niederwieser D, Chauncey TR, Pulsipher MA, Petersen FB, Sahebi F, Agura ED, Hari P, Bruno B, McSweeney PA, Maris MB, Maziarz RT, Langston AA, Bethge W, Vindeløv L, Franke GN, Laport GG, Yeager AM, Hübel K, Deeg HJ, Georges GE, Flowers ME, Martin PJ, Mielcarek M, Woolfrey AE, Maloney DG, Sandmaier BM) J Clin Oncol 2013 Apr 20;31(12):1530-8       141 Citations
3Outcome of transplantation for acute myelogenous leukemia in children with Down syndrome. (Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PA, CIBMTR Pediatric Cancer Working Committee) Biol Blood Marrow Transplant 2013 Jun;19(6):893-7       21 Citations
1Allogeneic hematopoietic cell transplantation for neuroblastoma: the CIBMTR experience. (Hale GA, Arora M, Ahn KW, He W, Camitta B, Bishop MR, Bitan M, Cairo MS, Chan K, Childs RW, Copelan E, Davies SM, Perez MA, Doyle JJ, Gale RP, Vicent MG, Horn BN, Hussein AA, Jodele S, Kamani NR, Kasow KA, Kletzel M, Lazarus HM, Lewis VA, Myers KC, Olsson R, Pulsipher M, Qayed M, Sanders JE, Shaw PJ, Soni S, Stiff PJ, Stadtmauer EA, Ueno NT, Wall DA, Grupp SA) Bone Marrow Transplant 2013 Aug;48(8):1056-64       16 Citations
1Diagnostic and therapeutic advances in blastic plasmacytoid dendritic cell neoplasm: a focus on hematopoietic cell transplantation. (Kharfan-Dabaja MA, Lazarus HM, Nishihori T, Mahfouz RA, Hamadani M) Biol Blood Marrow Transplant 2013 Jul;19(7):1006-12       54 Citations
1Birth order and transplantation outcome in HLA-identical sibling stem cell transplantation: an analysis on behalf of the Center for International Blood and Marrow Transplantation. (Dobbelstein C, Ahn KW, Haagenson M, Hale GA, van Rood JJ, Miklos D, Waller EK, Spellman SR, Fernandez-Vina M, Ganser A, Aljurf M, Bornhaeuser M, Gupta V, Marino SR, Pollack MS, Reddy V, Eder M, Lee SJ) Biol Blood Marrow Transplant 2013 May;19(5):741-5       5 Citations
5Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B cell lymphoma and grade III follicular lymphoma. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM) Biol Blood Marrow Transplant 2013 May;19(5):746-53       47 Citations
1Combined heart and liver transplant attenuates cardiac allograft vasculopathy compared with isolated heart transplantation. (Topilsky Y, Raichlin E, Hasin T, Boilson BA, Schirger JA, Pereira NL, Edwards BS, Clavell AL, Rodeheffer RJ, Frantz RP, Gandhi MJ, Maltais S, Park SJ, Daly RC, Lerman A, Kushwaha SS) Transplantation 2013 Mar 27;95(6):859-65       21 Citations
1Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer? (Alousi AM, Le-Rademacher J, Saliba RM, Appelbaum FR, Artz A, Benjamin J, Devine SM, Kan F, Laughlin MJ, Lazarus HM, Liesveld J, Perales MA, Maziarz RT, Sabloff M, Waller EK, Eapen M, Champlin RE) Blood 2013 Mar 28;121(13):2567-73       71 Citations
5Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. (Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM) Biol Blood Marrow Transplant 2013 Apr;19(4):625-31       41 Citations
2Mapping MHC haplotype effects in unrelated donor hematopoietic cell transplantation. (Petersdorf EW, Malkki M, Horowitz MM, Spellman SR, Haagenson MD, Wang T) Blood 2013 Mar 07;121(10):1896-905       39 Citations
1Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials. (Kharfan-Dabaja MA, Hamadani M, Reljic T, Nishihori T, Bensinger W, Djulbegovic B, Kumar A) J Hematol Oncol 2013 Jan 04;6:2       31 Citations
1Surviving the cure: long term followup of hematopoietic cell transplant recipients. (Majhail NS, Rizzo JD) Bone Marrow Transplant 2013 Sep;48(9):1145-51       78 Citations
1High readmission rates are associated with a significant economic burden and poor outcome in patients with grade III/IV acute GvHD. (Dignan FL, Potter MN, Ethell ME, Taylor M, Lewis L, Brennan J, McNamara L, Evans SO, Riley U, Davies FE, Dearden CE, Morgan GJ, Shaw BE) Clin Transplant 2013 Jan-Feb;27(1):E56-63       19 Citations
22013 report from the Center for International Blood and Marrow Transplant Research (CIBMTR): current uses and outcomes of hematopoietic cell transplants for blood and bone marrow disorders. (Pasquini M, Wang Z, Horowitz MM, Gale RP) Clin Transpl 2013:187-97       31 Citations
1Lymphocyte phenotype during therapy for acute graft-versus-host disease: a brief report from BMT-CTN 0302. (Bolaños-Meade J, Wu J, Logan BR, Levine JE, Ho VT, Alousi AM, Weisdorf DJ, Luznik L, Blood and Marrow Transplant Clinical Trials Network) Biol Blood Marrow Transplant 2013 Mar;19(3):481-5       5 Citations
2Cord-blood engraftment with ex vivo mesenchymal-cell coculture. (de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ) N Engl J Med 2012 Dec 13;367(24):2305-15       304 Citations
1Double unit grafts successfully extend the application of umbilical cord blood transplantation in adults with acute leukemia. (Scaradavou A, Brunstein CG, Eapen M, Le-Rademacher J, Barker JN, Chao N, Cutler C, Delaney C, Kan F, Isola L, Karanes C, Laughlin MJ, Wagner JE, Shpall EJ) Blood 2013 Jan 31;121(5):752-8       130 Citations
3Autologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research. (Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL) Biol Blood Marrow Transplant 2013 Feb;19(2):173-9       21 Citations
1Does matched unrelated donor transplantation have the same outcome as matched sibling transplantation in unselected patients? (Horowitz MM) Best Pract Res Clin Haematol 2012 Dec;25(4):483-6       22 Citations
1Retrospective analysis of fluoroquinolone prophylaxis in patients undergoing allogeneic hematopoietic stem cell transplantation. (Simondsen KA, Reed MP, Mably MS, Zhang Y, Longo WL) J Oncol Pharm Pract 2013 Dec;19(4):291-7       9 Citations
1Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. (Marsh RA, Rao K, Satwani P, Lehmberg K, Müller I, Li D, Kim MO, Fischer A, Latour S, Sedlacek P, Barlogis V, Hamamoto K, Kanegane H, Milanovich S, Margolis DA, Dimmock D, Casper J, Douglas DN, Amrolia PJ, Veys P, Kumar AR, Jordan MB, Bleesing JJ, Filipovich AH) Blood 2013 Feb 07;121(6):877-83       86 Citations
1HCT for nonmalignant disorders. (Tisdale JF, Eapen M, Saccardi R) Biol Blood Marrow Transplant 2013 Jan;19(1 Suppl):S6-9       2 Citations
1Review of multistate models in hematopoietic cell transplantation studies. (Logan BR) Biol Blood Marrow Transplant 2013 Jan;19(1 Suppl):S84-7       6 Citations
1Zero-mismatch deceased-donor kidney versus simultaneous pancreas-kidney transplantation. (Kamgar M, Huang E, Kamgar M, Nata N, Leeaphorn N, Kalantar-Zadeh K, Bunnapradist S) Transplantation 2012 Oct 27;94(8):822-9       1 Citation
2Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity? (Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, Fenske TS, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN, Lymphoma Working Committee of the CIBMTR) Blood 2012 Nov 15;120(20):4256-62       77 Citations
1Reappraising the role of autologous transplantation for indolent B-cell lymphomas in the chemoimmunotherapy era: is it still relevant? (Hamadani M) Bone Marrow Transplant 2013 Aug;48(8):1013-21       12 Citations
1Can fresh osteochondral allografts restore function in juveniles with osteochondritis dissecans of the knee? (Lyon R, Nissen C, Liu XC, Curtin B) Clin Orthop Relat Res 2013 Apr;471(4):1166-73       38 Citations
1Survival differences between adolescents/young adults and children with B precursor acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. (Burke MJ, Gossai N, Wagner JE, Smith AR, Bachanova V, Cao Q, MacMillan ML, Stefanski HS, Weisdorf DJ, Verneris MR) Biol Blood Marrow Transplant 2013 Jan;19(1):138-42       21 Citations
1Late effects in hematopoietic cell transplant recipients with acquired severe aplastic anemia: a report from the late effects working committee of the center for international blood and marrow transplant research. (Buchbinder D, Nugent DJ, Brazauskas R, Wang Z, Aljurf MD, Cairo MS, Chow R, Duncan C, Eldjerou LK, Gupta V, Hale GA, Halter J, Hayes-Lattin BM, Hsu JW, Jacobsohn DA, Kamble RT, Kasow KA, Lazarus HM, Mehta P, Myers KC, Parsons SK, Passweg JR, Pidala J, Reddy V, Sales-Bonfim CM, Savani BN, Seber A, Sorror ML, Steinberg A, Wood WA, Wall DA, Winiarski JH, Yu LC, Majhail NS) Biol Blood Marrow Transplant 2012 Dec;18(12):1776-84       21 Citations
2Allogeneic hematopoietic stem cell donation-standardized assessment of donor outcome data: a consensus statement from the Worldwide Network for Blood and Marrow Transplantation (WBMT). (Halter JP, van Walraven SM, Worel N, Bengtsson M, Hägglund H, Nicoloso de Faveri G, Shaw BE, Schmidt AH, Fechter M, Madrigal A, Szer J, Aljurf MD, Weisdorf D, Horowitz MM, Greinix H, Niederwieser D, Gratwohl A, Kodera Y, Confer D) Bone Marrow Transplant 2013 Feb;48(2):220-5       30 Citations
4Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. (Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M) Biol Blood Marrow Transplant 2012 Nov;18(11):1727-33       83 Citations
3Transplantation for autoimmune diseases in north and South America: a report of the Center for International Blood and Marrow Transplant Research. (Pasquini MC, Voltarelli J, Atkins HL, Hamerschlak N, Zhong X, Ahn KW, Sullivan KM, Carrum G, Andrey J, Bredeson CN, Cairo M, Gale RP, Hahn T, Storek J, Horowitz MM, McSweeney PA, Griffith LM, Muraro PA, Pavletic SZ, Nash RA) Biol Blood Marrow Transplant 2012 Oct;18(10):1471-8       39 Citations
1Allogeneic hematopoietic cell transplantation for myelofibrosis in the era of JAK inhibitors. (Gupta V, Hari P, Hoffman R) Blood 2012 Aug 16;120(7):1367-79       67 Citations
2Extracellular DNA traps are associated with the pathogenesis of TRALI in humans and mice. (Thomas GM, Carbo C, Curtis BR, Martinod K, Mazo IB, Schatzberg D, Cifuni SM, Fuchs TA, von Andrian UH, Hartwig JH, Aster RH, Wagner DD) Blood 2012 Jun 28;119(26):6335-43       171 Citations
2Impact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia. (Veys P, Wynn RF, Ahn KW, Samarasinghe S, He W, Bonney D, Craddock J, Cornish J, Davies SM, Dvorak CC, Duerst RE, Gross TG, Kapoor N, Kitko C, Krance RA, Leung W, Lewis VA, Steward C, Wagner JE, Carpenter PA, Eapen M) Blood 2012 Jun 21;119(25):6155-61       28 Citations
1No increased mortality from donor or recipient hepatitis B- and/or hepatitis C-positive serostatus after related-donor allogeneic hematopoietic cell transplantation. (Tomblyn M, Chen M, Kukreja M, Aljurf MD, Al Mohareb F, Bolwell BJ, Cahn JY, Carabasi MH, Gale RP, Gress RE, Gupta V, Hale GA, Ljungman P, Maziarz RT, Storek J, Wingard JR, Young JA, Horowitz MM, Ballen KK) Transpl Infect Dis 2012 Oct;14(5):468-78       12 Citations
1Allogeneic transplantation for aplastic anemia. (Eapen M) Hematology 2012 Apr;17 Suppl 1:S15-7       3 Citations
1Hematopoietic cell transplantation for chronic myeloid leukemia in developing countries: perspectives from Latin America in the post-tyrosine kinase inhibitor era. (Pasquini MC) Hematology 2012 Apr;17 Suppl 1:S79-82       9 Citations
1Hematopoietic cell transplantation in Latin America. (Eckrich M, Pasquini M) Hematology 2012 Apr;17 Suppl 1:S189-91       10 Citations
4Allogeneic hematopoietic cell transplantation for advanced polycythemia vera and essential thrombocythemia. (Ballen KK, Woolfrey AE, Zhu X, Ahn KW, Wirk B, Arora M, George B, Savani BN, Bolwell B, Porter DL, Copelan E, Hale G, Schouten HC, Lewis I, Cahn JY, Halter J, Cortes J, Kalaycio ME, Antin J, Aljurf MD, Carabasi MH, Hamadani M, McCarthy P, Pavletic S, Gupta V, Deeg HJ, Maziarz RT, Horowitz MM, Saber W) Biol Blood Marrow Transplant 2012 Sep;18(9):1446-54       15 Citations
2Long-term survival and late deaths after hematopoietic cell transplantation for primary immunodeficiency diseases and inborn errors of metabolism. (Eapen M, Ahn KW, Orchard PJ, Cowan MJ, Davies SM, Fasth A, Hassebroek A, Ayas M, Bonfim C, O'Brien TA, Gross TG, Horwitz M, Horwitz E, Kapoor N, Kurtzberg J, Majhail N, Ringden O, Szabolcs P, Veys P, Baker KS) Biol Blood Marrow Transplant 2012 Sep;18(9):1438-45       31 Citations
1Unrelated cord blood transplantation in adult and pediatric acute lymphoblastic leukemia: effect of minimal residual disease on relapse and survival. (Bachanova V, Burke MJ, Yohe S, Cao Q, Sandhu K, Singleton TP, Brunstein CG, Wagner JE, Verneris MR, Weisdorf DJ) Biol Blood Marrow Transplant 2012 Jun;18(6):963-8       26 Citations
1Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era. (Warlick E, Ahn KW, Pedersen TL, Artz A, de Lima M, Pulsipher M, Akpek G, Aljurf M, Cahn JY, Cairo M, Chen YB, Cooper B, Deol A, Giralt S, Gupta V, Khoury HJ, Kohrt H, Lazarus HM, Lewis I, Olsson R, Pidala J, Savani BN, Seftel M, Socié G, Tallman M, Ustun C, Vij R, Vindeløv L, Weisdorf D) Blood 2012 Apr 26;119(17):4083-90       38 Citations
1Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation. (Majhail NS, Rizzo JD, Lee SJ, Aljurf M, Atsuta Y, Bonfim C, Burns LJ, Chaudhri N, Davies S, Okamoto S, Seber A, Socie G, Szer J, Van Lint MT, Wingard JR, Tichelli A, Center for International Blood and Marrow Transplant Research, American Society for Blood and Marrow Transplantation, European Group for Blood and Marrow Transplantation, Asia-Pacific Blood and Marrow Transplantation Group, Bone Marrow Transplant Society of Australia and New Zealand, East Mediterranean Blood and Marrow Transplantation Group, Sociedade Brasileira de Transplante de Medula Ossea) Bone Marrow Transplant 2012 Mar;47(3):337-41       122 Citations
2HLA-matched sibling transplantation for severe aplastic anemia: impact of HLA DR15 antigen status on engraftment, graft-versus-host disease, and overall survival. (Battiwalla M, Wang T, Carreras J, Deeg HJ, Ayas M, Bajwa RP, George B, Gupta V, Pasquini R, Schrezenmeier H, Passweg JR, Schultz KR, Eapen M) Biol Blood Marrow Transplant 2012 Sep;18(9):1401-6       5 Citations
1Surgical resection as definitive treatment for refractory GVHD of the colon. (Cornell RF, Palmer J, Komorowski R, Drobyski WR) Bone Marrow Transplant 2012 Oct;47(10):1366-7       2 Citations
4Outcomes after matched unrelated donor versus identical sibling hematopoietic cell transplantation in adults with acute myelogenous leukemia. (Saber W, Opie S, Rizzo JD, Zhang MJ, Horowitz MM, Schriber J) Blood 2012 Apr 26;119(17):3908-16       163 Citations
1Transforming growth factor-β1 polymorphisms and the outcome of hematopoietic stem cell transplantation. (Arrieta-Bolaños E, Madrigal JA, Shaw BE) Int J Immunogenet 2012 Jun;39(3):192-202       4 Citations
1Follicular lymphoma: prognostic factors, conventional therapies, and hematopoietic cell transplantation. (Sehn LH, Fenske TS, Laport GG) Biol Blood Marrow Transplant 2012 Jan;18(1 Suppl):S82-91       14 Citations
1Monitoring and prevention of relapse after allogeneic hematopoietic cell transplantation for myeloid malignancies. (Bacher U, Talano JA, Bishop MR) Biol Blood Marrow Transplant 2012 Jan;18(1 Suppl):S62-73       16 Citations
1Second solid tumors: screening and management guidelines in long-term survivors after allogeneic stem cell transplantation. (Socié G, Rizzo JD) Semin Hematol 2012 Jan;49(1):4-9       19 Citations
1Role of cytotoxic therapy with hematopoietic stem cell transplantation in the treatment of pediatric acute lymphoblastic leukemia: update of the 2005 evidence-based review. (Oliansky DM, Camitta B, Gaynon P, Nieder ML, Parsons SK, Pulsipher MA, Dillon H, Ratko TA, Wall D, McCarthy PL Jr, Hahn T, American Society for Blood and Marrow Transplantation) Biol Blood Marrow Transplant 2012 Apr;18(4):505-22       38 Citations
1Sirolimus as primary immunosuppression attenuates allograft vasculopathy with improved late survival and decreased cardiac events after cardiac transplantation. (Topilsky Y, Hasin T, Raichlin E, Boilson BA, Schirger JA, Pereira NL, Edwards BS, Clavell AL, Rodeheffer RJ, Frantz RP, Maltais S, Park SJ, Daly RC, Lerman A, Kushwaha SS) Circulation 2012 Feb 07;125(5):708-20       75 Citations
1Higher infused CD34+ cell dose and overall survival in patients undergoing in vivo T-cell depleted, but not t-cell repleted, allogeneic peripheral blood hematopoietic cell transplantation. (Kanate AS, Craig M, Cumpston A, Saad A, Hobbs G, Leadmon S, Bunner P, Watkins K, Bulian D, Gibson L, Abraham J, Remick SC, Hamadani M) Hematol Oncol Stem Cell Ther 2011;4(4):149-56    
2Outcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure. (Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PN) Biol Blood Marrow Transplant 2012 Aug;18(8):1255-64       20 Citations
1Allogeneic cellular and autologous stem cell therapy for sickle cell disease: 'whom, when and how'. (Freed J, Talano J, Small T, Ricci A, Cairo MS) Bone Marrow Transplant 2012 Dec;47(12):1489-98       12 Citations
1Alternate donor hematopoietic cell transplantation (HCT) in non-Hodgkin lymphoma using lower intensity conditioning: a report from the CIBMTR. (Hale GA, Shrestha S, Le-Rademacher J, Burns LJ, Gibson J, Inwards DJ, Freytes CO, Bolwell BJ, Hsu JW, Slavin S, Isola L, Rizzieri DA, Gale RP, Laport GG, Montoto S, Lazarus HM, Hari PN) Biol Blood Marrow Transplant 2012 Jul;18(7):1036-1043.e1       13 Citations
1T cell-depleted partial matched unrelated donor transplant for advanced myeloid malignancy: KIR ligand mismatch and outcome. (Weisdorf D, Cooley S, Devine S, Fehniger TA, DiPersio J, Anasetti C, Waller EK, Porter D, Farag S, Drobyski W, Defor T, Haagenson M, Curtsinger J, Miller J) Biol Blood Marrow Transplant 2012 Jun;18(6):937-43       20 Citations
1Long-term outcomes among older patients following nonmyeloablative conditioning and allogeneic hematopoietic cell transplantation for advanced hematologic malignancies. (Sorror ML, Sandmaier BM, Storer BE, Franke GN, Laport GG, Chauncey TR, Agura E, Maziarz RT, Langston A, Hari P, Pulsipher MA, Bethge W, Sahebi F, Bruno B, Maris MB, Yeager A, Petersen FB, Vindeløv L, McSweeney PA, Hübel K, Mielcarek M, Georges GE, Niederwieser D, Blume KG, Maloney DG, Storb R) JAMA 2011 Nov 02;306(17):1874-83       190 Citations
3Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. (Majhail NS, Brazauskas R, Hassebroek A, Bredeson CN, Hahn T, Hale GA, Horowitz MM, Lazarus HM, Maziarz RT, Wood WA, Parsons SK, Joffe S, Rizzo JD, Lee SJ, Hayes-Lattin BM) Biol Blood Marrow Transplant 2012 Jun;18(6):861-73       34 Citations
2Risk factors for acute GVHD and survival after hematopoietic cell transplantation. (Jagasia M, Arora M, Flowers ME, Chao NJ, McCarthy PL, Cutler CS, Urbano-Ispizua A, Pavletic SZ, Haagenson MD, Zhang MJ, Antin JH, Bolwell BJ, Bredeson C, Cahn JY, Cairo M, Gale RP, Gupta V, Lee SJ, Litzow M, Weisdorf DJ, Horowitz MM, Hahn T) Blood 2012 Jan 05;119(1):296-307       315 Citations
2Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. (Khoury HJ, Kukreja M, Goldman JM, Wang T, Halter J, Arora M, Gupta V, Rizzieri DA, George B, Keating A, Gale RP, Marks DI, McCarthy PL, Woolfrey A, Szer J, Giralt SA, Maziarz RT, Cortes J, Horowitz MM, Lee SJ) Bone Marrow Transplant 2012 Jun;47(6):810-6       55 Citations
1Reduced-intensity conditioning allogeneic hematopoietic cell transplantation in adults with acute myeloid leukemia. (Hamadani M, Mohty M, Kharfan-Dabaja MA) Cancer Control 2011 Oct;18(4):237-45    
4Autologous haemopoietic stem-cell transplantation followed by allogeneic or autologous haemopoietic stem-cell transplantation in patients with multiple myeloma (BMT CTN 0102): a phase 3 biological assignment trial. (Krishnan A, Pasquini MC, Logan B, Stadtmauer EA, Vesole DH, Alyea E 3rd, Antin JH, Comenzo R, Goodman S, Hari P, Laport G, Qazilbash MH, Rowley S, Sahebi F, Somlo G, Vogl DT, Weisdorf D, Ewell M, Wu J, Geller NL, Horowitz MM, Giralt S, Maloney DG, Blood Marrow Transplant Clinical Trials Network (BMT CTN)) Lancet Oncol 2011 Dec;12(13):1195-203       202 Citations
2Effect of acute and chronic GVHD on relapse and survival after reduced-intensity conditioning allogeneic transplantation for myeloma. (Ringdén O, Shrestha S, da Silva GT, Zhang MJ, Dispenzieri A, Remberger M, Kamble R, Freytes CO, Gale RP, Gibson J, Gupta V, Holmberg L, Lazarus H, McCarthy P, Meehan K, Schouten H, Milone GA, Lonial S, Hari PN) Bone Marrow Transplant 2012 Jun;47(6):831-7       23 Citations
1Primary vascularization of the graft determines the immunodominance of murine minor H antigens during organ transplantation. (Kwun J, Malarkannan S, Burlingham WJ, Knechtle SJ) J Immunol 2011 Oct 15;187(8):3997-4006       11 Citations
2Characteristics of CliniMACS® System CD34-enriched T cell-depleted grafts in a multicenter trial for acute myeloid leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) protocol 0303. (Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Goldstein SC, Stadtmauer EA, O'Reilly RJ) Biol Blood Marrow Transplant 2012 May;18(5):690-7       40 Citations
2Classifying cytogenetics in patients with acute myelogenous leukemia in complete remission undergoing allogeneic transplantation: a Center for International Blood and Marrow Transplant Research study. (Armand P, Kim HT, Zhang MJ, Perez WS, Dal Cin PS, Klumpp TR, Waller EK, Litzow MR, Liesveld JL, Lazarus HM, Artz AS, Gupta V, Savani BN, McCarthy PL, Cahn JY, Schouten HC, Finke J, Ball ED, Aljurf MD, Cutler CS, Rowe JM, Antin JH, Isola LM, Di Bartolomeo P, Camitta BM, Miller AM, Cairo MS, Stockerl-Goldstein K, Sierra J, Savoie ML, Halter J, Stiff PJ, Nabhan C, Jakubowski AA, Bunjes DW, Petersdorf EW, Devine SM, Maziarz RT, Bornhauser M, Lewis VA, Marks DI, Bredeson CN, Soiffer RJ, Weisdorf DJ) Biol Blood Marrow Transplant 2012 Feb;18(2):280-8       52 Citations
2Donor characteristics affecting graft failure, graft-versus-host disease, and survival after unrelated donor transplantation with reduced-intensity conditioning for hematologic malignancies. (Passweg JR, Zhang MJ, Rocha V, Kan F, Champlin RE, Isola LM, Gee AP, Gibson J, Laughlin MJ, Lazarus HM, Loren A, Marks DI, Gratwohl A, Eapen M) Biol Blood Marrow Transplant 2011 Dec;17(12):1869-73       21 Citations
2Treatment of recurrent CNS disease post-bone marrow transplant in familial HLH. (Rangarajan HG, Grochowski D, Mulberry MF, Gheorghe G, Camitta BM, Talano JA) Pediatr Blood Cancer 2012 Jul 15;59(1):189-90       2 Citations
1Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. (Farag SS, Maharry K, Zhang MJ, Pérez WS, George SL, Mrózek K, DiPersio J, Bunjes DW, Marcucci G, Baer MR, Cairo M, Copelan E, Cutler CS, Isola L, Lazarus HM, Litzow MR, Marks DI, Ringdén O, Rizzieri DA, Soiffer R, Larson RA, Tallman MS, Bloomfield CD, Weisdorf DJ, Acute Leukemia Committee of the Center for International Blood and Marrow Transplant Research and Cancer and Leukemia Group B) Biol Blood Marrow Transplant 2011 Dec;17(12):1796-803       82 Citations
1Recurrence of Clostridium difficile infection after total colectomy in an allogeneic stem cell transplant patient. (Chang K, Kreuziger LM, Angell K, Young JA, Ustun C) Bone Marrow Transplant 2012 Apr;47(4):610-1       5 Citations
3Trends in allogeneic stem cell transplantation for multiple myeloma: a CIBMTR analysis. (Kumar S, Zhang MJ, Li P, Dispenzieri A, Milone GA, Lonial S, Krishnan A, Maiolino A, Wirk B, Weiss B, Freytes CO, Vogl DT, Vesole DH, Lazarus HM, Meehan KR, Hamadani M, Lill M, Callander NS, Majhail NS, Wiernik PH, Nath R, Kamble RT, Vij R, Kyle RA, Gale RP, Hari PN) Blood 2011 Aug 18;118(7):1979-88       58 Citations
2Effect of stem cell source on outcomes after unrelated donor transplantation in severe aplastic anemia. (Eapen M, Le Rademacher J, Antin JH, Champlin RE, Carreras J, Fay J, Passweg JR, Tolar J, Horowitz MM, Marsh JC, Deeg HJ) Blood 2011 Sep 01;118(9):2618-21       101 Citations
1Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. (Kamani NR, Kumar S, Hassebroek A, Eapen M, LeRademacher J, Casper J, Cowan M, Sánchez de Toledo J, Ferster A, Szabolcs P, Wingard JR, Horwitz E, Filipovich AH) Biol Blood Marrow Transplant 2011 Dec;17(12):1783-9       19 Citations
1Cardiac allograft hypertrophy is associated with impaired exercise tolerance after heart transplantation. (Raichlin E, Al-Omari MA, Hayes CL, Edwards BS, Frantz RP, Boilson BA, Clavell AL, Rodeheffer RJ, Schirger JA, Kushwaha SS, Allison TG, Pereira NL) J Heart Lung Transplant 2011 Oct;30(10):1153-60       8 Citations
1Local long-term expression of lentivirally delivered IL-10 in the lung attenuates obliteration of intrapulmonary allograft airways. (Hirayama S, Sato M, Liu M, Loisel-Meyer S, Yeung JC, Wagnetz D, Cypel M, Zehong G, Medin JA, Keshavjee S) Hum Gene Ther 2011 Nov;22(11):1453-60       17 Citations
1Allogeneic transplant physician and center capacity in the United States. (Majhail NS, Murphy EA, Omondi NA, Robinett P, Gajewski JL, LeMaistre CF, Confer D, Rizzo JD) Biol Blood Marrow Transplant 2011 Jul;17(7):956-61       35 Citations
1Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. (Brunstein CG, Fuchs EJ, Carter SL, Karanes C, Costa LJ, Wu J, Devine SM, Wingard JR, Aljitawi OS, Cutler CS, Jagasia MH, Ballen KK, Eapen M, O'Donnell PV, Blood and Marrow Transplant Clinical Trials Network) Blood 2011 Jul 14;118(2):282-8       373 Citations
3Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. (Wingard JR, Majhail NS, Brazauskas R, Wang Z, Sobocinski KA, Jacobsohn D, Sorror ML, Horowitz MM, Bolwell B, Rizzo JD, Socié G) J Clin Oncol 2011 Jun 01;29(16):2230-9       333 Citations
1Role of reduced intensity conditioning in allogeneic hematopoietic cell transplantation for patients with multiple myeloma. (Nishihori T, Kharfan-Dabaja MA, Ochoa-Bayona JL, Bazarbachi A, Pasquini M, Alsina M) Hematol Oncol Stem Cell Ther 2011;4(1):1-9    
2Trends of hematopoietic stem cell transplantation in the Eastern Mediterranean region, 1984-2007. (Ahmed SO, Ghavamzadeh A, Zaidi SZ, Baldomero H, Pasquini MC, Hussain F, Alimoghaddam K, Almohareb F, Ayas M, Hamidieh A, Mahmoud HK, Elhaddad A, Ben Othman T, Abdelkefi A, Sarhan M, Abdel-Rahman F, Adil S, Alkindi S, Bazarbachi A, Benchekroun S, Niederwieser D, Horowitz M, Gratwohl A, El Solh H, Aljurf M) Biol Blood Marrow Transplant 2011 Sep;17(9):1352-61       12 Citations
1Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. (Luger SM, Ringdén O, Zhang MJ, Pérez WS, Bishop MR, Bornhauser M, Bredeson CN, Cairo MS, Copelan EA, Gale RP, Giralt SA, Gulbas Z, Gupta V, Hale GA, Lazarus HM, Lewis VA, Lill MC, McCarthy PL, Weisdorf DJ, Pulsipher MA) Bone Marrow Transplant 2012 Feb;47(2):203-11    
1Drug eluting versus bare metal stents in cardiac allograft vasculopathy: a systematic review of literature. (Dasari TW, Hennebry TA, Hanna EB, Saucedo JF) Catheter Cardiovasc Interv 2011 Jun 01;77(7):962-9       27 Citations
1Allogeneic hematopoietic stem cell transplantation overcomes the adverse prognostic impact of CD20 expression in acute lymphoblastic leukemia. (Bachanova V, Sandhu K, Yohe S, Cao Q, Burke MJ, Verneris MR, Weisdorf D) Blood 2011 May 12;117(19):5261-3       9 Citations
1Unrelated donor peripheral blood stem cell transplants incorporating pre-transplant in-vivo alemtuzumab are not associated with any increased risk of significant acute or chronic graft-versus-host disease. (Shaw BE, Apperley JF, Russell NH, Craddock C, Liakopoulou E, Potter MN, Wynn R, Gibson B, Pearce RM, Kirkland K, Lee J, Madrigal JA, Cook G, Byrne JL) Br J Haematol 2011 Apr;153(2):244-52       15 Citations
1Higher busulfan dose intensity does not improve outcomes of patients undergoing allogeneic haematopoietic cell transplantation following fludarabine, busulfan-based reduced toxicity conditioning. (Hamadani M, Craig M, Phillips GS, Abraham J, Tse W, Cumpston A, Gibson L, Remick SC, Bunner P, Leadmon S, Elder P, Hofmeister C, Penza S, Efebera Y, Andritsos L, Garzon R, Benson DM Jr, Blum W, Devine SM) Hematol Oncol 2011 Dec;29(4):202-10       12 Citations
1Imatinib is effective for prevention and improvement of fibrotic fasciitis as a manifestation of chronic GVHD. (Osumi T, Miharu M, Tanaka R, Du W, Takahashi T, Shimada H) Bone Marrow Transplant 2012 Jan;47(1):139-40       6 Citations
2Low risk of chronic graft-versus-host disease and relapse associated with T cell-depleted peripheral blood stem cell transplantation for acute myelogenous leukemia in first remission: results of the blood and marrow transplant clinical trials network protocol 0303. (Devine SM, Carter S, Soiffer RJ, Pasquini MC, Hari PN, Stein A, Lazarus HM, Linker C, Stadtmauer EA, Alyea EP 3rd, Keever-Taylor CA, O'Reilly RJ) Biol Blood Marrow Transplant 2011 Sep;17(9):1343-51       90 Citations
1Review of stem-cell transplantation for myelodysplastic syndromes in older patients in the context of the Decision Memo for Allogeneic Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndrome emanating from the Centers for Medicare and Medicaid Services. (Giralt SA, Horowitz M, Weisdorf D, Cutler C) J Clin Oncol 2011 Feb 10;29(5):566-72       22 Citations
3Reducing the risk for transplantation-related mortality after allogeneic hematopoietic cell transplantation: how much progress has been made? (Horan JT, Logan BR, Agovi-Johnson MA, Lazarus HM, Bacigalupo AA, Ballen KK, Bredeson CN, Carabasi MH, Gupta V, Hale GA, Khoury HJ, Juckett MB, Litzow MR, Martino R, McCarthy PL, Smith FO, Rizzo JD, Pasquini MC) J Clin Oncol 2011 Mar 01;29(7):805-13       123 Citations
2HLA-matched sibling bone marrow transplantation for β-thalassemia major. (Sabloff M, Chandy M, Wang Z, Logan BR, Ghavamzadeh A, Li CK, Irfan SM, Bredeson CN, Cowan MJ, Gale RP, Hale GA, Horan J, Hongeng S, Eapen M, Walters MC) Blood 2011 Feb 03;117(5):1745-50       81 Citations
1Philadelphia chromosome-positive acute lymphoblastic leukemia in children: new and emerging treatment options. (Schultz KR, Prestidge T, Camitta B) Expert Rev Hematol 2010 Dec;3(6):731-42       10 Citations
1Autologous versus reduced-intensity allogeneic hematopoietic cell transplantation for patients with chemosensitive follicular non-Hodgkin lymphoma beyond first complete response or first partial response. (Tomblyn MR, Ewell M, Bredeson C, Kahl BS, Goodman SA, Horowitz MM, Vose JM, Negrin RS, Laport GG) Biol Blood Marrow Transplant 2011 Jul;17(7):1051-7       52 Citations
3Comparison of outcomes after transplantation of G-CSF-stimulated bone marrow grafts versus bone marrow or peripheral blood grafts from HLA-matched sibling donors for patients with severe aplastic anemia. (Chu R, Brazauskas R, Kan F, Bashey A, Bredeson C, Camitta B, Chiang KY, Frangoul H, Gale RP, Gee A, George B, Goldman FD, Gross TG, Gupta V, Hale GA, Isola L, Ispizua AU, Lazarus H, Marsh J, Russell J, Sabloff M, Waller EK, Eapen M) Biol Blood Marrow Transplant 2011 Jul;17(7):1018-24       45 Citations
1Clinical outcomes following hematopoietic stem cell transplantation for the treatment of mucopolysaccharidosis VI. (Turbeville S, Nicely H, Rizzo JD, Pedersen TL, Orchard PJ, Horwitz ME, Horwitz EM, Veys P, Bonfim C, Al-Seraihy A) Mol Genet Metab 2011 Feb;102(2):111-5       43 Citations
1Targeted complement inhibitors protect against posttransplant cardiac ischemia and reperfusion injury and reveal an important role for the alternative pathway of complement activation. (Atkinson C, He S, Morris K, Qiao F, Casey S, Goddard M, Tomlinson S) J Immunol 2010 Dec 01;185(11):7007-13       35 Citations
3Secondary solid cancers after allogeneic hematopoietic cell transplantation using busulfan-cyclophosphamide conditioning. (Majhail NS, Brazauskas R, Rizzo JD, Sobecks RM, Wang Z, Horowitz MM, Bolwell B, Wingard JR, Socie G) Blood 2011 Jan 06;117(1):316-22       124 Citations
1Protective effect of Lifor solution in experimental renal ischemia-reperfusion injury. (Regner KR, Nilakantan V, Ryan RP, Mortensen J, White SM, Shames BD, Roman RJ) J Surg Res 2010 Dec;164(2):e291-7       25 Citations
3Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children. (Woodard P, Carpenter PA, Davies SM, Gross TG, He W, Zhang MJ, Horn BN, Margolis DA, Perentesis JP, Sanders JE, Schultz KR, Seber A, Woods WG, Eapen M) Biol Blood Marrow Transplant 2011 May;17(5):723-8       16 Citations
1Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor. (Christian B, Zhao W, Hamadani M, Sotomayor EM, Navarro W, Devine SM, Racke F, Blum KA) J Clin Oncol 2010 Nov 01;28(31):e629-32       26 Citations
1One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. (Valcárcel D, Sierra J, Wang T, Kan F, Gupta V, Hale GA, Marks DI, McCarthy PL, Oudshoorn M, Petersdorf EW, Ringdén O, Setterholm M, Spellman SR, Waller EK, Gajewski JL, Marino SR, Senitzer D, Lee SJ) Biol Blood Marrow Transplant 2011 May;17(5):640-8       40 Citations
1Long term follow-up of allogeneic stem cell transplantation in patients with myelodysplastic syndromes using busulfan, cytosine arabinoside, and cyclophosphamide. (Atallah E, Abrams J, Ayash L, Bentley G, Abidi M, Ratanatharathorn V, Uberti J) Am J Hematol 2010 Aug;85(8):579-83       5 Citations
5Access to hematopoietic stem cell transplantation: effect of race and sex. (Joshua TV, Rizzo JD, Zhang MJ, Hari PN, Kurian S, Pasquini M, Majhail NS, Lee SJ, Horowitz MM) Cancer 2010 Jul 15;116(14):3469-76       61 Citations
3Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis. (Eapen M, Rocha V, Sanz G, Scaradavou A, Zhang MJ, Arcese W, Sirvent A, Champlin RE, Chao N, Gee AP, Isola L, Laughlin MJ, Marks DI, Nabhan S, Ruggeri A, Soiffer R, Horowitz MM, Gluckman E, Wagner JE, Center for International Blood and Marrow Transplant Research, Acute Leukemia Working Party Eurocord (the European Group for Blood Marrow Transplantation), National Cord Blood Program of the New York Blood Center) Lancet Oncol 2010 Jul;11(7):653-60       378 Citations
1Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study. (Prasad VK, Lucas KG, Kleiner GI, Talano JA, Jacobsohn D, Broadwater G, Monroy R, Kurtzberg J) Biol Blood Marrow Transplant 2011 Apr;17(4):534-41       206 Citations
1Novel approaches to prevent leukemia relapse following allogeneic hematopoietic cell transplantation. (Verneris MR, Burke MJ) Curr Hematol Malig Rep 2010 Jul;5(3):157-62       2 Citations
2Hematopoietic stem cell transplantation: a global perspective. (Gratwohl A, Baldomero H, Aljurf M, Pasquini MC, Bouzas LF, Yoshimi A, Szer J, Lipton J, Schwendener A, Gratwohl M, Frauendorfer K, Niederwieser D, Horowitz M, Kodera Y, Worldwide Network of Blood and Marrow Transplantation) JAMA 2010 Apr 28;303(16):1617-24       399 Citations
2Cardiac myocyte-specific overexpression of human GTP cyclohydrolase I protects against acute cardiac allograft rejection. (Ionova IA, Vásquez-Vivar J, Cooley BC, Khanna AK, Whitsett J, Herrnreiter A, Migrino RQ, Ge ZD, Regner KR, Channon KM, Alp NJ, Pieper GM) Am J Physiol Heart Circ Physiol 2010 Jul;299(1):H88-96       6 Citations
1Current status of donation after cardiac death liver transplantation. (Reich DJ, Hong JC) Curr Opin Organ Transplant 2010 Jun;15(3):316-21       49 Citations
3Obesity does not preclude safe and effective myeloablative hematopoietic cell transplantation (HCT) for acute myelogenous leukemia (AML) in adults. (Navarro WH, Agovi MA, Logan BR, Ballen K, Bolwell BJ, Frangoul H, Gupta V, Hahn T, Ho VT, Juckett M, Lazarus HM, Litzow MR, Liesveld JL, Moreb JS, Marks DI, McCarthy PL, Pasquini MC, Rizzo JD) Biol Blood Marrow Transplant 2010 Oct;16(10):1442-50       51 Citations
1The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. (Marks DI, Wang T, Pérez WS, Antin JH, Copelan E, Gale RP, George B, Gupta V, Halter J, Khoury HJ, Klumpp TR, Lazarus HM, Lewis VA, McCarthy P, Rizzieri DA, Sabloff M, Szer J, Tallman MS, Weisdorf DJ) Blood 2010 Jul 22;116(3):366-74       125 Citations
2NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: report from the Committee on the Epidemiology and Natural History of Relapse following Allogeneic Cell Transplantation. (Pavletic SZ, Kumar S, Mohty M, de Lima M, Foran JM, Pasquini M, Zhang MJ, Giralt S, Bishop MR, Weisdorf D) Biol Blood Marrow Transplant 2010 Jul;16(7):871-90       69 Citations
2Blockade of interleukin-23 signaling results in targeted protection of the colon and allows for separation of graft-versus-host and graft-versus-leukemia responses. (Das R, Komorowski R, Hessner MJ, Subramanian H, Huettner CS, Cua D, Drobyski WR) Blood 2010 Jun 24;115(25):5249-58       35 Citations
2Reduced-intensity conditioning regimens for allogeneic transplantation in children with acute lymphoblastic leukemia. (Verneris MR, Eapen M, Duerst R, Carpenter PA, Burke MJ, Afanasyev BV, Cowan MJ, He W, Krance R, Li CK, Tan PL, Wagner JE, Davies SM) Biol Blood Marrow Transplant 2010 Sep;16(9):1237-44       28 Citations
1Practice patterns for evaluation, consent, and care of related donors and recipients at hematopoietic cell transplantation centers in the United States. (O'Donnell PV, Pedersen TL, Confer DL, Rizzo JD, Pulsipher MA, Stroncek D, Leitman S, Anderlini P, Donor Health and Safety Working Committee from Center for International Blood and Marrow Transplant Research (CIBMTR)) Blood 2010 Jun 17;115(24):5097-101       43 Citations
2Leukocyte adhesion deficiency-III in an African-American patient. (Sabnis H, Kirpalani A, Horan J, McDowall A, Svensson L, Cooley A, Merck T, Jobe S, Hogg N, Briones M) Pediatr Blood Cancer 2010 Jul 15;55(1):180-2       16 Citations
2Relapse and late mortality in 5-year survivors of myeloablative allogeneic hematopoietic cell transplantation for chronic myeloid leukemia in first chronic phase. (Goldman JM, Majhail NS, Klein JP, Wang Z, Sobocinski KA, Arora M, Horowitz MM, Rizzo JD) J Clin Oncol 2010 Apr 10;28(11):1888-95       85 Citations
1Insufficient evidence for association of NOD2/CARD15 or other inflammatory bowel disease-associated markers on GVHD incidence or other adverse outcomes in T-replete, unrelated donor transplantation. (Nguyen Y, Al-Lehibi A, Gorbe E, Li E, Haagenson M, Wang T, Spellman S, Lee SJ, Davidson NO) Blood 2010 Apr 29;115(17):3625-31       29 Citations
1Standards, regulations and accreditation for registries involved in the worldwide exchange of hematopoietic stem cell donors and products. (Hurley CK, Foeken L, Horowitz M, Lindberg B, McGregor M, Sacchi N, WMDA Accreditation and Regulatory Committees) Bone Marrow Transplant 2010 May;45(5):819-24       15 Citations
1Donor safety: the role of the WMDA in ensuring the safety of volunteer unrelated donors: clinical and ethical considerations. (Shaw BE, Ball L, Beksac M, Bengtsson M, Confer D, Diler S, Fechter M, Greinix H, Koh M, Lee S, Nicoloso-De-Faveri G, Philippe J, Pollichieni S, Pulsipher M, Schmidt A, Yang E, van Walraven AM, Clinical Working Group, Ethics Working Group of the WMDA) Bone Marrow Transplant 2010 May;45(5):832-8       39 Citations
2Expression of natural killer receptors in T- and NK-cells: comparison of healthy individuals, patients with prior stem cell transplant, and patients undergoing chemotherapy. (Olteanu H, Schur BC, Bredeson C, Atallah E, Kroft SH) Leuk Lymphoma 2010 Mar;51(3):481-7       4 Citations
3Focal nodular hyperplasia in pediatric allogeneic hematopoietic cell transplant: case series. (Anderson L, Gregg D, Margolis D, Casper J, Talano J) Bone Marrow Transplant 2010 Aug;45(8):1357-9       16 Citations
3A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR. (Lazarus HM, Zhang MJ, Carreras J, Hayes-Lattin BM, Ataergin AS, Bitran JD, Bolwell BJ, Freytes CO, Gale RP, Goldstein SC, Hale GA, Inwards DJ, Klumpp TR, Marks DI, Maziarz RT, McCarthy PL, Pavlovsky S, Rizzo JD, Shea TC, Schouten HC, Slavin S, Winter JN, van Besien K, Vose JM, Hari PN) Biol Blood Marrow Transplant 2010 Jan;16(1):35-45       62 Citations
4Allogeneic transplantation for therapy-related myelodysplastic syndrome and acute myeloid leukemia. (Litzow MR, Tarima S, Pérez WS, Bolwell BJ, Cairo MS, Camitta BM, Cutler CS, de Lima M, Dipersio JF, Gale RP, Keating A, Lazarus HM, Luger S, Marks DI, Maziarz RT, McCarthy PL, Pasquini MC, Phillips GL, Rizzo JD, Sierra J, Tallman MS, Weisdorf DJ) Blood 2010 Mar 04;115(9):1850-7       140 Citations
1Limited role of MHC class I chain-related gene A (MICA) typing in assessing graft-versus-host disease risk after fully human leukocyte antigen-matched unrelated donor transplantation. (Anderson E, Grzywacz B, Wang H, Wang T, Haagenson M, Spellman S, Blazar BR, Miller JS, Verneris MR) Blood 2009 Nov 19;114(21):4753-4; author reply 4754-5       16 Citations
2Extracorporeal photopheresis for the prevention of acute GVHD in patients undergoing standard myeloablative conditioning and allogeneic hematopoietic stem cell transplantation. (Shaughnessy PJ, Bolwell BJ, van Besien K, Mistrik M, Grigg A, Dodds A, Prince HM, Durrant S, Ilhan O, Parenti D, Gallo J, Foss F, Apperley J, Zhang MJ, Horowitz MM, Abhyankar S) Bone Marrow Transplant 2010 Jun;45(6):1068-76       30 Citations
1Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. (Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R, European LeukemiaNet) J Clin Oncol 2009 Dec 10;27(35):6041-51       1010 Citations
1Outcomes of hematologic malignancies after unrelated donor hematopoietic cell transplantation according to place of residence. (Loberiza FR Jr, Lee SJ, Klein JP, Hassebroek A, Dehn JG, Frangoul HA, Hahn T, Hale G, Lazarus HM, LeMaistre CF, Maziarz RT, Rizzo JD, Majhail NS) Biol Blood Marrow Transplant 2010 Mar;16(3):368-75       16 Citations
2Outcome of transplantation for myelofibrosis. (Ballen KK, Shrestha S, Sobocinski KA, Zhang MJ, Bashey A, Bolwell BJ, Cervantes F, Devine SM, Gale RP, Gupta V, Hahn TE, Hogan WJ, Kröger N, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Schiller G, Schouten HC, Roy V, Wiernik PH, Horowitz MM, Giralt SA, Arora M) Biol Blood Marrow Transplant 2010 Mar;16(3):358-67       171 Citations
1Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. (Hamadani M, Blum W, Phillips G, Elder P, Andritsos L, Hofmeister C, O'Donnell L, Klisovic R, Penza S, Garzon R, Krugh D, Lin T, Bechtel T, Benson DM, Byrd JC, Marcucci G, Devine SM) Biol Blood Marrow Transplant 2009 Nov;15(11):1422-30       62 Citations
1Sibling versus unrelated donor allogeneic hematopoietic cell transplantation for chronic myelogenous leukemia: refined HLA matching reveals more graft-versus-host disease but not less relapse. (Weisdorf DJ, Nelson G, Lee SJ, Haagenson M, Spellman S, Antin JH, Bolwell B, Cahn JY, Cervantes F, Copelan E, Gale R, Gratwohl A, Khoury HJ, McCarthy P, Marks DI, Szer J, Woolfrey A, Cortes-Franco J, Horowitz MM, Arora M, Chronic Leukemia Working Committee) Biol Blood Marrow Transplant 2009 Nov;15(11):1475-8       32 Citations
3Hematopoietic stem cell transplantation for refractory or recurrent non-Hodgkin lymphoma in children and adolescents. (Gross TG, Hale GA, He W, Camitta BM, Sanders JE, Cairo MS, Hayashi RJ, Termuhlen AM, Zhang MJ, Davies SM, Eapen M) Biol Blood Marrow Transplant 2010 Feb;16(2):223-30       88 Citations
1Reduced-intensity conditioning allogeneic stem cell transplantation in HIV patients with hematologic malignancies: yes, we can. (Hamadani M, Devine SM) Blood 2009 Sep 17;114(12):2564-6       9 Citations
2The effect of smoking on allogeneic transplant outcomes. (Marks DI, Ballen K, Logan BR, Wang Z, Sobocinski KA, Bacigalupo A, Burns LJ, Gupta V, Ho V, McCarthy PL, Ringdén O, Schouten HC, Seftel M, Rizzo JD) Biol Blood Marrow Transplant 2009 Oct;15(10):1277-87       19 Citations
1Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). (Burke MJ, Cao Q, Trotz B, Weigel B, Kumar A, Smith A, Verneris MR) Pediatr Blood Cancer 2009 Dec 15;53(7):1289-94       20 Citations
1Association of functional polymorphisms of the transforming growth factor B1 gene with survival and graft-versus-host disease after unrelated donor hematopoietic stem cell transplantation. (Berro M, Mayor NP, Maldonado-Torres H, Cooke L, Kusminsky G, Marsh SG, Madrigal JA, Shaw BE) Haematologica 2010 Feb;95(2):276-83       8 Citations
1Combined heart and liver transplantation: a single-center experience. (Raichlin E, Daly RC, Rosen CB, McGregor CG, Charlton MR, Frantz RP, Clavell AL, Rodeheffer RJ, Pereira NL, Kremers WK, Kushwaha SS, Edwards BS) Transplantation 2009 Jul 27;88(2):219-25       87 Citations
1The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era. (Burke MJ, Willert J, Desai S, Kadota R) Pediatr Blood Cancer 2009 Dec;53(6):992-5       8 Citations
2Donor, recipient, and transplant characteristics as risk factors after unrelated donor PBSC transplantation: beneficial effects of higher CD34+ cell dose. (Pulsipher MA, Chitphakdithai P, Logan BR, Leitman SF, Anderlini P, Klein JP, Horowitz MM, Miller JP, King RJ, Confer DL) Blood 2009 Sep 24;114(13):2606-16       93 Citations
1Meshomania. (Gould JC) J Surg Res 2010 Apr;159(2):665    
1Effects of mismatching for minor histocompatibility antigens on clinical outcomes in HLA-matched, unrelated hematopoietic stem cell transplants. (Spellman S, Warden MB, Haagenson M, Pietz BC, Goulmy E, Warren EH, Wang T, Ellis TM) Biol Blood Marrow Transplant 2009 Jul;15(7):856-63       39 Citations
1Allogeneic hematopoietic cell transplantation in human immunodeficiency virus-positive patients with hematologic disorders: a report from the center for international blood and marrow transplant research. (Gupta V, Tomblyn M, Pedersen TL, Atkins HL, Battiwalla M, Gress RE, Pollack MS, Storek J, Thompson JC, Tiberghien P, Young JA, Ribaud P, Horowitz MM, Keating A) Biol Blood Marrow Transplant 2009 Jul;15(7):864-71       43 Citations
1Novel application of lentiviral vectors towards treatment of graft-versus-host disease. (Scaife MD, Neschadim A, Fowler DH, Medin JA) Expert Opin Biol Ther 2009 Jun;9(6):749-61       6 Citations
1Prolonged disease control by nonmyeloablative allogeneic transplantation for metastatic breast cancer. (de Souza JA, Davis ML, Rondon G, Cheng YC, Jones RB, Champlin RE, Ueno NT) Bone Marrow Transplant 2009 Jul;44(2):81-7       9 Citations
1Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas. (Hamadani M, Benson DM Jr, Hofmeister CC, Elder P, Blum W, Porcu P, Garzon R, Blum KA, Lin TS, Marcucci G, Devine SM) Biol Blood Marrow Transplant 2009 May;15(5):547-53       35 Citations
2Unrelated donor hematopoietic cell transplantation for non-hodgkin lymphoma: long-term outcomes. (van Besien K, Carreras J, Bierman PJ, Logan BR, Molina A, King R, Nelson G, Fay JW, Champlin RE, Lazarus HM, Vose JM, Hari PN) Biol Blood Marrow Transplant 2009 May;15(5):554-63       28 Citations
1Prior rituximab correlates with less acute graft-versus-host disease and better survival in B-cell lymphoma patients who received allogeneic peripheral blood stem cell transplantation. (Ratanatharathorn V, Logan B, Wang D, Horowitz M, Uberti JP, Ringden O, Gale RP, Khoury H, Arora M, Spellman S, Cutler C, Antin J, Bornhaüser M, Hale G, Verdonck L, Cairo M, Gupta V, Pavletic S, Center for International Blood and Marrow Transplant Research, Milwaukee, WI, USA) Br J Haematol 2009 Jun;145(6):816-24       54 Citations
1Acute cellular rejection and the subsequent development of allograft vasculopathy after cardiac transplantation. (Raichlin E, Edwards BS, Kremers WK, Clavell AL, Rodeheffer RJ, Frantz RP, Pereira NL, Daly RC, McGregor CG, Lerman A, Kushwaha SS) J Heart Lung Transplant 2009 Apr;28(4):320-7       98 Citations
1Sepiapterin decreases acute rejection and apoptosis in cardiac transplants independently of changes in nitric oxide and inducible nitric-oxide synthase dimerization. (Pieper GM, Ionova IA, Cooley BC, Migrino RQ, Khanna AK, Whitsett J, Vásquez-Vivar J) J Pharmacol Exp Ther 2009 Jun;329(3):890-9       13 Citations
1Combination therapy using three novel prolactin receptor antagonist-based fusion proteins effectively inhibits tumor recurrence and metastasis in HER2/neu transgenic mice. (Tomblyn S, Springs AE, Langenheim JF, Chen WY) Int J Oncol 2009 Apr;34(4):1139-46       4 Citations
2Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. (Landgren O, Gilbert ES, Rizzo JD, Socié G, Banks PM, Sobocinski KA, Horowitz MM, Jaffe ES, Kingma DW, Travis LB, Flowers ME, Martin PJ, Deeg HJ, Curtis RE) Blood 2009 May 14;113(20):4992-5001       251 Citations
1Aortic valve replacement in a diseased bicuspid valve eleven years after transplantation. (Joyce DL, Russell SD, Conte JV, Cattaneo SM) Interact Cardiovasc Thorac Surg 2009 May;8(5):594-5       6 Citations
1Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients. (Burke MJ, Trotz B, Luo X, Weisdorf DJ, Baker KS, Wagner JE, Verneris MR) Bone Marrow Transplant 2009 Aug;44(3):169-74       10 Citations
1Effects of modified ultrafiltration on coagulation as measured by the thromboelastograph. (Steffens TG, Kohmoto T, Edwards N, Wolman RL, Holt DW) J Extra Corpor Technol 2008 Dec;40(4):229-33       6 Citations
1Recommendations for a standard UK approach to incorporating umbilical cord blood into clinical transplantation practice: conditioning protocols and donor selection algorithms. (Shaw BE, Veys P, Pagliuca A, Addada J, Cook G, Craddock CF, Gennery AR, Goldman J, Mackinnon S, Madrigal JA, Marks DI, Navarrete C, Potter MN, Querol S, Regan F, Russell NH, Hough RE) Bone Marrow Transplant 2009 Jul;44(1):7-12       12 Citations
1An early CT-diagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. (Dignan FL, Evans SO, Ethell ME, Shaw BE, Davies FE, Dearden CE, Treleaven JG, Riley UB, Morgan GJ, Potter MN) Bone Marrow Transplant 2009 Jul;44(1):51-6       49 Citations
2Unrelated donor reduced-intensity allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma. (Devetten MP, Hari PN, Carreras J, Logan BR, van Besien K, Bredeson CN, Freytes CO, Gale RP, Gibson J, Giralt SA, Goldstein SC, Gupta V, Marks DI, Maziarz RT, Vose JM, Lazarus HM, Anderlini P) Biol Blood Marrow Transplant 2009 Jan;15(1):109-17       83 Citations
1Cardiac allograft remodeling after heart transplantation is associated with increased graft vasculopathy and mortality. (Raichlin E, Villarraga HR, Chandrasekaran K, Clavell AL, Frantz RP, Kushwaha SS, Rodeheffer RJ, McGregor CG, Daly RC, Park SJ, Kremers WK, Edwards BS, Pereira NL) Am J Transplant 2009 Jan;9(1):132-9       29 Citations
1Proliferation signal inhibitors and cardiac allograft vasculopathy. (Raichlin E, Kushwaha SS) Curr Opin Organ Transplant 2008 Oct;13(5):543-50       17 Citations
1Unrelated donor hematopoietic cell transplantation: factors associated with a better HLA match. (Dehn J, Arora M, Spellman S, Setterholm M, Horowitz M, Confer D, Weisdorf D) Biol Blood Marrow Transplant 2008 Dec;14(12):1334-40       35 Citations
1Sirolimus as primary immunosuppressant reduces left ventricular mass and improves diastolic function of the cardiac allograft. (Raichlin E, Chandrasekaran K, Kremers WK, Frantz RP, Clavell AL, Pereira NL, Rodeheffer RJ, Daly RC, McGregor CG, Edwards BS, Kushwaha SS) Transplantation 2008 Nov 27;86(10):1395-400       36 Citations
2Use of biological assignment in hematopoietic stem cell transplantation clinical trials. (Logan B, Leifer E, Bredeson C, Horowitz M, Ewell M, Carter S, Geller N) Clin Trials 2008;5(6):607-16       17 Citations
1Allogeneic hematopoietic cell transplantation for primary immune deficiency diseases: current status and critical needs. (Griffith LM, Cowan MJ, Kohn DB, Notarangelo LD, Puck JM, Schultz KR, Buckley RH, Eapen M, Kamani NR, O'Reilly RJ, Parkman R, Roifman CM, Sullivan KE, Filipovich AH, Fleisher TA, Shearer WT) J Allergy Clin Immunol 2008 Dec;122(6):1087-96       51 Citations
2Solid cancers after allogeneic hematopoietic cell transplantation. (Rizzo JD, Curtis RE, Socié G, Sobocinski KA, Gilbert E, Landgren O, Travis LB, Travis WD, Flowers ME, Friedman DL, Horowitz MM, Wingard JR, Deeg HJ) Blood 2009 Jan 29;113(5):1175-83       292 Citations
1Feasibility of allogeneic hematopoietic stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma. (Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Benson DM, Blum KA, Devine SM) Leuk Lymphoma 2008 Oct;49(10):1893-8       8 Citations
1Nonmyeloablative conditioning for relapsed follicular lymphoma. (van Besien K, Hari P) Blood 2008 Sep 15;112(6):2585-6; author reply 2586-7       1 Citation
1Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. (Cutler C, Stevenson K, Kim HT, Richardson P, Ho VT, Linden E, Revta C, Ebert R, Warren D, Choi S, Koreth J, Armand P, Alyea E, Carter S, Horowitz M, Antin JH, Soiffer R) Blood 2008 Dec 01;112(12):4425-31       102 Citations
3Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide. (Bredeson CN, Zhang MJ, Agovi MA, Bacigalupo A, Bahlis NJ, Ballen K, Brown C, Chaudhry MA, Horowitz MM, Kurian S, Quinlan D, Muehlenbien CE, Russell JA, Savoie L, Rizzo JD, Stewart DA) Biol Blood Marrow Transplant 2008 Sep;14(9):993-1003       71 Citations
1Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant. (Shaw BE, Mufti GJ, Mackinnon S, Cavenagh JD, Pearce RM, Towlson KE, Apperley JF, Chakraverty R, Craddock CF, Kazmi MA, Littlewood TJ, Milligan DW, Pagliuca A, Thomson KJ, Marks DI, Russell NH) Bone Marrow Transplant 2008 Dec;42(12):783-9       77 Citations
1No impact of NOD2/CARD15 on outcome after SCT: a reply. (Mayor NP, Shaw BE, Madrigal JA, Marsh SG) Bone Marrow Transplant 2008 Dec;42(12):837-8       2 Citations
1Addition of infliximab to standard acute graft-versus-host disease prophylaxis following allogeneic peripheral blood cell transplantation. (Hamadani M, Hofmeister CC, Jansak B, Phillips G, Elder P, Blum W, Penza S, Lin TS, Klisovic R, Marcucci G, Farag SS, Devine SM) Biol Blood Marrow Transplant 2008 Jul;14(7):783-9       41 Citations
1Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival. (Weisdorf D, Spellman S, Haagenson M, Horowitz M, Lee S, Anasetti C, Setterholm M, Drexler R, Maiers M, King R, Confer D, Klein J) Biol Blood Marrow Transplant 2008 Jul;14(7):748-58       163 Citations
1Impact of graft-versus-host disease on survival. (Pasquini MC) Best Pract Res Clin Haematol 2008 Jun;21(2):193-204       37 Citations
1Allogeneic hematopoietic cell transplantation in children with relapsed acute lymphoblastic leukemia isolated to the central nervous system. (Harker-Murray PD, Thomas AJ, Wagner JE, Weisdorf D, Luo X, DeFor TE, Verneris MR, Dusenbery KE, MacMillan ML, Tolar J, Baker KS, Orchard PJ) Biol Blood Marrow Transplant 2008 Jun;14(6):685-92       16 Citations
3On the probability of using cord blood. (Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM) Biol Blood Marrow Transplant 2008 Jun;14(6):724-5       5 Citations
3Donor leukocyte infusions to treat hematologic malignancy relapse following allo-SCT in a pediatric population. (Levine JE, Barrett AJ, Zhang MJ, Arora M, Pulsipher MA, Bunin N, Fort J, Loberiza F, Porter D, Giralt S, Drobyski W, Wang D, Pavletic S, Ringden O, Horowitz MM, Collins R Jr) Bone Marrow Transplant 2008 Aug;42(3):201-5       37 Citations
1Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. (Raichlin E, McConnell JP, Bae JH, Kremers WK, Lerman A, Frantz RP) Transplantation 2008 Apr 15;85(7):963-8       17 Citations
1Individual physician practice variation in hematopoietic cell transplantation. (Lee SJ, Joffe S, Artz AS, Champlin RE, Davies SM, Jagasia M, Kernan NA, Loberiza FR Jr, Soiffer RJ, Eapen M) J Clin Oncol 2008 May 01;26(13):2162-70       37 Citations
1The impact of HMG-CoA reductase inhibition on the incidence and severity of graft-versus-host disease in patients with acute leukemia undergoing allogeneic transplantation. (Hamadani M, Awan FT, Devine SM) Blood 2008 Apr 01;111(7):3901-2       37 Citations
1Allogeneic hematopoietic stem cell transplantation for peripheral T cell lymphomas; evidence of graft-versus-T cell lymphoma effect. (Hamadani M, Awan FT, Elder P, Lin TS, Porcu P, Blum KA, Devine SM) Biol Blood Marrow Transplant 2008 Apr;14(4):480-3       27 Citations
1Recurrence of hepatocellular carcinoma following liver transplantation: a review of preoperative and postoperative prognostic indicators. (Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Hong J, Busuttil RW) Arch Surg 2008 Feb;143(2):182-8; discussion 188       189 Citations
3Lifetime probabilities of hematopoietic stem cell transplantation in the U.S. (Nietfeld JJ, Pasquini MC, Logan BR, Verter F, Horowitz MM) Biol Blood Marrow Transplant 2008 Mar;14(3):316-22       43 Citations
1Allogeneic stem cell transplantation in a patient with relapsed Ewing sarcoma. (Lucas KG, Schwartz C, Kaplan J) Pediatr Blood Cancer 2008 Jul;51(1):142-4       22 Citations
3HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. (Schlenk RF, Pasquini MC, Pérez WS, Zhang MJ, Krauter J, Antin JH, Bashey A, Bolwell BJ, Büchner T, Cahn JY, Cairo MS, Copelan EA, Cutler CS, Döhner H, Gale RP, Ilhan O, Lazarus HM, Liesveld JL, Litzow MR, Marks DI, Maziarz RT, McCarthy PL, Nimer SD, Sierra J, Tallman MS, Weisdorf DJ, Horowitz MM, Ganser A, CIBMTR Acute Leukemia Working Committee) Biol Blood Marrow Transplant 2008 Feb;14(2):187-96       38 Citations
2Allogeneic transplants in follicular lymphoma: higher risk of disease progression after reduced-intensity compared to myeloablative conditioning. (Hari P, Carreras J, Zhang MJ, Gale RP, Bolwell BJ, Bredeson CN, Burns LJ, Cairo MS, Freytes CO, Goldstein SC, Hale GA, Inwards DJ, Lemaistre CF, Maharaj D, Marks DI, Schouten HC, Slavin S, Vose JM, Lazarus HM, van Besien K) Biol Blood Marrow Transplant 2008 Feb;14(2):236-45       129 Citations
2Comparing treatments in the presence of crossing survival curves: an application to bone marrow transplantation. (Logan BR, Klein JP, Zhang MJ) Biometrics 2008 Sep;64(3):733-40       37 Citations
2State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. (Kamani N, Spellman S, Hurley CK, Barker JN, Smith FO, Oudshoorn M, Bray R, Smith A, Williams TM, Logan B, Eapen M, Anasetti C, Setterholm M, Confer DL, National Marrow Donor Program) Biol Blood Marrow Transplant 2008 Jan;14(1):1-6       65 Citations
2Allogeneic hematopoietic cell transplantation for metastatic breast cancer. (Ueno NT, Rizzo JD, Demirer T, Cheng YC, Hegenbart U, Zhang MJ, Bregni M, Carella A, Blaise D, Bashey A, Bitran JD, Bolwell BJ, Elfenbein GJ, Fields KK, Freytes CO, Gale RP, Lazarus HM, Champlin RE, Stiff PJ, Niederwieser D) Bone Marrow Transplant 2008 Mar;41(6):537-45       35 Citations
2Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research. (Bishop MR, Logan BR, Gandham S, Bolwell BJ, Cahn JY, Lazarus HM, Litzow MR, Marks DI, Wiernik PH, McCarthy PL, Russell JA, Miller CB, Sierra J, Milone G, Keating A, Loberiza FR Jr, Giralt S, Horowitz MM, Weisdorf DJ) Bone Marrow Transplant 2008 Apr;41(7):635-42       37 Citations
1Alteration of load sharing of anterior cervical implants with change in cervical sagittal alignment. (Wang M, Gourab K, McGrady LM, Rao RD) Med Eng Phys 2008 Jul;30(6):768-73       9 Citations
1Conversion to sirolimus as primary immunosuppression attenuates the progression of allograft vasculopathy after cardiac transplantation. (Raichlin E, Bae JH, Khalpey Z, Edwards BS, Kremers WK, Clavell AL, Rodeheffer RJ, Frantz RP, Rihal C, Lerman A, Kushwaha SS) Circulation 2007 Dec 04;116(23):2726-33       135 Citations
1CD3+ cell dose and disease status are important factors determining clinical outcomes in patients undergoing unmanipulated haploidentical blood and marrow transplantation after conditioning including antithymocyte globulin. (Dong L, Wu T, Zhang MJ, Gao ZY, Lu DP) Biol Blood Marrow Transplant 2007 Dec;13(12):1515-24       27 Citations
3Peripheral blood grafts from unrelated donors are associated with increased acute and chronic graft-versus-host disease without improved survival. (Eapen M, Logan BR, Confer DL, Haagenson M, Wagner JE, Weisdorf DJ, Wingard JR, Rowley SD, Stroncek D, Gee AP, Horowitz MM, Anasetti C) Biol Blood Marrow Transplant 2007 Dec;13(12):1461-8       146 Citations
1Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium 2007. (Ferrara JL, Anasetti C, Stadtmauer E, Antin J, Wingard J, Lee S, Levine J, Schultz K, Appelbaum F, Negrin R, Giralt S, Bredeson C, Heslop H, Horowitz M) Biol Blood Marrow Transplant 2007 Nov;13(11):1268-85       22 Citations
1Treatment options for the management of acute leukaemia relapsing following an allogeneic transplant. (Shaw BE, Russell NH) Bone Marrow Transplant 2008 Mar;41(5):495-503       24 Citations
1Multiple myeloma: charging toward a bright future. (Katzel JA, Hari P, Vesole DH) CA Cancer J Clin 2007 Sep-Oct;57(5):301-18       83 Citations
1A novel technique for NOD2/CARD15 genotyping using PCR-SSP. (Mayor NP, Shaw BE, Keshav S, Madrigal JA, Marsh SG) J Immunol Methods 2007 Oct 31;327(1-2):82-7       2 Citations
1Vocal fold medialization in children: injection laryngoplasty, thyroplasty, or nerve reinnervation? (Sipp JA, Kerschner JE, Braune N, Hartnick CJ) Arch Otolaryngol Head Neck Surg 2007 Aug;133(8):767-71       44 Citations
1Pulmonary Nocardia and Aspergillus co-infection in a patient with chronic graft-versus-host disease. (Hamadani M, Benson DM Jr, Blum W, Garzon R, Devine SM) Transpl Infect Dis 2008 Feb;10(1):24-6       10 Citations
1Mapping MHC-resident transplantation determinants. (Malkki M, Gooley TA, Horowitz MM, Absi L, Christiansen FT, Cornelissen JJ, Dormoy A, Dubois V, Gagne K, Gluckman E, Haagenson MD, Oudshoorn M, Spellman S, Petersdorf EW, International Histocompatibility Working Group in Transplantation) Biol Blood Marrow Transplant 2007 Aug;13(8):986-95       15 Citations
3Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. (Giralt S, Logan B, Rizzo D, Zhang MJ, Ballen K, Emmanouilides C, Nath R, Parker P, Porter D, Sandmaier B, Waller EK, Barker J, Pavletic S, Weisdorf D) Biol Blood Marrow Transplant 2007 Jul;13(7):844-52       59 Citations
1Chimerism does not predict for outcome after alemtuzumab based conditioning. (Michaelis L, Lin S, Joseph L, Artz AS, Kline J, Pollyea D, Stock W, Rich E, Collins-Jones D, Casey B, Del Cerro P, van Besien K) Bone Marrow Transplant 2007 Jul;40(2):181       7 Citations
2Worse outcome and more chronic GVHD with peripheral blood progenitor cells than bone marrow in HLA-matched sibling donor transplants for young patients with severe acquired aplastic anemia. (Schrezenmeier H, Passweg JR, Marsh JC, Bacigalupo A, Bredeson CN, Bullorsky E, Camitta BM, Champlin RE, Gale RP, Fuhrer M, Klein JP, Locasciulli A, Oneto R, Schattenberg AV, Socie G, Eapen M) Blood 2007 Aug 15;110(4):1397-400       205 Citations
1Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia. (Giralt SA, Arora M, Goldman JM, Lee SJ, Maziarz RT, McCarthy PL, Sobocinski KA, Horowitz MM, Chronic Leukemia Working Committee, Center for International Blood and Marrow Transplant Research) Br J Haematol 2007 Jun;137(5):461-7       64 Citations
2Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. (Panepinto JA, Walters MC, Carreras J, Marsh J, Bredeson CN, Gale RP, Hale GA, Horan J, Hows JM, Klein JP, Pasquini R, Roberts I, Sullivan K, Eapen M, Ferster A, Non-Malignant Marrow Disorders Working Committee, Center for International Blood and Marrow Transplant Research) Br J Haematol 2007 Jun;137(5):479-85       126 Citations
1Clinical impact of MRSA in a stem cell transplant unit: analysis before, during and after an MRSA outbreak. (Shaw BE, Boswell T, Byrne JL, Yates C, Russell NH) Bone Marrow Transplant 2007 May;39(10):623-9       24 Citations
1Significant increase in end-stage renal disease after hematopoietic stem cell transplantation. (Cohen EP, Drobyski WR, Moulder JE) Bone Marrow Transplant 2007 May;39(9):571-2       32 Citations
1Analyzing survival curves at a fixed point in time. (Klein JP, Logan B, Harhoff M, Andersen PK) Stat Med 2007 Oct 30;26(24):4505-19       152 Citations
1Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT. (Miller JS, Cooley S, Parham P, Farag SS, Verneris MR, McQueen KL, Guethlein LA, Trachtenberg EA, Haagenson M, Horowitz MM, Klein JP, Weisdorf DJ) Blood 2007 Jun 01;109(11):5058-61       217 Citations
1Hematopoietic cell transplantation for Chediak-Higashi syndrome. (Eapen M, DeLaat CA, Baker KS, Cairo MS, Cowan MJ, Kurtzberg J, Steward CG, Veys PA, Filipovich AH) Bone Marrow Transplant 2007 Apr;39(7):411-5       65 Citations
1Central nervous system post-transplant lymphoproliferative disorder despite negative serum and spinal fluid Epstein-Barr virus DNA PCR. (Hamadani M, Martin LK, Benson DM, Copelan EA, Devine SM, Hofmeister CC) Bone Marrow Transplant 2007 Feb;39(4):249-51       14 Citations
3Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens. (Champlin RE, Perez WS, Passweg JR, Klein JP, Camitta BM, Gluckman E, Bredeson CN, Eapen M, Horowitz MM) Blood 2007 May 15;109(10):4582-5       127 Citations
1The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myeloid leukemia in children: an evidence-based review. (Oliansky DM, Rizzo JD, Aplan PD, Arceci RJ, Leone L, Ravindranath Y, Sanders JE, Smith FO 3rd, Wilmot F, McCarthy PL Jr, Hahn T) Biol Blood Marrow Transplant 2007 Jan;13(1):1-25       61 Citations
2Suppressive anti-HCV therapy for prevention of donor to recipient transmission in stem cell transplantation. (Surapaneni SN, Hari P, Knox J, Daniel J, Saeian K) Am J Gastroenterol 2007 Feb;102(2):449-51       12 Citations
1The impact of human herpesvirus 6B reactivation on early complications following allogeneic hematopoietic stem cell transplantation. (Wang LR, Dong LJ, Zhang MJ, Lu DP) Biol Blood Marrow Transplant 2006 Oct;12(10):1031-7       39 Citations
2New questions about transplantation in multiple myeloma. (Hari P, Pasquini MC, Vesole DH) Oncology (Williston Park) 2006 Sep;20(10):1230-42; discussion 1242, 1244, 1249-50       3 Citations
4Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. (Schmitz N, Eapen M, Horowitz MM, Zhang MJ, Klein JP, Rizzo JD, Loberiza FR, Gratwohl A, Champlin RE, International Bone Marrow Transplant Registry, European Group for Blood and Marrow Transplantation) Blood 2006 Dec 15;108(13):4288-90       135 Citations
1Autologous or allogeneic stem cell transplantation in patients with Waldenstrom's macroglobulinemia. (Anagnostopoulos A, Hari PN, Pérez WS, Ballen K, Bashey A, Bredeson CN, Freytes CO, Gale RP, Gertz MA, Gibson J, Goldschmidt H, Lazarus HM, McCarthy PL, Reece DE, Vesole DH, Giralt SA) Biol Blood Marrow Transplant 2006 Aug;12(8):845-54       52 Citations
1The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry. (Farag SS, Bacigalupo A, Eapen M, Hurley C, Dupont B, Caligiuri MA, Boudreau C, Nelson G, Oudshoorn M, van Rood J, Velardi A, Maiers M, Setterholm M, Confer D, Posch PE, Anasetti C, Kamani N, Miller JS, Weisdorf D, Davies SM, KIR Study Group, Center for International Blood and Marrow Transplantation Research) Biol Blood Marrow Transplant 2006 Aug;12(8):876-84       187 Citations
1Low frequency of telomerase RNA mutations among children with aplastic anemia or myelodysplastic syndrome. (Field JJ, Mason PJ, An P, Kasai Y, McLellan M, Jaeger S, Barnes YJ, King AA, Bessler M, Wilson DB) J Pediatr Hematol Oncol 2006 Jul;28(7):450-3       24 Citations
1Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. (Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, Larson R, Niederwieser D, Silver R, Hehlmann R, European LeukemiaNet) Blood 2006 Sep 15;108(6):1809-20       986 Citations
1Topical issues in unrelated donor haematopoietic stem cell transplants: a report from a workshop convened by the Anthony Nolan Trust in London - 2005. (Duarte RF, Pamphilon D, Cornish J, Shaw BE, Samson D, Craddock C, Marks D, Mufti GJ, Powles RL, Apperley JF, Madrigal JA, Goldman JM) Bone Marrow Transplant 2006 May;37(10):901-8       3 Citations
1Graft-versus-leukemia and graft-versus-host reactions after donor lymphocyte infusion are initiated by host-type antigen-presenting cells and regulated by regulatory T cells in early and long-term chimeras. (Xia G, Truitt RL, Johnson BD) Biol Blood Marrow Transplant 2006 Apr;12(4):397-407       50 Citations
2A comparison of cyclophosphamide and total body irradiation with etoposide and total body irradiation as conditioning regimens for patients undergoing sibling allografting for acute lymphoblastic leukemia in first or second complete remission. (Marks DI, Forman SJ, Blume KG, Pérez WS, Weisdorf DJ, Keating A, Gale RP, Cairo MS, Copelan EA, Horan JT, Lazarus HM, Litzow MR, McCarthy PL, Schultz KR, Smith DD, Trigg ME, Zhang MJ, Horowitz MM) Biol Blood Marrow Transplant 2006 Apr;12(4):438-53       120 Citations
3Outcomes after HLA-matched sibling transplantation or chemotherapy in children with B-precursor acute lymphoblastic leukemia in a second remission: a collaborative study of the Children's Oncology Group and the Center for International Blood and Marrow Transplant Research. (Eapen M, Raetz E, Zhang MJ, Muehlenbein C, Devidas M, Abshire T, Billett A, Homans A, Camitta B, Carroll WL, Davies SM, Children's Oncology Group, Center for International Blood and Marrow Transplant Research) Blood 2006 Jun 15;107(12):4961-7       115 Citations
2Autotransplantation versus HLA-matched unrelated donor transplantation for acute myeloid leukaemia: a retrospective analysis from the Center for International Blood and Marrow Transplant Research. (Lazarus HM, Pérez WS, Klein JP, Kollman C, Bate-Boyle B, Bredeson CN, Gale RP, Geller RB, Keating A, Litzow MR, Marks DI, Miller CB, Douglas Rizzo J, Spitzer TR, Weisdorf DJ, Zhang MJ, Horowitz MM) Br J Haematol 2006 Mar;132(6):755-69       52 Citations
4Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. (Passweg JR, Pérez WS, Eapen M, Camitta BM, Gluckman E, Hinterberger W, Hows JM, Marsh JC, Pasquini R, Schrezenmeier H, Socié G, Zhang MJ, Bredeson C) Bone Marrow Transplant 2006 Apr;37(7):641-9       91 Citations
1Delayed myeloid engraftment due to vancomycin in allogeneic haematopoietic stem cell transplant recipients. (Kamble RT, Hamadani M, Selby GB) J Antimicrob Chemother 2006 Apr;57(4):795-6       1 Citation
1Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, the Center for International Blood and Marrow Transplant Research, and the American Society of Blood and Marrow Transplantation. (Rizzo JD, Wingard JR, Tichelli A, Lee SJ, Van Lint MT, Burns LJ, Davies SM, Ferrara JL, Socié G) Biol Blood Marrow Transplant 2006 Feb;12(2):138-51       195 Citations
1A pilot study of nonmyeloablative allogeneic hematopoietic stem cell transplant for advanced systemic mastocytosis. (Nakamura R, Chakrabarti S, Akin C, Robyn J, Bahceci E, Greene A, Childs R, Dunbar CE, Metcalfe DD, Barrett AJ) Bone Marrow Transplant 2006 Feb;37(4):353-8       61 Citations
1Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. (Lu DP, Dong L, Wu T, Huang XJ, Zhang MJ, Han W, Chen H, Liu DH, Gao ZY, Chen YH, Xu LP, Zhang YC, Ren HY, Li D, Liu KY) Blood 2006 Apr 15;107(8):3065-73       361 Citations
1ABO blood group barrier in allogeneic bone marrow transplantation revisited. (Seebach JD, Stussi G, Passweg JR, Loberiza FR Jr, Gajewski JL, Keating A, Goerner M, Rowlings PA, Tiberghien P, Elfenbein GJ, Gale RP, van Rood JJ, Reddy V, Gluckman E, Bolwell BJ, Klumpp TR, Horowitz MM, Ringdén O, Barrett AJ, GVHD Working Committee of Center for International Blood and Marrow Transplant Research) Biol Blood Marrow Transplant 2005 Dec;11(12):1006-13       95 Citations
1131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission. (Pagel JM, Appelbaum FR, Eary JF, Rajendran J, Fisher DR, Gooley T, Ruffner K, Nemecek E, Sickle E, Durack L, Carreras J, Horowitz MM, Press OW, Gopal AK, Martin PJ, Bernstein ID, Matthews DC) Blood 2006 Mar 01;107(5):2184-91       117 Citations
1Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. (Khoury HJ, Loberiza FR Jr, Ringdén O, Barrett AJ, Bolwell BJ, Cahn JY, Champlin RE, Gale RP, Hale GA, Urbano-Ispizua A, Martino R, McCarthy PL, Tiberghien P, Verdonck LF, Horowitz MM) Blood 2006 Feb 15;107(4):1712-6       61 Citations
1APE chemotherapy for children with relapsed Hodgkin disease: a Pediatric Oncology Group trial. (Wimmer RS, Chauvenet AR, London WB, Villaluna D, de Alarcon PA, Schwartz CL) Pediatr Blood Cancer 2006 Mar;46(3):320-4       6 Citations
1Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. (Ho VT, Cutler C, Carter S, Martin P, Adams R, Horowitz M, Ferrara J, Soiffer R, Giralt S) Biol Blood Marrow Transplant 2005 Aug;11(8):571-5       268 Citations
4Risk factors for bronchiolitis obliterans in allogeneic hematopoietic stem-cell transplantation for leukemia. (Santo Tomas LH, Loberiza FR Jr, Klein JP, Layde PM, Lipchik RJ, Rizzo JD, Bredeson CN, Horowitz MM) Chest 2005 Jul;128(1):153-61       123 Citations
1Chromophobe renal cell carcinoma in a pediatric living-related kidney transplant recipient. (Greco AJ, Baluarte JH, Meyers KE, Sellers MT, Suchi M, Biegel JA, Kaplan BS) Am J Kidney Dis 2005 Jun;45(6):e105-8       16 Citations
1Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma. (Kröger N, Shaw B, Iacobelli S, Zabelina T, Peggs K, Shimoni A, Nagler A, Binder T, Eiermann T, Madrigal A, Schwerdtfeger R, Kiehl M, Sayer HG, Beyer J, Bornhäuser M, Ayuk F, Zander AR, Marks DI, Clinical Trial Committee of the British Society of Blood and Marrow Transplantation and the German Cooperative Transplant Group) Br J Haematol 2005 Jun;129(5):631-43       90 Citations
1A case of retroperitoneal fibrosis in a patient following HSCT. (Nanda A, Rizzo JD, Vogelsang GB) Bone Marrow Transplant 2005 Jun;35(11):1125-6       2 Citations
1The implication of follicular lymphoma patients receiving allogeneic stem cell transplantation from donors carrying t(14;18)-positive cells. (McGregor DK, Keever-Taylor CA, Bredeson C, Schur B, Vesole DH, Logan B, Chang CC) Bone Marrow Transplant 2005 Jun;35(11):1049-54       4 Citations
1Emergent autoimmunity in graft-versus-host disease. (Tivol E, Komorowski R, Drobyski WR) Blood 2005 Jun 15;105(12):4885-91       94 Citations
1Histologic and mechanical evaluation of impaction grafting for femoral component revision in a goat model. (Malkani AL, Voor MJ, Hellman EJ, Khalily C, Capello W, Wang M, Bauer TW, Crawford CH) Orthopedics 2005 Jan;28(1):49-58       5 Citations
2Higher mortality after allogeneic peripheral-blood transplantation compared with bone marrow in children and adolescents: the Histocompatibility and Alternate Stem Cell Source Working Committee of the International Bone Marrow Transplant Registry. (Eapen M, Horowitz MM, Klein JP, Champlin RE, Loberiza FR Jr, Ringdén O, Wagner JE) J Clin Oncol 2004 Dec 15;22(24):4872-80       186 Citations
1The role of allogeneic transplantation in high-risk acute myelogenous leukemia. (Drobyski WR) Leukemia 2004 Oct;18(10):1565-8       19 Citations
4Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant. (Eapen M, Giralt SA, Horowitz MM, Klein JP, Wagner JE, Zhang MJ, Tallman MS, Marks DI, Camitta BM, Champlin RE, Ringdén O, Bredeson CN, Martino R, Gale RP, Cairo MS, Litzow MR, deLima M) Bone Marrow Transplant 2004 Oct;34(8):721-7       160 Citations
3Myeloablative allogeneic hematopoietic stem cell transplantation in patients who experience relapse after autologous stem cell transplantation for lymphoma: a report of the International Bone Marrow Transplant Registry. (Freytes CO, Loberiza FR, Rizzo JD, Bashey A, Bredeson CN, Cairo MS, Gale RP, Horowitz MM, Klumpp TR, Martino R, McCarthy PL, Molina A, Pavlovsky S, Pecora AL, Serna DS, Tsai T, Zhang MJ, Vose JM, Lazarus HM, van Besien K, Lymphoma Working Committee of the International Bone Marrow Transplant Registry) Blood 2004 Dec 01;104(12):3797-803       95 Citations
1Use of anti-CD40 ligand monoclonal antibody as antirejection therapy in a murine peripheral nerve allograft model. (Jensen JN, Tung TH, Mackinnon SE, Brenner MJ, Hunter DA) Microsurgery 2004;24(4):309-15       23 Citations
1Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants. (Passweg JR, Walker I, Sobocinski KA, Klein JP, Horowitz MM, Giralt SA, Chronic Leukemia Study Writing Committee of the International Bone Marrow Transplant Registry) Br J Haematol 2004 Jun;125(5):613-20       76 Citations
2Inhibition of nitrosylation, nitration, lymphocyte proliferation, and gene expression in acute and delayed cardiac allograft rejection by an orally active dithiocarbamate. (Pieper GM, Khanna AK, Kampalath BN, Felix CC, Hilton G, Johnson CP, Adams MB, Roza AM) J Cardiovasc Pharmacol 2004 Apr;43(4):522-30       9 Citations
1Host conditioning is a primary determinant in modulating the effect of IL-7 on murine graft-versus-host disease. (Gendelman M, Hecht T, Logan B, Vodanovic-Jankovic S, Komorowski R, Drobyski WR) J Immunol 2004 Mar 01;172(5):3328-36       29 Citations
1Persisting posttransplantation cytomegalovirus antigenemia correlates with poor lymphocyte proliferation to cytomegalovirus antigen and predicts for increased late relapse and treatment failure. (Nakamura R, Battiwalla M, Solomon S, Follmann D, Chakrabarti S, Cortez K, Hensel N, Childs R, Barrett AJ) Biol Blood Marrow Transplant 2004 Jan;10(1):49-57       46 Citations
1Variable efficacy of N6-(1-iminoethyl)-L-lysine in acute cardiac transplant rejection. (Pieper GM, Nilakantan V, Hilton G, Zhou X, Khanna AK, Halligan NL, Felix CC, Kampalath B, Griffith OW, Hayward MA, Roza AM, Adams MB) Am J Physiol Heart Circ Physiol 2004 Feb;286(2):H525-34       8 Citations
2Evaluation of histogenesis of B-lymphocytes in pediatric EBV-related post-transplant lymphoproliferative disorders. (Abed N, Casper JT, Camitta BM, Margolis D, Trost B, Orentas R, Chang CC) Bone Marrow Transplant 2004 Feb;33(3):321-7       13 Citations
1Selective elimination of alloreactive donor T cells attenuates graft-versus-host disease and enhances T-cell reconstitution. (Gendelman M, Yassai M, Tivol E, Krueger A, Gorski J, Drobyski WR) Biol Blood Marrow Transplant 2003 Dec;9(12):742-52       10 Citations
1Herpes simplex thymidine kinase gene-transduced donor lymphocyte infusions. (Burt RK, Drobyski WR, Seregina T, Traynor A, Oyama Y, Keever-Taylor C, Stefka J, Kuzel TM, Brush M, Rodriquez J, Burns W, Tennant L, Link C) Exp Hematol 2003 Oct;31(10):903-10       40 Citations
1Allogeneic immune replacement as cancer immunotherapy. (Chakrabarti S, Childs R) Expert Opin Biol Ther 2003 Oct;3(7):1051-60       4 Citations
2Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. (Bierman PJ, Sweetenham JW, Loberiza FR Jr, Taghipour G, Lazarus HM, Rizzo JD, Schmitz N, van Besien K, Vose JM, Horowitz M, Goldstone A, Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation) J Clin Oncol 2003 Oct 15;21(20):3744-53       128 Citations
3Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. (van Besien K, Loberiza FR Jr, Bajorunaite R, Armitage JO, Bashey A, Burns LJ, Freytes CO, Gibson J, Horowitz MM, Inwards DJ, Marks DI, Martino R, Maziarz RT, Molina A, Pavlovsky S, Pecora AL, Schouten HC, Shea TC, Lazarus HM, Rizzo JD, Vose JM) Blood 2003 Nov 15;102(10):3521-9       299 Citations
1Optimistic expectations and survival after hematopoietic stem cell transplantation. (Lee SJ, Loberiza FR, Rizzo JD, Soiffer RJ, Antin JH, Weeks JC) Biol Blood Marrow Transplant 2003 Jun;9(6):389-96       39 Citations
2Mechanisms of the protective action of diethyldithiocarbamate-iron complex on acute cardiac allograft rejection. (Pieper GM, Nilakantan V, Hilton G, Halligan NL, Felix CC, Kampalath B, Khanna AK, Roza AM, Johnson CP, Adams MB) Am J Physiol Heart Circ Physiol 2003 May;284(5):H1542-51       13 Citations
1Elimination of leukemia in the absence of lethal graft-versus-host disease after allogenic bone marrow transplantation. (Drobyski WR, Gendelman M, Vodanovic-Jankovic S, Gorski J) J Immunol 2003 Mar 15;170(6):3046-53       16 Citations
1Non-heme iron protein: a potential target of nitric oxide in acute cardiac allograft rejection. (Pieper GM, Halligan NL, Hilton G, Konorev EA, Felix CC, Roza AM, Adams MB, Griffith OW) Proc Natl Acad Sci U S A 2003 Mar 18;100(6):3125-30       27 Citations
1Access to stem cell transplantation: do women fare as well as men? (Mehta P, Pollock BH, Nugent M, Horowitz M, Wingard JR) Am J Hematol 2003 Feb;72(2):99-102       12 Citations
1Partial corpectomy for cervical spondylosis. (Groff MW, Sriharan S, Lee SM, Maiman DJ) Spine (Phila Pa 1976) 2003 Jan 01;28(1):14-20       15 Citations
1Regulation of alloresponses after bone marrow transplantation using donor T cells expressing a thymidine kinase suicide gene. (Drobyski WR, Gendelman M) Leuk Lymphoma 2002 Oct;43(10):2011-6       8 Citations
1Failure of cyclosporin a to rescue peripheral nerve allografts in acute rejection. (Chen DL, Mackinnon SE, Jensen JN, Hunter DA, Grand AG) Ann Plast Surg 2002 Dec;49(6):660-7       12 Citations
3A comparison of allogeneic and autologous bone marrow transplantation for lymphoblastic lymphoma. (Levine JE, Harris RE, Loberiza FR Jr, Armitage JO, Vose JM, Van Besien K, Lazarus HM, Horowitz MM, Bashey A, Bolwell BJ, Burns LJ, Cairo MS, Champlin RE, Freytes CO, Gibson J, Goldstein SC, Laughlin MJ, Lister J, Marks DI, Maziarz RT, Miller AM, Milone GA, Pavlovsky S, Pecora AL, Rizzo JD, Schiller G, Schouten HC, Zhang MJ, Lymphoma Study Writing Committee, International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry) Blood 2003 Apr 01;101(7):2476-82       113 Citations
1CD25+ immunoregulatory T-cells of donor origin suppress alloreactivity after BMT. (Johnson BD, Konkol MC, Truitt RL) Biol Blood Marrow Transplant 2002;8(10):525-35       77 Citations
1The spectrum of complications of immunosuppression: is the time right for hand transplantation? (Brenner MJ, Tung TH, Jensen JN, Mackinnon SE) J Bone Joint Surg Am 2002 Oct;84(10):1861-70       67 Citations
2A comparison between recipients receiving matched kidney and those receiving mismatched kidney from the same cadaver donor. (Bresnahan BA, Johnson CP, McIntosh MJ, Stablein D, Hariharan S) Am J Transplant 2002 Apr;2(4):366-72       18 Citations
1Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse. (Lee SJ, Klein JP, Barrett AJ, Ringden O, Antin JH, Cahn JY, Carabasi MH, Gale RP, Giralt S, Hale GA, Ilhan O, McCarthy PL, Socie G, Verdonck LF, Weisdorf DJ, Horowitz MM) Blood 2002 Jul 15;100(2):406-14       388 Citations
1Autologous versus allogeneic unrelated donor transplantation for acute lymphoblastic leukemia: comparative toxicity and outcomes. (Weisdorf D, Bishop M, Dharan B, Bolwell B, Cahn JY, Cairo M, Giralt S, Klein J, Lazarus H, Litzow M, Marks D, McCarthy P, Miller C, Milone G, Russell J, Schultz KR, Sierra J, Wiernik P, Keating A, Loberiza F, Kollman C, Horowitz M) Biol Blood Marrow Transplant 2002;8(4):213-20       46 Citations
2Effect of tolerance to noninherited maternal antigens on the occurrence of graft-versus-host disease after bone marrow transplantation from a parent or an HLA-haploidentical sibling. (van Rood JJ, Loberiza FR Jr, Zhang MJ, Oudshoorn M, Claas F, Cairo MS, Champlin RE, Gale RP, Ringdén O, Hows JM, Horowitz MH) Blood 2002 Mar 01;99(5):1572-7       218 Citations
1A survey of diagnosis, management, and grading of chronic GVHD. (Lee SJ, Vogelsang G, Gilman A, Weisdorf DJ, Pavletic S, Antin JH, Horowitz MM, Akpek G, Flowers ME, Couriel D, Martin PJ) Biol Blood Marrow Transplant 2002;8(1):32-9       80 Citations
2Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alternative donor grafts. (Drobyski WR, Klein J, Flomenberg N, Pietryga D, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 2002 Feb 01;99(3):806-14       81 Citations
1Improving the outcome of unrelated donor stem cell transplantation by molecular matching. (Shaw BE, Madrigal JA, Potter M) Blood Rev 2001 Dec;15(4):167-74       19 Citations
2Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation. (Levine JE, Braun T, Penza SL, Beatty P, Cornetta K, Martino R, Drobyski WR, Barrett AJ, Porter DL, Giralt S, Leis J, Holmes HE, Johnson M, Horowitz M, Collins RH Jr) J Clin Oncol 2002 Jan 15;20(2):405-12       203 Citations
4Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. (Keever-Taylor CA, Bredeson C, Loberiza FR, Casper JT, Lawton C, Rizzo D, Burns WH, Margolis DA, Vesole DH, Horowitz M, Zhang MJ, Juckett M, Drobyski WR) Biol Blood Marrow Transplant 2001;7(11):620-30       52 Citations
1Risk factors for renal allograft survival from pediatric cadaver donors: an analysis of united network for organ sharing data. (Bresnahan BA, McBride MA, Cherikh WS, Hariharan S) Transplantation 2001 Jul 27;72(2):256-61       97 Citations
1In vitro T-cell receptor V beta repertoire analysis may identify which T-cell V beta families mediate graft-versus-leukaemia and graft-versus-host responses after human leucocyte antigen-matched sibling stem cell transplantation. (Epperson DE, Margolis DA, McOlash L, Janczak T, Barrett AJ) Br J Haematol 2001 Jul;114(1):57-62       18 Citations
2Transplant registries: guiding clinical decisions and improving outcomes. (Horowitz MM, Loberiza FR, Bredeson CN, Rizzo JD, Nugent ML) Oncology (Williston Park) 2001 May;15(5):649-59; discussion 663-4, 666       28 Citations
1Antioxidant treatment inhibits activation of myocardial nuclear factor kappa B and inhibits nitrosylation of myocardial heme protein in cardiac transplant rejection. (Pieper GM, Olds C, Hilton G, Lindholm PF, Adams MB, Roza AM) Antioxid Redox Signal 2001 Feb;3(1):81-8    
1Protection from lethal murine graft-versus-host disease without compromise of alloengraftment using transgenic donor T cells expressing a thymidine kinase suicide gene. (Drobyski WR, Morse HC 3rd, Burns WH, Casper JT, Sandford G) Blood 2001 Apr 15;97(8):2506-13       26 Citations
1Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant. (Regn S, Raffegerst S, Chen X, Schendel D, Kolb HJ, Roskrow M) Bone Marrow Transplant 2001 Jan;27(1):53-64       45 Citations
1Impact of donor type on outcome of bone marrow transplantation for Wiskott-Aldrich syndrome: collaborative study of the International Bone Marrow Transplant Registry and the National Marrow Donor Program. (Filipovich AH, Stone JV, Tomany SC, Ireland M, Kollman C, Pelz CJ, Casper JT, Cowan MJ, Edwards JR, Fasth A, Gale RP, Junker A, Kamani NR, Loechelt BJ, Pietryga DW, Ringdén O, Vowels M, Hegland J, Williams AV, Klein JP, Sobocinski KA, Rowlings PA, Horowitz MM) Blood 2001 Mar 15;97(6):1598-603       216 Citations
1FK506 rescues peripheral nerve allografts in acute rejection. (Feng FY, Ogden MA, Myckatyn TM, Grand AG, Jensen JN, Hunter DA, Mackinnon SE) J Neurotrauma 2001 Feb;18(2):217-29       43 Citations
4Factors affecting longevity of homograft valves used in right ventricular outflow tract reconstruction for congenital heart disease. (Tweddell JS, Pelech AN, Frommelt PC, Mussatto KA, Wyman JD, Fedderly RT, Berger S, Frommelt MA, Lewis DA, Friedberg DZ, Thomas JP Jr, Sachdeva R, Litwin SB) Circulation 2000 Nov 07;102(19 Suppl 3):III130-5       191 Citations
2Effect of postremission chemotherapy before human leukocyte antigen-identical sibling transplantation for acute myelogenous leukemia in first complete remission. (Tallman MS, Rowlings PA, Milone G, Zhang MJ, Perez WS, Weisdorf D, Keating A, Gale RP, Geller RB, Laughlin MJ, Lazarus HM, Luger SM, McCarthy PL, Rowe JM, Saez RA, Vowels MR, Horowitz MM) Blood 2000 Aug 15;96(4):1254-8       91 Citations
2Infiltrating T cells during liver graft-versus-host disease show a restricted T-cell repertoire. (Margolis DA, Casper JT, Segura AD, Janczak T, McOlash L, Fisher B, Miller K, Gorski J) Biol Blood Marrow Transplant 2000;6(4):408-15       17 Citations
1Evolving strategies to address adverse transplant outcomes associated with T cell depletion. (Drobyski WR) J Hematother Stem Cell Res 2000 Jun;9(3):327-37       23 Citations
1Ingested interferon-alpha prevents allograft islet transplant rejection. (Brod SA, Katz S, Phan T, Stepkowski S) Transplantation 2000 May 27;69(10):2162-6       6 Citations
3T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. (Champlin RE, Passweg JR, Zhang MJ, Rowlings PA, Pelz CJ, Atkinson KA, Barrett AJ, Cahn JY, Drobyski WR, Gale RP, Goldman JM, Gratwohl A, Gordon-Smith EC, Henslee-Downey PJ, Herzig RH, Klein JP, Marmont AM, O'Reilly RJ, Ringdén O, Slavin S, Sobocinski KA, Speck B, Weiner RS, Horowitz MM) Blood 2000 Jun 15;95(12):3996-4003       122 Citations
2Blood stem cells compared with bone marrow as a source of hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and Stem Cell Sources Working Committee and the European Group for Blood and Marrow Transplantation (EBMT). (Champlin RE, Schmitz N, Horowitz MM, Chapuis B, Chopra R, Cornelissen JJ, Gale RP, Goldman JM, Loberiza FR Jr, Hertenstein B, Klein JP, Montserrat E, Zhang MJ, Ringdén O, Tomany SC, Rowlings PA, Van Hoef ME, Gratwohl A) Blood 2000 Jun 15;95(12):3702-9       442 Citations
1Composite tissue allotransplantation: a comprehensive review of the literature--part III. (Jensen JN, Mackinnon SE) J Reconstr Microsurg 2000 Apr;16(3):235-51       23 Citations
1Adoptive immunotherapy using donor leukocyte infusions to treat relapsed hematologic malignancies after allogeneic bone marrow transplantation. (Drobyski WR) Cancer Treat Res 1999;101:233-66       1 Citation
1Composite tissue allotransplantation: a comprehensive review of the literature--Part II. (Jensen JN, Mackinnon SE) J Reconstr Microsurg 2000 Feb;16(2):141-57       22 Citations
1Current status of allogeneic bone marrow transplantation in acquired aplastic anemia. (Horowitz MM) Semin Hematol 2000 Jan;37(1):30-42       88 Citations
1Composite tissue allotransplantation: a comprehensive review of the literature--part 1. (Jensen JN, Mackinnon SE) J Reconstr Microsurg 2000 Jan;16(1):57-68       21 Citations
1Effect of short-term interferon therapy on the outcome of subsequent HLA-identical sibling bone marrow transplantation for chronic myelogenous leukemia: an analysis from the international bone marrow transplant registry. (Giralt S, Szydlo R, Goldman JM, Veum-Stone J, Biggs JC, Herzig RH, Klein JP, McGlave PB, Schiller G, Gale RP, Rowlings PA, Horowitz MM) Blood 2000 Jan 15;95(2):410-5       28 Citations
1Photochemical treatment with S-59 psoralen and ultraviolet A light to control the fate of naive or primed T lymphocytes in vivo after allogeneic bone marrow transplantation. (Truitt RL, Johnson BD, Hanke C, Talib S, Hearst JE) J Immunol 1999 Nov 01;163(9):5145-56       45 Citations
1Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation. (Rowlings PA, Curtis RE, Passweg JR, Deeg HJ, Socié G, Travis LB, Kingma DW, Jaffe ES, Sobocinski KA, Horowitz MM) J Clin Oncol 1999 Oct;17(10):3122-7    
1Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. (Curtis RE, Travis LB, Rowlings PA, Socié G, Kingma DW, Banks PM, Jaffe ES, Sale GE, Horowitz MM, Witherspoon RP, Shriner DA, Weisdorf DJ, Kolb HJ, Sullivan KM, Sobocinski KA, Gale RP, Hoover RN, Fraumeni JF Jr, Deeg HJ) Blood 1999 Oct 01;94(7):2208-16       520 Citations
1Graft-facilitating doses of ex vivo activated gammadelta T cells do not cause lethal murine graft-vs.-host disease. (Drobyski WR, Majewski D, Hanson G) Biol Blood Marrow Transplant 1999;5(4):222-30       41 Citations
1Long-term follow-up of patients who achieved complete remission after donor leukocyte infusions. (Porter DL, Collins RH Jr, Shpilberg O, Drobyski WR, Connors JM, Sproles A, Antin JH) Biol Blood Marrow Transplant 1999;5(4):253-61       95 Citations
3T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. (Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA) Blood 1999 Jul 15;94(2):434-41       74 Citations
1Graft-vs.-host and graft-vs.-leukemia reactions after delayed infusions of donor T-subsets. (Johnson BD, Becker EE, Truitt RL) Biol Blood Marrow Transplant 1999;5(3):123-32       51 Citations
1Bone marrow transplants for paroxysmal nocturnal haemoglobinuria. (Saso R, Marsh J, Cevreska L, Szer J, Gale RP, Rowlings PA, Passweg JR, Nugent ML, Luzzatto L, Horowitz MM, Gordon-Smith EC) Br J Haematol 1999 Feb;104(2):392-6       101 Citations
1Hepatocellular carcinoma after renal transplantation in the absence of cirrhosis or viral hepatitis: a case series. (Saeian K, Franco J, Komorowski RA, Adams MB) Liver Transpl Surg 1999 Jan;5(1):46-9       17 Citations
2The use of the polymerase chain reaction to predict for subsequent relapse in unrelated marrow transplantation for chronic myelogenous leukemia. (Drobyski WR, Hessner MJ) Leuk Lymphoma 1998 Oct;31(3-4):317-23       3 Citations
1Sca1(+)/Mac1(+) nitric oxide-producing cells in the spleens of recipients early following bone marrow transplant suppress T cell responses in vitro. (Johnson BD, Hanke CA, Becker EE, Truitt RL) Cell Immunol 1998 Nov 01;189(2):149-59       12 Citations
1Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. (Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D, Fay JW, Nademanee A, Antin JH, Christiansen NP, van der Jagt R, Herzig RH, Litzow MR, Wolff SN, Longo WL, Petersen FB, Karanes C, Avalos B, Storb R, Buell DN, Maher RM, Fitzsimmons WE, Wingard JR) Blood 1998 Oct 01;92(7):2303-14       414 Citations
1Allogeneic bone marrow transplantation for low-grade lymphoma. (van Besien K, Sobocinski KA, Rowlings PA, Murphy SC, Armitage JO, Bishop MR, Chaekal OK, Gale RP, Klein JP, Lazarus HM, McCarthy PL Jr, Raemaekers JM, Reiffers J, Phillips GL, Schattenberg AV, Verdonck LF, Vose JM, Horowitz MM) Blood 1998 Sep 01;92(5):1832-6       236 Citations
2Successful unrelated marrow transplantation for patients over the age of 40 with chronic myelogenous leukemia. (Drobyski WR, Pelz C, Kabler-Babbitt C, Hessner M, Baxter-Lowe LA, Keever-Taylor CA) Biol Blood Marrow Transplant 1998;4(1):3-12       5 Citations
2Influence of protective isolation on outcome of allogeneic bone marrow transplantation for leukemia. (Passweg JR, Rowlings PA, Atkinson KA, Barrett AJ, Gale RP, Gratwohl A, Jacobsen N, Klein JP, Ljungman P, Russell JA, Schaefer UW, Sobocinski KA, Vossen JM, Zhang MJ, Horowitz MM) Bone Marrow Transplant 1998 Jun;21(12):1231-8       111 Citations
1Pyoderma gangrenosum of the breast: sequential grafting. (Havlik RJ, Giles PD, Havlik NL) Plast Reconstr Surg 1998 Jun;101(7):1909-14       27 Citations
4T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. (Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B, Casper J, Drobyski WR, Hanson G, Horowitz M, Lawton C, Margolis J, Peitryga D, Vesole D) Bone Marrow Transplant 1998 May;21(9):893-9       48 Citations
1Related donor bone marrow transplantation for chronic myelogenous leukemia. (Passweg JR, Rowlings PA, Horowitz MM) Hematol Oncol Clin North Am 1998 Feb;12(1):81-92       8 Citations
3Graft-versus-leukemia effects in T lineage and B lineage acute lymphoblastic leukemia. (Passweg JR, Tiberghien P, Cahn JY, Vowels MR, Camitta BM, Gale RP, Herzig RH, Hoelzer D, Horowitz MM, Ifrah N, Klein JP, Marks DI, Ramsay NK, Rowlings PA, Weisdorf DJ, Zhang MJ, Barrett AJ) Bone Marrow Transplant 1998 Jan;21(2):153-8       99 Citations
1Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis. (Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH) Ann Intern Med 1997 Dec 15;127(12):1080-8       63 Citations
2Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia. (Drobyski WR, Endean DJ, Klein JP, Hessner MJ) Br J Haematol 1997 Aug;98(2):458-66       23 Citations
1Donor gamma delta T lymphocytes promote allogeneic engraftment across the major histocompatibility barrier in mice. (Drobyski WR, Majewski D) Blood 1997 Feb 01;89(3):1100-9       32 Citations
1Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. (Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J) J Clin Oncol 1997 Feb;15(2):433-44    
1Successful formation of a chimeric human thymus allograft following transplantation of cultured postnatal human thymus. (Markert ML, Kostyu DD, Ward FE, McLaughlin TM, Watson TJ, Buckley RH, Schiff SE, Ungerleider RM, Gaynor JW, Oldham KT, Mahaffey SM, Ballow M, Driscoll DA, Hale LP, Haynes BF) J Immunol 1997 Jan 15;158(2):998-1005       59 Citations
1The graft-versus-leukemia effect of post-transplant donor leukocyte infusion. (Johnson BD, Hanke CA, Truitt RL) Leuk Lymphoma 1996 Sep;23(1-2):1-9       13 Citations
1Treatment of donor mice with an alpha beta T-cell receptor monoclonal antibody induces prolonged T-cell nonresponsiveness and effectively prevents lethal graft-versus-host disease in murine recipients of major histocompatibility complex (MHC)-matched and MHC-mismatched donor marrow grafts. (Drobyski WR, Majewski D) Blood 1996 Jun 15;87(12):5355-69       11 Citations
1Autoimmune hemolytic anemia following T cell-depleted allogeneic bone marrow transplantation. (Drobyski WR, Potluri J, Sauer D, Gottschall JL) Bone Marrow Transplant 1996 Jun;17(6):1093-9       86 Citations
1Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. (Horowitz MM, Rowlings PA, Passweg JR) Bone Marrow Transplant 1996 May;17 Suppl 3:S5-6       106 Citations
1Bone marrow transplants from HLA-identical siblings in advanced Hodgkin's disease. (Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, Herzig RH, Hurd DD, Jagannath S, Klein JP, Lazarus HM, McCarthy PL Jr, Pavlovsky S, Peterson FB, Rowlings PA, Russell JA, Silver SM, Vose JM, Wiernik PH, Bortin MM, Horowitz MM) J Clin Oncol 1996 Feb;14(2):572-8    
2Chemotherapy versus transplants for acute myelogenous leukemia in second remission. (Gale RP, Horowitz MM, Rees JK, Gray RG, Oken MM, Estey EH, Kim KM, Zhang MJ, Ash RC, Atkinson K, Champlin RE, Dicke KA, Gajewski JL, Goldman JM, Helbig W, Henslee-Downey PS, Hinterberger W, Jacobsen N, Keating A, Klein JP, Marmont AM, Prentice HG, Reiffers J, Rimm AA, Bortin MM) Leukemia 1996 Jan;10(1):13-9       63 Citations
3Use of unrelated marrow grafts compensates for reduced graft-versus-leukemia reactivity after T-cell-depleted allogeneic marrow transplantation for chronic myelogenous leukemia. (Hessner MJ, Endean DJ, Casper JT, Horowitz MM, Keever-Taylor CA, Roth M, Flomenberg N, Drobyski WR) Blood 1995 Nov 15;86(10):3987-96       56 Citations
1Preliminary experience with a novel model assessing in vivo mechanical strength of bone grafts and substitute materials. (Hamson KR, Toth JM, Stiehl JB, Lynch KL) Calcif Tissue Int 1995 Jul;57(1):64-8       10 Citations
1Modulation of alloreactivity in transplant recipients by phenotypic manipulation of donor endothelium. (Quigley RL, Switzer SS, Victor TA, Goldschmidt RA, Salinger MH, Arentzen CE, Alexander JC, Anderson RW) J Thorac Cardiovasc Surg 1995 May;109(5):905-9       1 Citation
2Report from the International Bone Marrow Transplant Registry and Autologous Blood and Marrow Transplant Registry - North America. (Passweg JR, Rowlings PA, Armitage JO, Gale RP, Pelz CJ, Sobocinski KA, Klein JP, Zhang MJ, Horowitz MM) Clin Transpl 1995:117-27       25 Citations
1Availability and appropriateness of allogeneic bone marrow transplantation for chronic myeloid leukemia in 10 countries. (Silberman G, Crosse MG, Peterson EA, Weston RC, Horowitz MM, Appelbaum FR, Cheson BD) N Engl J Med 1994 Oct 20;331(16):1063-7       52 Citations
2Free radicals in pancreatic and cardiac allograft rejection. (Roza AM, Pieper G, Moore-Hilton G, Johnson CP, Adams MB) Transplant Proc 1994 Apr;26(2):544-5       11 Citations
1Component processing and intraoperative autotransfusion during bone marrow harvest. (Cook-Craig A, Owen A, Reeder G, Drobyski W, Horowitz M, Brunner J, Flomenberg N, Keever C) Prog Clin Biol Res 1994;389:613-9       1 Citation
2Delayed cardiac allograft rejection due to combined cyclosporine and antioxidant therapy. (Slakey DP, Roza AM, Pieper GM, Johnson CP, Adams MB) Transplantation 1993 Dec;56(6):1305-9       35 Citations
2Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. (Drobyski WR, Keever CA, Roth MS, Koethe S, Hanson G, McFadden P, Gottschall JL, Ash RC, van Tuinen P, Horowitz MM) Blood 1993 Oct 15;82(8):2310-8       311 Citations
1Outcome after allogeneic bone marrow transplant for leukemia in older adults. (Ringdén O, Horowitz MM, Gale RP, Biggs JC, Gajewski J, Rimm AA, Speck B, Veum-Stone JA, de Witte T, Bortin MM) JAMA 1993 Jul 07;270(1):57-60       121 Citations
1Early detection of acute allograft rejection in rat heart transplantation: flowcytometric monitoring of interleukin 2 receptor expression on CD8 positive lymphocytes. (Kohmoto T, Arai S, Senoo Y, Teramoto S) Acta Med Okayama 1993 Jun;47(3):145-50       2 Citations
2Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. (Johnson BD, Drobyski WR, Truitt RL) Bone Marrow Transplant 1993 Apr;11(4):329-36       127 Citations
2Prospective randomized comparison of quadruple vs triple therapy for first cadaver transplants with immediate function. (Johnson CP, Slakey DP, Callaluce RD, Browne BJ, Roza AM, Adams MB) Transplant Proc 1993 Feb;25(1 Pt 1):585-6       6 Citations
1Results of bone marrow transplants from human leukocyte antigen-identical sibling donors for treatment of childhood leukemias. A report from the International Bone Marrow Transplant Registry. (Horowitz MM, Bortin MM) Am J Pediatr Hematol Oncol 1993 Feb;15(1):56-64       18 Citations
1Detection of residual leukemia by the polymerase chain reaction and sequence-specific oligonucleotide probe hybridization after allogeneic bone marrow transplantation for AKR leukemia: a murine model for minimal residual disease. (Drobyski WR, Baxter-Lowe LA, Truitt RL) Blood 1993 Jan 15;81(2):551-9       11 Citations
1Molecular remission occurring after donor leukocyte infusions for the treatment of relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation. (Drobyski WR, Roth MS, Thibodeau SN, Gottschall JL) Bone Marrow Transplant 1992 Sep;10(3):301-4       38 Citations
1Changing trends in allogeneic bone marrow transplantation for leukemia in the 1980s. (Bortin MM, Horowitz MM, Gale RP, Barrett AJ, Champlin RE, Dicke KA, Gluckman E, Kolb HJ, Marmont AM, Mrsic M) JAMA 1992 Aug 05;268(5):607-12       70 Citations
2Alterations in intestinal flora following small bowel transplantation. (Browne BJ, Johnson CP, Edmiston CE, Hlava MA, Moore G, Roza AM, Telford GL, Adams MB) Transplant Proc 1992 Jun;24(3):1102       2 Citations
1Increasing utilization of allogeneic bone marrow transplantation. Results of the 1988-1990 survey. (Bortin MM, Horowitz MM, Rimm AA) Ann Intern Med 1992 Mar 15;116(6):505-12       120 Citations
1Allogeneic marrow transplantation using T cell depletion for patients with juvenile chronic myelogenous leukemia without HLA-identical siblings. (Bunin NJ, Casper JT, Lawton C, Murray K, Camitta BM, Greenwood M, Geil J, Ash RC) Bone Marrow Transplant 1992 Feb;9(2):119-22       22 Citations
1Current status of allogeneic bone marrow transplantation. (Sobocinski KA, Horowitz MM, Rimm AA, Bortin MM) Biomed Pharmacother 1992;46(2-3):57-69       7 Citations
1Allogeneic bone marrow transplants for Fanconi anemia. A preliminary report from the International Bone Marrow Transplant Registry. (Gluckman E, Auerbach A, Ash RC, Biggs JC, Bortin MM, Camitta BM, Champlin RE, Friedrich W, Gale RP, Good RA) Bone Marrow Transplant 1992;10 Suppl 1:53-7       8 Citations
1Progress in allogeneic bone marrow transplantation for acute lymphoblastic leukemia in the 1980's: a report from the IBMTR. The International Bone Marrow Transplant Registry. (Bortin MM, Barrett AJ, Horowitz MM, Gale RP, Sobocinski KA, Rimm AA) Leukemia 1992;6 Suppl 2:196-7       11 Citations
1Immunogenicity, antigenicity, and endothelial viability of aortic valves preserved at 4 degrees C in a nutrient medium. (Lupinetti FM, Christy JP, King DM, el Khatib H, Thompson SA) J Card Surg 1991 Dec;6(4):454-61       28 Citations
2Allogeneic bone marrow transplantation for relapsed and refractory lymphoma using genotypically HLA-identical and alternative donors. (Lundberg JH, Hansen RM, Chitambar CR, Lawton CA, Gottlieb M, Anderson T, Ash RC) J Clin Oncol 1991 Oct;9(10):1848-59       30 Citations
1Glucose tolerance in children with renal allografts and effect of growth hormone treatment. (Van Dop C, Donohoue PA, Jabs KL, Bock GH, Fivush BA, Harmon WE) J Pediatr 1991 May;118(5):708-14       13 Citations
1Progress in bone marrow transplantation for leukemia: a preliminary report from the Advisory Committee of the International Bone Marrow Transplant Registry. (Bortin MM, Horowitz MM, Mrsic M, Rimm AA, Sobocinski KA) Transplant Proc 1991 Feb;23(1 Pt 1):61-2       14 Citations
1Serotonin initiation of delayed-type hypersensitivity: mediation by a primitive Thy-1+ antigen-specific clone or by specific monoclonal IgE antibody. (Askenase PW, Herzog WR, Millet I, Paliwal V, Ramabhadran R, Rochester C, Geba GP, Ptak W) Skin Pharmacol 1991;4 Suppl 1:25-42       25 Citations
1The transfusion effect is influenced by the nature of MHC antigen presentation. (Grindel SI, Wiederkehr JC, Pollak R) Curr Surg 1990 Sep-Oct;47(5):321-6       2 Citations
2Plasma IL-2 levels and diagnosis of renal transplant rejection. (Johnson CP, Chaharmohal A, Buchmann E, Roza AM, Adams MB) Transplant Proc 1990 Aug;22(4):1849-51       12 Citations
1Graft-versus-leukemia in bone marrow transplantation. The Advisory Committee of the International Bone Marrow Transplant Registry. (Gale RP, Horowitz MM) Bone Marrow Transplant 1990 Jul;6 Suppl 1:94-7       26 Citations
2Elimination of OX8+ cells prolongs cardiac but not pancreatic allograft survival across minor (non-MHC) histocompatibility barriers. (Roza AM, Johnson CP, Adams MB, Naji A) Transplant Proc 1990 Apr;22(2):747-8       1 Citation
2Local procurement with pulsatile perfusion gives excellent results and minimizes initial cost associated with renal transplantation. (Johnson CP, Roza AM, Adams MB) Transplant Proc 1990 Apr;22(2):385-7       15 Citations
1Current status of allogeneic bone marrow transplantation. (Horowitz MM, Bortin MM) Clin Transpl 1990:41-52       10 Citations
1Effect of prolonged monoclonal antibody administration on cardiac allograft survival in the rat. (Roza AM, Kimura H, Markmann J, Naji A) Scand J Immunol 1989 Sep;30(3):333-8       11 Citations
1Temporal relationships between the major complications of bone marrow transplantation for leukemia. (Bortin MM, Ringdén O, Horowitz MM, Rozman C, Weiner RS, Rimm AA) Bone Marrow Transplant 1989 Jul;4(4):339-44       34 Citations
2An evaluation of early cyclosporine versus ALG therapy for primary cadaver renal allografts with immediate function. (Adams MB, Johnson CP, Roza AM) Transplant Proc 1989 Feb;21(1 Pt 2):1606-8       2 Citations
1Bone marrow transplantation for acute lymphoblastic leukaemia in first and second remission. (Barrett AJ, Horowitz MM, McCarthy DM, Kanfer E, Bortin MM) Bone Marrow Transplant 1989 Jan;4 Suppl 1:247-9       2 Citations
1Intravenous immunoglobulin may lessen all forms of infection in patients receiving allogeneic bone marrow transplantation for acute lymphoblastic leukemia: a pediatric oncology group study. (Graham-Pole J, Camitta B, Casper J, Elfenbein G, Gross S, Herzig R, Koch P, Mahoney D, Marcus R, Munoz L) Bone Marrow Transplant 1988 Nov;3(6):559-66       43 Citations
1[The removal of HLA DR antigens in human epidermis by complement dependent monoclonal antibody mediated cytotoxicity--a preliminary report]. (Chiang SS, Fang RH, King YH, Dzwierzynski W, Gottlieb LJ, Ma A, Krizek TJ) Zhonghua Yi Xue Za Zhi (Taipei) 1988 Jul;42(1):17-22    
1[Dental care of patients with bone marrow transplants. Preventive program and initial results]. (Rateitschak KH, Rateitschak EM, Hefti A, Lori A, Gratwohl A, Speck B) Schweiz Monatsschr Zahnmed 1988;98(5):472-7       2 Citations
1Pneumococcal vaccine immunization of patients with renal impairment. (Rytel MW, Dailey MP, Schiffman G, Hoffmann RG, Piering WF) Proc Soc Exp Biol Med 1986 Sep;182(4):468-73       39 Citations
1Renal failure in children with hepatic failure undergoing liver transplantation. (Ellis D, Avner ED, Starzl TE) J Pediatr 1986 Mar;108(3):393-8       46 Citations
1Concentration of In-111-oxine-labeled autologous leukocytes in noninfected and nonrejecting renal allografts: concise communication. (Collier BD, Isitman AT, Kaufman HM, Rao SA, Knobel J, Hellman RS, Zielonka JS, Pelc L) J Nucl Med 1984 Feb;25(2):156-9       5 Citations
1Recent approaches to the treatment of acute lymphocytic leukemia in childhood. (Holcenberg JS, Camitta BM) Annu Rev Pharmacol Toxicol 1981;21:231-49       4 Citations
1Regression on oxymetholone-induced hepatic tumors after bone marrow transplantation in aplastic anemia. (Montgomery RR, Ducore JM, Githens JH, August CS, Johnson ML) Transplantation 1980 Aug;30(2):90-6       9 Citations
1Stability of renal transplant function with alternate-day corticosteroid therapy. (Breitenfield RV, Hebert LA, Lemann J Jr, Piering WF, Kauffman HM, Sampson D, Kalbfleisch J, Beres JA) JAMA 1980 Jul 11;244(2):151-6       14 Citations
1Different mechanisms for the increased enzymatic activity of renin in plasma of patients with chronic renal failure and patients receiving glucocorticoid therapy. (Talwalkar RT, Kotchen TA, Welch WJ, Curtis JJ, Galla JH) J Clin Endocrinol Metab 1980 Jun;50(6):989-93       3 Citations
1Correction of infantile agranulocytosis (Kostmann's syndrome) by allogeneic bone marrow transplantation. (Rappeport JM, Parkman R, Newburger P, Camitta BM, Chusid MJ) Am J Med 1980 Apr;68(4):605-9       66 Citations
1Acute motor paralytic bladder in renal transplant patients with anogenital herpes infection. (Jacobs SC, Herbert LA, Piering WF, Lawson RK) J Urol 1980 Mar;123(3):426-7       6 Citations
1Plasma dopamine-beta-hydroxylase in uremia--increase in enzyme activity after renal transplantation. (Wang DM, Sasse EA, Itskovitz HD, Piering WF, Kochar MS, Doumas BT) Clin Chim Acta 1980 Feb 28;101(2-3):241-9       2 Citations
1A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. (Camitta BM, Thomas ED, Nathan DG, Gale RP, Kopecky KJ, Rappeport JM, Santos G, Gordon-Smith EC, Storb R) Blood 1979 Mar;53(3):504-14       362 Citations
1Pathogenesis of severe aplastic anemia: inferences from therapeutic trials. (Camitta BM) Haematol Blood Transfus 1979;24:161-5    
1Mortality of chronic hemodialysis comparable to that of renal transplantation in pediatric end-stage renal disease. (Avner ED, Harmon WE, Ingelfinger JR, Levey RH, Grupe WE) Proc Clin Dial Transplant Forum 1979;9:1-4       2 Citations
1Successful use of multiagent immunosuppression in the bone marrow transplantation of sensitized patients. (Parkman R, Rappeport J, Camitta B, Levey RH, Nathan DG) Blood 1978 Dec;52(6):1163-9       30 Citations
1Severe aplastic anaemia: a prospective study of the effect of androgens or transplantation on haematological recovery and survival. (Camitta BM, Thomas ED) Clin Haematol 1978 Oct;7(3):587-95       30 Citations
1Prognostic value of antibody-dependent assays for presensitization in bone marrow transplant recipients. (Parkman R, Rappeport J, Camitta B, Levey R, Rosen FS) Transplant Proc 1978 Mar;10(1):71-3       3 Citations
1An animal model for the study of chronic hypoxemia including long-term follow-up results. (Litwin SB, Rosenthal A, Skogen WF, Wright KA, Youker JE, Laver MB) J Surg Res 1978 Feb;24(2):107-12       1 Citation
1Matching of blood platelets for transfusion. (Aster RH) Am J Hematol 1978;5(4):373-8       10 Citations
1Bone marrow transplantation for an infant with neutrophil dysfunction. (Camitta BM, Quesenberry PJ, Parkman R, Boxer LA, Stossel TP, Cassady JR, Rappeport JM, Nathan DG) Exp Hematol 1977 Mar;5(2):109-16       14 Citations
1Dental management of patients undergoing bone marrow transplantation for aplastic anemia. (Lasser SD, Camitta BM, Needleman HL) Oral Surg Oral Med Oral Pathol 1977 Feb;43(2):181-9       7 Citations
1Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. (Buffington GA, Dominguez JH, Piering WF, Hebert LA, Kauffman HM Jr, Lemann J Jr) JAMA 1976 Oct 25;236(17):1958-60       87 Citations
1Severe aplastic anemia: a prospective study of the effect of early marrow transplantation on acute mortality. (Camitta BM, Thomas ED, Nathan DG, Santos G, Gordon-Smith EC, Gale RP, Rappeport JM, Storb R) Blood 1976 Jul;48(1):63-70       405 Citations
1Prevalence of hypertension in a renal transplant population on alternate-day steroid therapy. (Curtis JJ, Galla JH, Kotchen TA, Lucas B, McRoberts JW, Luke RG) Clin Nephrol 1976 Mar;5(3):123-7       39 Citations
1Detection of genetically determined histocompatibility antigen differences between HL-A identical and MLC nonreactive siblings. (Parkman R, Rosen FS, Rappeport J, Camitta B, Levey RL, Nathan DG) Transplantation 1976 Feb;21(2):110-6       29 Citations
1Modification of gastrointestinal symptoms following irradiation by low dose rate technique. (Cassady JR, Order S, Camitta B, Marck A) Int J Radiat Oncol Biol Phys 1975 Oct-Nov;1(1-2):15-20       15 Citations
1Evidence of gentamicin nephrotoxicity in patients with renal allografts. (Wellwood JM, Simpson PM, Tighe JR, Thompson AE) Br Med J 1975 Aug 02;3(5978):278-81       55 Citations
1Arteriography of renal transplants. (Foley WD, Bookstein JJ, Tweist M, Gikas PW, Mayor GH, Turcotte JG) Radiology 1975 Aug;116(02):271-7    
1Reduction of renal renin content by hypothermic pulsatile perfusion. (Desai SG, Kotchen TA, Luke RG, McRoberts JW) Transplantation 1975 Mar;19(3):272-3       1 Citation
1Selection of patients for bone marrow transplantation in severe aplastic anemia. (Camitta BM, Rappeport JM, Parkman R, Nathan DG) Blood 1975 Mar;45(3):355-63       172 Citations
1The medical ethics of bone marrow transplantation in childhood. (Levine MD, Camitta BM, Nathan D, Curran WJ) J Pediatr 1975 Jan;86(1):145-50       20 Citations
1Posthepatitic severe aplastic anemia--an indication for early bone marrow transplantation. (Camitta BM, Nathan DG, Forman EN, Parkman R, Rappeport JM, Orellana TD) Blood 1974 Apr;43(4):473-83       60 Citations
1Influence of acute stimuli on plasma aldosterone concentration in anephric man and kidney allograft recipients. (McCaa RE, Read VH, Cowley AW Jr, Bower JD, Smith GV, McCaa CS) Circ Res 1973 Sep;33(3):313-22    
1The supporting role of community hospitals in a kidney transplant program. (Kauffman HM, Hodgson NB, Piering WF, Kuban DJ, Rodgers RE) Wis Med J 1970 Oct;69(10):223-6    
jenkins-FCD Prod-480 9a4deaf152b0b06dd18151814fff2e18f6c05280